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Background:  Increases in the prevalence of overweight and obesity states, and in their 
associated adverse health outcomes, have been well described in the general population.  
However, in type 1 diabetes (T1D), a disease traditionally characterized by a lean phenotype, 
time trends in overweight and obesity and the role of adiposity on complications in TID have not 
been well investigated.  We therefore investigated time trends in overweight and obesity and the 
association of adiposity with mortality and coronary artery calcification (CAC), a subclinical 
marker of coronary artery disease in the Pittsburgh Epidemiology of Diabetes Complications 
cohort of childhood onset T1D. 
Methods: Participants were first seen in 1986-1988 and followed biennially thereafter.  
Mortality was censored at January 1, 2007.  Body mass index (BMI) was defined as kg/m² and 
Waist circumference (WC) was measured.  CAC, visceral adiposity (VAT) and subcutaneous 
adiposity (SAT) by electron beam tomography.  Free fatty acids (FFA) were determined by in 
vitro colorimetry. 
Results: After 18 years of follow-up, the prevalence of overweight increased by 47%; the 
prevalence of obesity increased 7-fold.  BMI demonstrated a quadratic relationship with 
mortality.  Adjustment for waist circumference eliminated the increased risk in the obese.  
Weight gain was positively related to intensive insulin therapy and inversely with mortality.  
 v 
There was a positive relationship between the presence of CAC and adiposity measures, however 
the degree of CAC was not associated with any adiposity measure, except negatively with SAT 
in women.  Finally, FFA were not associated with any adiposity measure and showed no 
association with CAC. 
Conclusion:  Adiposity is increasing in T1D and shows a complex association with coronary 
artery disease and mortality.  These results have great public health significance by suggesting 
that avoidance of overweight, per se, in type 1 diabetes should not be a major priority; rather 
attention should focus on maximizing glucose control even though it may result in weight gain. 
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PREFACE 
 
It was about a year ago that I was sitting in Dr. Orchard’s office going over descriptive statistics 
of Epidemiology of Diabetes Complications (EDC) Study participants whom we had collected 
data on skin fluorescence.  Although generally in epidemiology the descriptive data we look at 
are means and standardized deviations about the mean, it was a small sample so we were looking 
at the each characteristics of each participant, such as age, years of type diabetes, number of 
diabetes complications, complications at baseline and number of complications at baseline, and 
whether the participant was free of any long term diabetes complications.  Looking at this 
population that by definition had had diabetes since childhood, a couple of the participants 
jumped out at him.  In a moment of quiet awe and surprise he said, “We have participants with 
60 years of diabetes duration!  We have someone in this population pushing 70 years of age!”  It 
was then that I realized that he was far more intricately wrapped up in this population than I had 
imagined.  This had been more than a career for him.  It had been a life’s work.  Although this 
was still a middle aged population and the average age of the deceased at death was still in the 
early to mid-forties, so was the average age of those still alive, representing more than 75% of 
the original cohort.  These few participants, now senior citizens and one approaching old age, 
although extremes in the population, were tell tale signs of things to come.  We were standing on 
the brink of witnessing the extension of life in an entire population to a full lifespan.  [And he 
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had been a primary mover behind it.]  It was then that I understood the value of the EDC study.  
Although its focus was neither type 1 diabetes etiology nor cure, in a different way it was 
seeking a similar end: the normalization of a population and a full lifespan.  And as reflected in 
this dissertation, in a single generation, despite the wasting nature of the disease, we have 
witnessed a characteristically lean/thin population achieve weight gain to the point that the 
prevalence of overweight and obesity are no different from the general population with an effect 
on mortality similar to that in the general population when an protective effect would have been 
expected.  Sitting in his office that day looking at those extremes in the population, we really did 
appear to be witnessing the normalization of a population.  What more can one ask for out of 
one’s life’s work.  The physician and the researcher had been one.  To Dr. Orchard I would like 
to say thank you for your work for people with type 1 diabetes, thank you for the training you 
have given me, and thank you for your extreme patience with my personality. 
I would also like to thank the participants of the EDC study for their participation in this 
research for the past 20 years.  Despite the suffering and morbidity imposed by this disease 
words on paper can not do justice to, and even the cynicism that some of them have expressed 
that there will ever be a cure, they continue to participate in hopes that they are making life better 
for future children.  This characteristic has amazed me.  Like Dr. Orchard, they too have an 
intricate relationship with the study.  It really is a relationship. 
I would also like to thank my other committee members.  Thank you to Dr. Evans, who 
had a very quiet way of strongly motivating and whose classes were not only eclectic, but were 
among the most interesting I have taken at this university.  How he managed to do that with 
biochemistry classes speaks highly of him.  Thanks also for training me in the assaying of free 
fatty acids. 
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Thank you to Dr. Fried, who although by far one of the most intelligent people I have 
known somehow managed not to intimidate or hurt my shallow doctoral self-esteem.  Somehow 
I always knew her criticisms were about my work, not me.  She was also very helpful. 
Thank you to Dr. Kelsey, who strengthened my skills base in statistical analyses.  Thanks 
to her I can now do time-varying, in addition to time-dependent, survival analyses, generalized 
linear modeling, repeated measures analyses, and intraclass correlations on relatively large 
populations.  Good job market skills.  I still have a few books she ‘lent’ me.  But you know the 
saying, “Ever lend send somebody a book and got it back?” 
Thank you to my parents for whom at this moment this PhD means more to than me. 
Thank you to my stepfather John, who did not survive the fight with this disease, but who 
did motivate me to achieve high academically.  He helped me more than I could help him. 
Finally, thank you to Glenn, whose friendship has been a real source of support during 
my doctoral experience and who helped guide me in this research, and the meaning behind the 
research, in only ways that he could.  And for other reasons you are my hero. 
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1.0  INTRODUCTION 
While the increase in overweight and obesity and associated adverse outcomes have been well 
documented in the general population, time trends in populations with pre-existing disease, such 
as type 1 diabetes (T1D), have not been as thoroughly investigated.  The relevance of this is 
emphasized by studies showing that within populations with pre-existing disease, obesity 
associations are often opposite of that seen in the general population, a phenomenon termed the 
obesity paradox (1).  In T1D, further complexity is added in that the primary mediator of energy 
absorption, the anabolic hormone insulin, is either severely deficient or absent and must be 
exogenously administered.  Without this hormone, T1D results in a progressive wasting to death.  
With initiation of insulin therapy, there is a relative normalization of weight.  With 
intensification of insulin therapy there is (often) further weight gain and a reduction in, or 
delayed progression to, long term complications of the disease.   
Given the widespread adaptation of intensive insulin therapy in the mid 1990s after the 
release of the results from the Diabetes Control and Complications Trial (DCCT) showing a 
reduction in microvascular complications (2, 3), investigating the association of weight gain, 
overweight, and obesity with complications of T1D is critical.  This is particularly so since 
intensive insulin therapy in the DCCT was also associated with excessive weight gain (4, 5), and 
the association of tightened glycemic control with coronary artery disease, the leading cause of 
death in type 1 diabetes, continues to yield conflicting results (6-12).   
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This dissertation focuses on adiposity, that is, the excess of adipose tissue, or the degree 
of “fatness”, in individuals with type T1D.  The two main components that will be the focus of 
this dissertation are overall adiposity (as well as trends over time) and its distribution.  The 
impact of both of these factors on heart disease and mortality in T1D will be examined.  
3 
 
2.0  BACKGROUND 
“Some people are born to fatness. Others have to get there.” –Les 
Murray 
 
 
  2.1     TIME TRENDS 
Obesity is the result of a chronic positive energy imbalance.  Marti el al (13)define obesity as ‘a 
pathological condition accompanied by an excessive fat deposition as compared to expected 
values for a given stature, sex, and age.’  It is an excess accumulation of body fat, operationally 
defined as a body mass index (BMI) greater than or equal to thirty.  
Until the 1960s, obesity was relative rare.  It increased by 10% between 1961 and 1978 
(14).  Since 1984, the prevalence of obesity in the United States has doubled (14).  Today nearly 
one-third of all Americans are obese (15).  This epidemic rise in overweight and obesity is not 
limited to the United States, nor to developed countries.  Developing countries are beginning to 
see a marked rise in obesity, with countries such as Samoa having an obesity prevalence of 
greater than 50% (16).  Over forty% of Kuwait and French Polynesian women are obese (16).  
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Worldwide, approximately 1 in 6 people are overweight (17).  As of 2002, 65% of the U.S. adult 
population was either overweight or obese and 30% were clinically obese, compared to 47 and 
15%, respectively, in 1980 (15).  In the United States, obesity accounts for approximately 7% of 
the health care budget (18), with an economic impact greater than 100 billion dollars annually 
(19).   
Theories for the rising prevalence of overweight and obesity are numerous, including 
both extrinsic and intrinsic factors.  Extrinsic factors include technology, transportation, change 
in the energy demands of employment, change in the family structure, decreased cost and 
increased availability of food, a change in the energy-density (14, 20, 21), and a change in the 
biochemical make-up of food, i.e. the switch from glucose to fructose, and its different metabolic 
routing, as the primary added sweetener in food (21-25).   
Putative intrinsic risk factors may evolve around the “thrifty-gene” hypothesis.  The 
thrifty-gene hypothesis postulates that the relative ability to gain weight and store fat is a result 
of selective survival (26-28).  Until recently, mankind was plagued with periodic famines (26).  
Limited food availability was a survival pressure, and those who were able to more efficiently 
store excess energy were preferentially able to survive.  As a result, man evolved the ability to 
more efficiently store fuel for times of energy deprivation (26).  As Per Bjorntorp (26) points out, 
“adipose tissue development is a necessary survival characteristic of species which do not have 
constant access to food.”  The reason for this selected survival may not have been limited to 
periods of famine, but to plague and illness as well.  Those with greater energy reserves may 
have been better able to handle the illness-induced starvation state of disease.  They may also 
have had greater immune responses, i.e. increased secretion of inflammatory proteins, to disease.  
Body fat gain may have been an adaptive mechanism for survival (28), not only against famine, 
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but also illness.  Weighed against the more imminent survival, the effects of long-term exposure 
to obesity, e.g. dyslipidemia, hypertension, and insulin resistance, was relatively unimportant 
(28).  The comorbidities of obesity are generally diseases of longevity, a relatively recent 
phenomenon.  
The present environment of abundant, easily accessible food, and reduced energy 
demands in the face of genes selectively survived to efficiently store energy may be the etiologic 
cause of the rapid rise in overweight and obesity over the last few decades. This rising 
prevalence of overweight and obesity seems to be due to a maladaptation of man to his changing 
environment (27).   
 
2.2 COMPLICATIONS OF OBESITY 
Evidence of this maladaptation can be observed from the morbidity and mortality associated with 
increased weight and fat mass.  A study reported in a 1999 issue of JAMA (29) found that 
obesity was responsible for approximately 300,000 deaths annually, deaths largely due to the 
comorbidites of obesity, i.e. disease for which obesity is a major risk factor.  While this assertion 
has been recently challenged (30), by putting the number at approximately 112,000 excess 
deaths, the impact of obesity on mortality is still substantial.   
The evidence implicating a role of overweight and obesity in chronic diseases such as 
cardiovascular disease and T2D is strong.  A study by Rimm et al (31) found that BMI, waist-to-
hip ratio, and weight gain in adulthood were associated with increased risk of coronary heart 
disease (CHD).  Overweight middle-aged men (BMI 25.0-28.9) had a 75% greater risk of 
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developing CHD than men with BMIs below 23.  Men with BMIs >33 were three-and-a-half 
times more likely to develop CHD as the lean men (BMI<23).  A meta-analysis of 11 studies 
found a 2.71 and 2.80 relative risk for coronary heart disease in obese women and men, 
respectively (32), and found that a weight gain in adulthood of 15 kg was associated with a 46% 
increased risk of a coronary event in men and an 83% increased risk in women.  Cardiovascular 
disease is the leading cause of death in the United States (33), accounting for approximately 
700,000 deaths (15) in 2002.   
Along with the rise in the prevalence of overweight and obesity in the past few decades, 
there has also been a similar rise the prevalence of diabetes, particularly T2D, behind which 
obesity seems to be the driving force (34, 35).  The relationship between obesity and diabetes is 
so strong that it has often been termed diabesity (36, 37).  Although most obese individuals do 
not develop diabetes, 90 percent of type 2 diabetics are obese (38).  Diabetes is especially high 
among the morbidly obese, with as many as 30% having diabetes (39).  Even in far lesser 
degrees of obesity, a substantial dose-response relationship is evident.  For example, the Nurses 
health study found that those with a BMI of 30 were 35 times more likely to develop T2D than 
those with a BMI of 21 (40).  The Male Health Professionals Study found similar results, with 
men with a BMI ≥ 35 (compared to <22) forty-two times more likely to develop T2D (41).  
There is an approximate 25% increased relative risk in diabetes for every unit rise in BMI above 
22 (39).  The following table (Table 2-1) lists studies showing relationships between adiposity 
and diabetes risk. 
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Table 2-1.  Studies on Diabetes and Obesity. 
 
Investigator Population Outcome 
Colditz et al, 1995 (40) The Nurses’ Health Study 
N=114, 824 
Diabetes risk in women significantly associated with both BMI 
and weight gain in adulthood independent of BMI.  RR=5 BMI 
24.0 to 24.9 compared to BMI<22. 
Chan et al, 1994(41)  Male health professionals 
n=51,529 
Obesity associated with increased diabetes risk.  BMI ≥ 35 
compared to <22, RR=42.1 Weight gain during adulthood 
associated with increased risk 
Ohlson et al, 1985 (42) Swedish men n=558 BMI and WHR independent of BMI positively significantly 
associated with diabetes risk 
West et al, 1971 (43) 10 different populations around 
the world 
Prevalence of diabetes strongly associated with prevalence of 
obesity 
Resnick et al, 2000 (44) Cohort of overweight 
nondiabetic  men n=1929 
Diabetes incidence increased by 26.2% for a BMI≥37. For each 
kilogram weight gain per year, diabetes RR=1.49.  For each 
kilogram weight loss, there was a 33% decreased risk of NIDDM. 
Boykyo et al, 2000(45) (36) Japanese American cohort Visceral obesity associated with later development of diabetes 
Kern et al, 1997(46)  In vitro study Impaired insulin signaling by TNF-α 
Boden et al, 1999 (47) Diabetic and nondiabetic 
subjects 
Infusion with lipid and heparin resulted in reduction in glucose 
uptake into peripheral tissues 
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The pathophysiology of increased adiposity begins with an excess in fat mass on organs, 
particularly visceral organs, an alteration in adipokine and inflammatory peptide secretion, an 
increase in free fatty acid (FFA) production, and a modification in hemodynamics and lipid 
metabolism (48).  Hypertension and dyslipidemia are a common part of the sequelea of obesity.  
Elevated levels of triglycerides, small low dense lipoprotein (LDL), and apoliprotein B, but 
depressed levels of high dense lipoprotein, are seen in obesity, putting the obese at a greatly 
increased risk of cardiovascular disease (CVD), the leading cause of death in the United States.  
In fact, obesity is the second leading modifiable risk factor in CVD (49, 50).  Obesity is also 
associated with an increased risk of respiratory diseases, some cancers, T2D, other major chronic 
diseases, and mortality (30, 50, 51).  Table 2-2 lists studies showing the impact of adiposity on 
various chronic diseases. 
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Table 2-2.  Obesity's Association with Common Chronic Diseases. 
 
Investigator Population Outcome 
Kenchiah et al, 2002 
(51) 
Framingham Heart Study 
N=5881 
Obesity associated with increased heart failure risk. HR=2.12 for men 
and 1.90 for women.  Increase in BMI category and heart failure 
HR=1.46 for women and 1.37 for men 
Anderson and Konz, 
2001 (32)  
Meta-analysis CAD RR=2.71 and 2.80 in obese men and women, respectively 
Zhou et al, 2002 (52) 10 cohorts in China, n=9213 BMI an independent risk factor for coronary heart disease (CHD) and 
stroke, CHD RR=1.23 and stroke RR=1.09 for each 2-unit increase in 
BMI 
Association found at lower BMI levels than in Western countries 
Rimm et al, 1995 (31)  The Health Professionals Follow-up 
Study n=29,122 
Increasing RR of CHD with increasing BMI in men.  Men aged 40-64, 
BMI ≥33 RR=3.44 compared to BMI< 23.  Men aged ≥ 65, WHR a 
strong predictor of CHD 
Manson et al, 1990 (53)  The Nurses’ Health Study 
n=115,886 
Adjusting for smoking, BMI positively related to CHD starting at BMI 
≥21.  BMI≥29 three –fold increase in CHD.  70% of CHD in the group 
(BMI≥29) attributed to adiposity  
Rexrode et al, 1997 
(54) 
The Nurses’ Health Study 
n=116,759 
RR for ischemic stroke increased with increase in BMI category, starting 
at BMI ≥27 compared to BMI <21 
Tishler et al, 2003 (55) The Cleveland Family Study n=286 Increasing BMI significantly associated with sleep-disordered breathing. 
Increased apnea hypopnea index OR=1.14 for each unit increase in BMI  
Baik et al, 2000 (56) Male and female health 
professionals n=104,491 
Obesity associates with increased risk of pneumonia.  RR=2 for weight 
gain >40 pounds in adulthood 
Calle et al, 2003(57)  The Cancer Prevention Study II 
n=900,053 
Overweight and obesity accounted for 14% and 20% of cancer mortality 
in men and women, respectively 
Huang et al, 1997 (58) The Nurses’ Health Study cohort 
n=92256 
Weight gain after age 18 associated with increased breast cancer risk 
after menopause.  P=.006 
Murphy et al, 2000 (59) The Cancer Prevention Study II 
n=875,406 
Obesity highly associated with colon cancer mortality in men.  Dose 
response relationship evident in men.  A weaker positive, but significant 
association seen in women. 
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Although not the focus of this dissertation, the cluster of risk factors mentioned above, 
namely obesity, specifically abdominal obesity, hypertension, and an abnormal lipid profile, 
along with disturbed glucose tolerance has often been called the metabolic syndrome (60-62)a 
concept also referred to as the insulin resistance syndrome (63) as reflected in the WHO criteria 
(64).  The metabolic syndrome is a cluster of risk factors used to identify individuals at increased 
risk of CVD (60, 61).  Those with this condition are at greatly increased risk of CVD death (65) 
There is an ongoing discussion about whether the central feature is insulin resistance or central 
adiposity, as reflected in the recent JDF criteria (61).  Central to this concept of the metabolic 
syndrome are insulin resistance and the role of adipose tissue.  Recently Reaven (35) suggested 
that inflammation might be another link between the metabolic syndrome and CVD. 
 
2.3 ADIPOCYTE PATHOPHYSIOLOGY 
The adipocyte is a metabolically active cell, functioning not only as a lipid depot, but as an 
endocrine organ as well (66, 67).  It releases the hormone leptin, tumor necrosis factor (TNF)-α, 
visfatin, resistin, C-reactive protein (CRP), plasminogen activator inhibitor 1 (PAI-1), and other 
cytokines, complement proteins, adiponectin, prothrombotic agents, enzymes such as 
angiotensinogen, and substrates such as free fatty acids (FFA) (13, 68, 69).  In obesity, there is 
an alteration of secretions of adipokines, with an over expression of some and a suppression of 
others (13, 70). 
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Specifically addressing FFAs, FFA production is increased in obesity, particularly from 
visceral fat (21, 71).  The elevated FFAs seen in obesity may lead to hepatic insulin resistance 
via (72).  Elevated levels of FFAs reduce glucose uptake in the peripheral tissues and increase 
hepatic glucose production, resulting in insulin resistance (38, 71).  Insulin resistance in type 2 
diabetes and in the general population is associated with a markedly increased risk of CAD (60, 
61).  Additionally, FFAs have been postulated to be in the biological pathway between insulin 
resistance and cardiomyopathy (73). 
TNF-α also plays a role in insulin resistance (74).  It induces a reduction in insulin 
receptors and it also increases lipolysis and the subsequent release of FFAs.  In addition to its 
role in insulin resistance, it increases the expression of leptin, IL-6, and other inflammatory 
mediators and reduces the expression of adiponectin (73), thereby potentially increasing the risk 
of cardiovascular disease.  Increased levels of this proinflammatory adipokine are seen in obesity 
(73, 74). 
The following diagrams (Figure 2-1) demonstrate how increased fat stores, particularly 
visceral fat stores, may play a role in heart disease. 
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Figure 2-1.  Adiposity's pathological route to atherosclerosis 
Adapted from Bray G (75) and Raz I (76)  
General Fat
Stores
macrophage
TNF-α
Insulin resistance
CRP
induction
Induction of general 
systemic inflammation
Activation of endothelial
and smooth muscle NF-kB
Induction of vascular adhesion
molecules and cytokines
Inflammation and foam cell accumulation
Visceral Fat 
Stores
Portal
FFAs
Hepatic 
Insulin 
clearance
Plasma insulin
Hepatic vLDL
LDLc PAI-1 HDLc
LDLc oxidation
Atherosclerosis
Coronary heart disease
 13 
IL-6 is a proinflammatory cytokine also secreted from the adipocyte, among other 
sources, and overexpressed in obesity, particularly visceral obesity.  There is evidence that this 
cytokine increases hepatic gluconeogenesis and stimulates the release of glucagon and cortisol 
(77). 
Leptin, the recombinant protein encoded by the ob gene, is secreted almost exclusively 
by adipocytes.  Leptin up-regulates inflammatory responses (13), implicated in the pathogenesis 
of atherosclerosis in chronic low-level inflammation (78).  It also stimulates platelet aggregation 
(79).  A case-control study conducted by Wallace et al (79) found that a one standard deviation 
increase in circulating leptin was associated with a 20% increase in coronary events, independent 
of BMI and other classic risk factors. 
Plasminogen activator inhibitor-1 (PAI- 1), produced in the liver, endothelial cells, 
thrombocytes, like many other markers of inflammation, is also produced in adipose tissue (80-
83).  PAI-1 is also associated with many of the components of the metabolic syndrome and CVD 
(81, 84).  Elevated levels of PAI-1 are found in obesity, particularly in visceral obesity, being 
preferentially synthesized in visceral relative to subcutaneous adipose tissue (81, 82).  Elevated 
levels are also found in insulin resistance, hypertension, elevated levels of triglycerides and low 
density lipoprotein (LDL), and smoking (80-83).  Due to the association of PAI-1 with factors of 
the metabolic syndrome, impaired fibrynolysis has been included in Reaven’s expanded 
definition of the metabolic syndrome (80, 81, 85).  In fact, most of PAI-1’s association with 
CVD appears to be due to the metabolic syndrome (82). 
CRP is an acute-phase reactant protein synthesized by hepatocytes.  Elevated levels of 
this inflammatory marker correlate with BMI, weight, visceral adiposity, and insulin resistance 
(86).   Elevated levels of CRP are also associated with increased CVD morbidity and mortality. 
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Furthermore, CRP has been shown to provide further prediction of atherosclerosis and CVD 
beyond the traditional key risk factor, LDL (87).  In the Women’s Health Study, baseline CRP 
levels were more predictive of CVD events than LDL (87).  Other studies have also 
demonstrated the predictive power of CRP in CVD.  In the Cholesterol and Recurrent Events 
trial, those in the highest quartile of CRP levels were 75% more likely to experience a recurrent 
myocardial infarction (MI) than those in the lowest quartile (87).  The Honolulu Heart Study, the 
odds of MI rose with increasing CRP levels over a course of twenty years (87).   
Adiponectin is a 3-kDa monomer hormone secreted by adipocytes and found to be 
cardioprotective in the general population (86).    Adiponectin increases insulin sensitivity, 
inhibits glucose production, is anti-atherogenic and anti-inflammatory (86, 88).  Levels of this 
hormone are inversely associated with adiposity.  Although lower levels of this cardioprotective 
peptide are seen in the obese, higher levels are observed in those with T1D (89), a population at 
much higher risk for CVD.  De Block et al (90) found adiponectin to be negatively correlated 
with waist-to-hip ratio and waist circumference and positively correlated with HDL cholesterol 
and A1C in individuals with T1D. Although they did not investigate the association of 
adiponectin with CAD in their population, they did look at its relationship with retinopathy and 
neuropathy and found no differences in adiponectin levels in those with and without these 
complications.  However, Costacou et al (91) did find adiponectin to be predictive of CAD in 
T1D and observed an inverse correlation between adiponectin levels and (p=0.07) and waist-to-
hip ratio (p=0.003).  Increased levels of inflammatory markers, including adiponectin, were 
observed cross-sectionally in those with proliferative and nonproliferative retinopathy in the 
EURODIAB study (92).  In this same population, BMI was also positively associated with 
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retinopathy.  Since the adipocyte is a primary source of the inflammatory markers investigated, 
increased adiposity may have played a role in the development of retinopathy in this population. 
Finally, visfatin, or pre-B-cell colony-enhancing factor, another insulin sensitizer, is a 
protein mainly expressed in bone marrow, liver, and muscle (93).  It was termed visfatin when it 
was discovered that higher levels of this hormone were observed in visceral rather than 
subcutaneous adipose tissue.  Visfatin seems to play a paradoxical role in adiposity.  
Counterintuitively, although visfatin expression is increased in visceral adiposity, rather than 
increasing insulin resistance, visfatin acts as an insulin mimetic and increases insulin sensitivity 
and glucose uptake into tissues.  This may be an adaptive mechanism of the body to counteract 
the effects of obesity-induced insulin resistance.  In type 1 diabetes, a state of absence of 
endogenous insulin, increased expression of this insulin mimetic may play a protective role in 
hyperglycemia. 
In summary, the pathophysiology of increased adiposity begins with an alteration in 
adipokine and inflammatory peptide secretion, an increase in FFA production, and an excess in 
fat mass on organs, particularly visceral organs.  The elevated production and secretion of 
peptides from adipose tissue may result in increased muscle insulin resistance, leading to 
increased insulin requirements and pancreatic insulin secretion, looping back to increased insulin 
resistance.  Raised plasma FFA circulation leads to insulin resistance, ultimately resulting in 
pancreatic beta cell failure and T2D.  Elevated visceral adiposity leads to an increase in portal 
FFAs followed by a decrease in insulin clearance, and an increase in plasma insulin.  This 
increase in plasma insulin upregulates Na+ reabsorption and the sympathetic nervous system 
activity, finally resulting in hypertension.  Increased levels of portal FFAs also cause an 
upregulation of hepatic vLDL production resulting in an increase in LDL cholesterol and LDL 
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oxidation, an increase in HDL cholesterol, and an increase in PAI-1.  A final sequelae is 
atherosclerosis and coronary heart disease.   
In order for obesity to be a risk factor for, and play an etiologic role in, a disease it has to 
exhibit temporality.  For diseases like CVD or T2D, where obesity is a risk factor for the disease, 
this temporal relationship may be relatively clear.  However, for diseases in which obesity occurs 
within the context of another preexisting disease, this relationship becomes more complex.  One 
such disease is type 1 diabetes (T1D), the focus of this proposal. 
 
2.4 TYPE 1 DIABETES 
2.4.1 Epidemiology of Type 1 Diabetes 
T1D is the most frequently occurring type of diabetes in children and adolescents.  In the U. S., 
T1D affects about 1:400-600 children and adolescents (94), making it one of the leading chronic 
diseases in this age group (95, 96).  In the year 2000, the global prevalence of T1D was 4.9 
million, i.e. about 0.09% of the world’s population (97).   The highest prevalence of T1D is 
found in Europe, affecting approximately 1.27 million, followed by North America, with a 
prevalence of approximately 1.04 million(97).   
T1D results from an autoimmune destruction of pancreatic beta cells (98).  Acute 
complications of T1D are severe hypoglycemia and diabetic ketoacidosis (98, 99).  The major 
long term complications of T1D include retinopathy, neuropathy, nephropathy, early CAD and 
cerebrovascular disease, peripheral arterial disease, and early mortality (98, 99).  Diabetic 
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retinopathy is the leading cause of blindness in the U.S. (99) and diabetic nephropathy the 
leading cause of renal failure (99), of with type 1 diabetes accounts for approximately half of all 
cases (100).  Cardiovascular disease occurs several decades earlier in T1D and is the leading 
cause of death in this population (100).  The excess mortality in T1D is 2 to 4-fold compared to 
age-matched non-diabetics (101, 102).  
2.4.2 Complications in Type 1 Diabetes 
Recent studies in Scotland and Pittsburgh have shed light on the incidence of major T1D 
complications.  The mortality rate in 1997 for T1D in Tayside, Scotland was 14.6 per 1000 
(103).  The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study population, with 
an average age of eight years at diagnosis, depending upon the calendar year of diagnosis, had 
mortality rate ranging from 23 to 39% after thirty years of disease (104).  Annual incidence rates 
of major diabetes complications in the two populations are as follows (age-unadjusted for the 
Scotland cohort).  The annual incidence rates of proliferative retinopathy and registered 
blindness was 5.4% and 0.1 % in the EDC and Scotland populations, respectively.  The 
incidence rate for peripheral vascular disease was 0.5% in the Scotland population (no data 
available for the EDC cohort).  The incidence rates for distal symmetric polyneuropathy and 
symptomatic autonomic neuropathy were 1.5% and 0.8% per year, respectively, after 30 years of 
disease duration in the EDC cohort (no data available for the Scotland population).  The annual 
incidence rate for end stage renal failure was 0.6% in both populations.  The incidence rate for 
myocardial infarction was 0.9 % in the Scotland cohort, while it was lower in the EDC cohort, at 
0.3% for myocardial infarction and fatal coronary artery disease (CAD).  The incidence rate for 
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total CAD was 0.4% in the EDC cohort (data not available for Scotland cohort), and was the 
leading cause of death in this population. 
2.4.3 Overweight and Obesity in T1D Complications 
While there appears to be some association of overweight and obesity with T1D complications, it 
is unclear as to the extent of overweight/obesity’s impact on complications in T1D.  A recent 
study by De Block et al (90) found that being overweight was cross-sectionally associated with 
increased retinopathy and neuropathy in those with T1D and that higher BMI l was associated 
with greater severity; however, these overweight individuals were also older than the non-
overweight. Overweight was not independently associated with neuropathy and after blood 
pressure was excluded from the model, was no longer significantly associated with retinopathy 
either. Insulin resistance was not observed in this study as the insulin dose/kg bodyweight was 
similar in both weight groups. In the Diabetes Control and Complications Trial (DCCT), Zhang 
et al (105) found that baseline BMI positively predicted retinopathy (OR=1.1, p=0.04) in T1D. 
 Dorchy et al (106) also found an association with overweight and progression from background 
to proliferative retinopathy in T1D.  
In the EDC cohort of T1D, Stuhldreher et al (107) also found WHR cross-sectionally to 
be positively associated with proliferative retinopathy and peripheral vascular disease 
univariately in both genders and neuropathy and nephropathy in males.  After controlling for 
hypertension, LDL and total cholesterol, and fibrinogen, WHR was only significantly associated 
with peripheral vascular disease in females and neuropathy in males.  In looking at the impact of 
weight gain in the EDC population, Williams et al (108) observed that after seven years of 
follow-up, although the prevalence of overweight was lower than in the general population, the 
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incidence of overweight was similar.  Those who gained the most weight had the greatest 
improvement of glycemic control.  Weight gain with improved glycemic control was associated 
with an improved lipid and blood pressure profile, i.e. CAD risk factors, while weight gain in the 
absence of improved glycemic control was associated with a worsening of lipid and 
hemodynamic factors.  Overall, although weight gain was associated with an improvement in 
glycemic control, it was also associated with an increased incidence of hypertension and overt 
nephropathy. 
These data concerning the interaction between weight gain and improvement in glycemic 
control with contrast to the results from the DCCT which showed that participants on intensive 
insulin therapy who gained the most weight had a worse cardiovascular lipid risk profile at the 
end of follow-up (5), suggesting that they might be at increased risk of CAD.  A similar more 
detailed observation was made by Sibley et al (109) in a subgroup of the DCCT participants five 
years after the close of the trial.  An atherogenic lipid profile was observed in those with central 
adiposity. 
Adiposity, particularly visceral adiposity, has been found to be associated with coronary 
artery calcification (CAC), a subclinical marker of atherosclerosis.  Allison and Wright (110) 
found higher calcification to be associated with higher abdominal visceral fat and higher 
quartiles of BMI in both men and women.  CAC in the EDC population was shown to be highly 
predictive of future clinical CAD (111). 
Stuhldreher et al (112) cross-sectionally found WHR, a marker of visceral adiposity, to 
be positively associated with total and LDL cholesterol and triglycerides, i.e., CAD risk factors, 
in the EDC cohort, implicating WHR in insulin resistance in this population.  The mechanism 
whereby overweight and obesity may increase CAD risk is via an altered lipid and adipokine 
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profile, increased secretion of FFAs, and insulin resistance.  Higher triglyceride and FFA 
production may result in increased lipid deposition in the coronary arteries.  Additionally, higher 
levels of adipokine secretion and other inflammatory markers may also lead to atherosclerotic 
plaque build-up as well as to insulin resistance.  Coronary artery disease is the leading cause of 
death in type 1 diabetes.  In the EDC population, adiposity has been related to complications (9, 
113, 114), in particular, WHR with CAD.  
As stated just above, CAD is the number one cause of mortality in T1D.  Although 
adiposity appears to be associated with many chronic diseases, there is some evidence that this 
relationship may not be so straightforward, particularly in the most chronic complication of them 
all, mortality.  Jarret and Shipley (115) found BMI to be nonsignificantly negatively associated 
with coronary heart disease mortality (OR=0.29, 0.7-1.1) after ten years in 168 middle-age civil 
service men, more than one-third of whom had T1D.  Similarly, in the EDC population, there 
was a non-significant inverse relationship between BMI and mortality in both men and women 
(men: OR=0.89, 0.7-1.2; women: OR=0.82, 0.6-1.2) during six years of follow-up (116).  A 
revisit of the CDC study looking at annual excess deaths associated with obesity found that being 
overweight (BMI 25.0-29.9) was actually associated with 86,094 fewer deaths than being of 
normal weight (BMI 18.5-24.9).  Furthermore, contrary to expectations, being in the obesity 
class 1 category (BMI 30.0-34.9) was associated with fewer deaths than being underweight (30).  
The relationship between BMI and mortality was not linear, but rather had a U-shaped 
distribution. 
The previously mentioned studies demonstrating an effect on BMI or WHR with 
complications of T1D were not designed specifically to do so; therefore a non-linear relationship 
may not have been accounted for.  Going back to the ‘thrifty-gene’ hypothesis, nonsignificant  
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inverse relationship between BMI and mortality in those with diabetes and the U-shaped 
distribution in the general population seem to indicate that the adiposity-disease relationship is 
muddled, particularly in the context of a pre-existing disease.  Those ‘thrifty genes’ may not be 
entirely outdated. 
 
2.5 CONCLUSION AND RATIONALE 
Obesity’s impact on disease is not clear.  The ability and manner in which overweight and 
obesity affects health may be different in T1D, where the key hormone, insulin, has to be 
systemically administered.  Furthermore, the association between obesity and complications in 
T1D may be complicated by the effect of intensive insulin therapy.  Many of the studies looking 
at obesity in T1D have been cross-sectional.  Additionally, it is not clear whether overweight and 
obesity are associated with an increased mortality in T1D.  While overweight/obesity in general 
is a ‘maladaptation to overnutrition of genes selected to survive undernutrition’ (27), it is not 
known whether the same is true in type 1 diabetes (T1D) or whether it is the proper adaptation to 
a chronic emergency state.  Perhaps those with T1D who are ‘well-adapted to privation’ are 
better able to survive when privation is less of a problem.   
Although there is some evidence that the prevalence of overweight and obesity are 
increasing in T1D, time trends in weight change have not been well studied in this population 
nor whether overweight and obesity are associated with an altered risk of diabetes complications.  
Additionally, the impact of overweight and obesity on overall survival in T1D has not been 
investigated.  Therefore, the purpose of the proposed study is to investigate these aspects of 
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overweight and obesity in T1D, namely the prevalence, incidence, and time trends, and the 
associations with complications, specifically coronary artery disease and mortality.  A further 
component will focus on possible mediators, e.g. FFA. 
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3.0  SPECIFIC AIMS 
The proposed research was to investigate the role of overweight and obesity in the complications 
of type 1 diabetes in a cohort of 658 individuals with childhood onset childhood diabetes from 
the Pittsburgh Epidemiology of Diabetes Complications Study.  Specifically, this research 
proposed: 
1.  To assess time trends in overweight and obesity and predictors of weight gain 
in T1D. 
 The following null hypotheses were tested: 
  Hypothesis 1:  Overweight is not increasing in T1D. 
  Hypothesis 2:  Obesity is not increasing in T1D.   
Hypothesis 3: Overweight and obesity are not increasing in T1D after 
controlling for intensive insulin therapy. 
 
2.  To determine whether overweight or obesity was associated with mortality in 
type 1 diabetes.  The following null hypotheses were tested: 
Hypothesis 4: Overweight is not associated with risk of mortality in T1D. 
Hypothesis 5: Obesity is not associated with risk of mortality in T1D. 
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Hypothesis 6:  Any association of overweight/obesity with mortality in 
T1D is not independent of standard correlates of overweight/obesity, 
including blood pressure, dyslipidemia, and intensive insulin therapy. 
 
3.  To determine the role of free fatty acids in explaining any association of 
         adiposity with coronary artery calcification in T1D.  The following null 
         hypothesis was tested: 
Hypothesis 7: There is no significant difference in the commonly used 
measurements of overweight and obesity and their association with 
coronary artery calcification.  
Hypothesis 7: Free fatty acids do not attenuate the association of adiposity 
with coronary artery calcification in T1D. 
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4.0  METHODS 
4.1 STUDY POPULATION 
In order to answer the above questions, data from the Pittsburgh Epidemiology of Complications 
(EDC) Study, Phases I and II were investigated.  The EDC study is an observational cohort study 
of 658 individuals with childhood onset type 1 diabetes first diagnosed at Children’s Hospital in 
Pittsburgh between 1950 and 1980.  The study began in 1986 with baseline exams between 1986 
and 1988 and has involved continuous biennial follow-up.  At study baseline, mean age and 
duration were 28 and 19 years, respectively.  As of July, 2006, a total of 132 subjects had died, 
21 had requested no further contact, and 36 had been lost to follow-up.  The study was in its 
18th-year of follow-up.   
 
4.2 SPECIFIC AIM 1: TIME TRENDS IN OVERWEIGHT AND OBESITY IN TYPE 
1 DIABETES 
Study design and hypotheses 
The purpose of Specific Aim 1 was to assess time trends in overweight and obesity and 
predictors of weight gain in T1D.  The following null hypotheses were tested: 
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Hypothesis 1:  Overweight is not increasing in T1D. 
 Hypothesis 2:  Obesity is not increasing in T1D.   
Hypothesis 3: Overweight and obesity are not increasing in T1D after controlling 
for intensive insulin therapy. 
 
Population, Study Design, and Time Period 
The population for Specific Aim 1 consisted of the entire EDC cohort.  This was a 
longitudinal study cohort design.  The study time period was from 1986-2007.   
 
Method of data collection 
Time trends in weight change and BMI category from study baseline to 18 years of 
follow-up were investigated.  Correlates of baseline BMI category and risk factors for change in 
BMI category were assessed.  In this substudy, BMI categories were defined as follows: 
BMI<20: Underweight.  20≤BMI<25: Normal weight.  25≤BMI<30: Overweight.   
BMI≥30: Obese.   
All data were collected by biennial surveys and medical exams.  Before attending each 
cycle of examinations, information was collected by questionnaire concerning demographic 
characteristics, medical history, and health care behaviors.  At each cycle, both a standardized 
medical history and clinical examination were performed by a trained internist to document 
complications of diabetes. 
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Anthropometric data 
During biennial exams, participants were weighed in light clothing on balance beam 
scale.  Height was measured using a wall-mounted stadiometer.  Body mass index was calculated 
as the weight in kilograms divided by the square of the height in meters.  For the first ten years 
of follow-up, all height and weight were measured.  Beginning in 1998, exams were limited to 
certain subgroups, so measured height and weight data were not fully available.  Between 2004 
and 2007, an eighteen year follow-up exam was again made available to all participants.  Self-
reported data from the medical history questionnaire were used when measured data were not 
available.  
Lipid, Glucose, and Hemodynamic data 
Fasting blood samples were assayed for lipids, lipoproteins, hemoglobin (HbA1), 
creatinine, and Hct.  High-density lipoprotein (HDL) cholesterol was determined by a heparin 
and manganese procedure, a modification of the Lipid Research Clinics method (117).  
Cholesterol was measured enzymatically (118), as were triglycerides. Low-density lipoprotein 
(LDL) cholesterol levels were calculated from measurements of the levels of total cholesterol, 
triglycerides, and HDL cholesterol.  Stable glycosylated HbA1 was originally measured in 
saline-incubated samples by microcolumn cation exchange chromatography (Isolab, Akron, 
Ohio, USA).  On October 26, 1987, the method was changed to high-performance liquid 
chromatography (HPLC) (Diamat, Bio-Rad Laboratories, Hercules, CA, USA).  The two 
methods were highly correlated (r = 0.95; Diamat HbA1 = 0.18±1.00 Isolab HbA1).  Beginning 
in 1998, HbA1c was measured using the DCA2000 analyzer.  Original HbA1 (1986 to 1998) and 
A1c (1998 to 2004) were converted to Diabetes Control and Complications Trial (DCCT) aligned 
HbA1c values using regression formulas derived from duplicate analyses (DCCT HbA1c = [0.83 * 
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EDC HbA1] + 0.14; DCCT HbA1c = [EDC HbA1c − 1.13]/0.81).  Blood pressure was measured 
by a random-zero sphygmomanometer according to a standardized protocol (119) after a 5-
minute rest period.  Blood pressure levels were analyzed, using the mean of the second and third 
readings.   
 
Variables 
The variables used and how they were analyzed are listed in Table 4-1 below. 
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Table 4-1.  Variable List for Specific Aim 1. 
 
Dependent Variables 
 Type 
BMI (weight in kg/ht in m^2) Continuous/ Categorical 
Independent Variables 
 Type  
Age (years) Continuous/Categorical 
Diabetes Duration (years) Continuous 
HbA1, HbA1c (%) Continuous 
Insulin Injections (#) Continuous/Categorical 
Insulin Dose (U/kg/dy) Continuous 
SBP (mm Hg) Continuous 
DBP (mm Hg) Continuous 
Hypertension Categorical 
HDLc (mg/dL) Continuous 
non-HDLc (mg/dL) Continuous 
Estimated Glucose Disposal Rate (mg/kg/min) Continuous 
Kilocalories (kcal/wk) Continuous 
History of Smoking Categorical 
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Statistical Analysis 
All software analyses were performed using SAS software (version 9.1; SAS Institute, 
Cary, NC) with a significance level of p < 0.05.  Simple percentages were used to determine the 
prevalence and incidence of overweight and obesity.  Pearson’s and Spearman’s correlations 
Cochran-Mantel-Haenszel chi-square tests were used to test for trends in continuous and 
categorical variables, respectively, across BMI categories for a given time period.  Simple linear 
regression, generalized linear models, and Cox proportional hazards models were used to 
determine the predictors of weight change. 
 
 
4.3 SPECIFIC AIM 2: OVERWEIGHT AND OBESITY AND COMPLICATIONS IN 
TYPE 1 DIABETES 
 
Population, Study Design, and Time Period 
The population for Specific Aim 2 consisted of the entire EDC cohort.  This substudy used a 
longitudinal cohort design.  The study time period was from 1986-2007.   
 
Method of data collection 
Methods for the collection of body mass index, blood glucose, and hemodynamic 
measurements were described above.  Waist circumference measurements were taken by a 
standard medical measuring tape, measuring from the mid-point of the iliac crest and the lower 
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costal margin in the mid-axillary line.  Waist circumference measurements were taken at the 1st 
and 2nd, 5th through 9th (18-year follow-up) medical exams.  Creatinine clearance and albumin 
excretion rate was estimated from timed urine collections.   
Nephropathy status was be determined based on consistent results from at least two of 
three timed urine collections (24-hour, overnight, random timed post-clinic) and urine and 
albumin excretion rate (AER).  Urinary albumin was determined immunonephelometrically.  
Overt nephropathy was defined as an AER ≥200μg/min or end-stage renal disease (ESRD; renal 
dialysis or transplant).  CAD was defined as myocardial infarction, ischemia (Minnesota Codes 
1.1-1.3, 4.1-4.3, 5.1-5.3 and 7.1), or fatal CAD verified from death certificates, autopsy and/or 
medical records using standard criteria, revascularization, or EDC clinic diagnosed angina.  
Proliferative retinopathy was determined by stereoscopic fundus photographs taken in fields 1, 2, 
and 4 and read and classified by the Fundus Photography Center as the University of Wisconsin-
Madison.  Lesions were classified by the Arlie House system.  Symptomatic autonomic 
neuropathy was determined by an abnormal heart rate response to deep breathing (expiration-
inspiration ratio less than 1.1) and two or more symptoms of autonomic neuropathy assessed in 
the physician’s exam based on the DCCT standardized clinical protocol (120). Confirmed distal 
symmetric polyneuropathy was determined based on the DCCT protocol for distal symmetrical 
polyneuropathy (121) and confirmed by an abnormal age-specific vibratory threshold.  Lower 
extremity arterial disease was defined as an ankle-brachial index <0.8, claudication, or 
amputation.  All deaths and hospitalized cardiovascular events were investigated by obtaining 
autopsy, coroner, or medical records.  Deaths were clarified by two physicians (TO, JF) 
according to DERI procedures.  Supplementary data were obtained on some CVD hospitalized 
events.  
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Variables 
The variables used and how they were analyzed are listed in Table 4-2 below. 
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Table 4-2.  Variable List for Specific Aim 2. 
 
                                                            Dependent Variables 
 Type 
Mortality Dichotomous 
Independent Variables 
Independent Variables Type 
BMI (kg/ m²) Continuous/ Categorical 
Waist Circumference (cm) Continuous/ Categorical 
Coronary Artery Disease Dichotomous 
Overt Nephropathy Dichotomous 
Lower Extremity Arterial Disease Dichotomous 
Proliferative Retinopathy Dichotomous 
Symptomatic autonomic Neuropathy Dichotomous 
Distal Symmetrical Polyneuropathy Dichotomous 
Age (years) Continuous/Categorical 
Diabetes Duration (years) Continuous 
HbA1, HbA1c (%) Continuous 
Insulin Injections (#) Continuous/Categorical 
Insulin Dose (U/kg/dy) Continuous 
SBP (mm Hg) Continuous 
DBP (mm Hg) Continuous 
Hypertension Categorical 
HDLc (mg/dl) Continuous 
non-HDLc (mg/dL) Continuous 
Physical activity (kcal/ week) Continuous 
History of Smoking Categorical 
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Statistical Analyses 
T-tests and chi-square frequencies were used to test for baseline differences in continuous 
and categorical variables, respectively, by the prevalence of overweight and obesity.  Time-
dependent Cox Models were used to determine the relationship of BMI category and waist 
circumference with mortality. 
 
4.4 SPECIFIC AIM 3:  FREE FATTY ACIDS: THEIR IMPACT ON CORONARY 
ARTERY DISEASE IN TYPE 1 DIABETES 
 
Population, Study Design, and Time Period 
The population for Specific Aim 3 consisted of 315 participants in the EDC study who 
completed medical exams during the 16-year and 18-year follow-up period, i.e. 2000-2007.  This 
substudy utilized a cross-sectectional study design.   
 
Method of data collection 
The data for Specific Aim 3 was collected in the same manner as that for Specific Aims 1 
and 2.  Additionally coronary artery calcification and direct measurements of abdominal 
adiposity (visceral and total adipose tissue surface area) were measured by electron beam 
tomography scanning (Imatron C150).  Scans of abdominal adiposity were taken between the 
fourth and fifth lumbar regions. FFAs from stored blood samples, collected at 16 year follow-up 
exam, were analyzed to determine their association with adiposity and coronary artery 
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calcification in T1D.  FFAs were assayed using the in vitro colorimetric method using the NEFA 
C test kit (Wako Pure Chemical Industries, Ltd) in the Heinz Laboratory of the University of 
Pittsburgh, Graduate School of Public Health.   
 
Variables 
The variables used and how they were analyzed are listed in Table 4-3 below. 
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Table 4-3.  Variable List for Specific Aim 3. 
 
Variables Measurement Test 
Independent  GLM/Logistic regression 
Visceral abdominal adiposity (cm²) Categorical  
Subcutaneous abdominal adiposity (cm²) Categorical  
Body mass index (kg/m²) Categorical  
Waist Circumference (cm) Dichotomous/Categorical  
Free fatty acids (mmol/L) Continuous  
   
Dependent   
CAC (volume score) Continuous/Dichotomous  
Covariates  GLM/Logistic 
regression/student’s T/ 
Wilcoxin’s rank 
Age  (years) Continuous  
Diabetes Duration (years) Continuous  
HBA1c (%) Continuous  
 Insulin Injections (#) Continuous/  
Insulin Dose (U/kg/dy)) Continuous  
Estimated glucose disposal rate  continuous  
SBP (mm Hg) Continuous  
DBP (mm Hg) Continuous  
HDL (mg/dl) Continuous  
non-HDLc (mg/dL) Continuous  
History of Smoking Categorical  
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Statistical Analysis 
SAS software (version 9) was used to conduct the statistical analysis.  The Student’s t test 
was used to compare normally distributed variables and Wilcoxon’s rank test was used to 
calculate non-normally distributed variables.  ORs and 95% confidence intervals were calculated 
using Logistic regression.  Generalized linear models and logistic regression were used to assess 
the association of adiposity with coronary artery calcification.  
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5.1 ABSTRACT 
Background: Time trends in overweight and obesity in the general population have been well 
documented; however, such temporal patterns in populations with pre-existing disease, such as 
type 1 diabetes (T1D), have not been as thoroughly investigated.   
Methods: We therefore assessed the time trends in overweight and obesity and predictors of 
weight change in 655 individuals from the Pittsburgh Epidemiology of Diabetes Complications 
(EDC) Study, a cohort of childhood onset (age <17 years) type 1 diabetes.  Participants were first 
seen in 1986-1988, when mean age and diabetes duration at study baseline were 28 and 19 years, 
respectively, and biennially thereafter for up to 18 years.  Body mass index (BMI) was calculated 
as the weight in kilograms divided by the square of the height in meters.  Overweight was 
defined as a BMI between 25 and 29.9kg/m².  Obese was defined as a BMI less than 30 kg/m².  
Results: At baseline, the prevalence of overweight and obesity were 28.6% and 3.3%, 
respectively. After 18 years of follow-up, the prevalence of overweight increased by 47% while 
the prevalence of obesity increased 7-fold.  Seven percent of the population was on intensive 
insulin therapy (3+ insulin injections per day or on insulin pump) at baseline; by 2004-2007, this 
had increased to 82%.  Predictors of weight change were a higher HbA1c at baseline, 
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symptomatic autonomic neuropathy (inversely), overt nephropathy (inversely), and going onto 
intensive insulin therapy during follow-up.   
Conclusion: These data demonstrate dramatic weight gain in type 1 diabetes and underscore the 
complexity of weight change in this disease. 
5.2 INTRODUCTION 
Time trends in overweight and obesity in the general population have been well documented (1, 
2, 3); however, such temporal patterns in populations with pre-existing disease, such as type 1 
diabetes (T1D), have not been as thoroughly investigated.  Traditionally, the phenotype of T1D 
was normal or underweight; however, there is evidence that this may be changing.  A lower 
prevalence of overweight and obesity in the Pittsburgh Epidemiology of Diabetes Complications 
(EDC) Study, relative to the general population has been reported, although the incidence (12%) 
in both populations was similar over a mean of 7 years of follow-up (4).   
The effect of weight gain on cardiovascular risk factors in T1D diabetes has been noted 
to interact with intensive insulin therapy and improved glycemic control.  Reports from the 
Diabetes Complications and Control Trial/ Epidemiology of Diabetes Interventions and 
Complications Study (DCCT/EDIC) (5) and the EDC (4) study have demonstrated an adverse 
lipid and hemodynamic profile with increased adiposity as well as cross-sectional associations 
with long-term complications (6).  However, the EDC study also showed that excess weight in 
association with improved glycemic control was less harmful in terms of cardiovascular disease 
risk profile (4).  As T1D is a disease characterized by insulin deficiency leading to an abnormal 
fuel utilization and acute complications such as ketoacidosis, weight loss, or a lower weight, may 
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partially reflect inadequate insulin therapy.  Furthermore, some of the long term complications 
like neuropathy and nephropathy may also be associated with anorexia, wasting, and weight loss.  
Thus the causes, and consequences, of weight change in T1D may be different than in the 
general population, and add complexity to the concern about a rise in overweight and obesity in 
T1D.   
The purpose of this report was therefore to extend our previous EDC follow-up and 
determine the prevalence and incidence of overweight and obesity over eighteen years of follow-
up, as well as to identify potential risk factors for weight gain in T1D.  In an accompanying 
report we describe the impact of adiposity and change in adiposity on mortality. 
 
5.3 METHODS 
The EDC study is a prospective study of a well-defined cohort (n=658) with childhood-onset 
(<17 years) type 1 diabetes, first diagnosed between January 1, 1950 and May 30, 1980 at 
Children’s Hospital of Pittsburgh.  Participants were first seen for baseline examination between 
1986 and 1988 and biennially thereafter for ten years, after which they were followed by survey 
with exams limited to certain subgroups.  Between 2004 and 2007, an eighteen year follow-up 
was conducted for all participants.  The design and methods of the study have been previously 
described (7).  Participants were followed for up to eighteen years.  For this report, because of 
the variability introduced by the growth spurt, and differing body compositions in children and 
adolescents, we focus on the population 18 years and older (n=589 at baseline). 
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Before each cycle of examinations, information was collected by questionnaire 
concerning demographic characteristics, medical history, and health care behaviors as previously 
reported (7).  Participants were weighed in light clothing and without shoes on a balance beam 
scale.  Height was measured using a wall-mounted stadiometer.  Body mass index (BMI) was 
calculated as the weight in kilograms divided by the square of the height in meters.  Beginning in 
1998, where height and weight data were less available from follow-up clinical exams, self-
reported data from the medical history questionnaire were used, representing approximately 20% 
of the data for this time period.  Overweight was defined as a BMI ≥25 kg/m².  Obesity was 
defined as a BMI ≥30 kg/m².  Weight change was defined as the difference between baseline 
BMI and BMI at last follow-up.    Only measured height and weight were used to determine 
weight change.   
Fasting blood samples were assayed for lipids, lipoproteins, and glycosylated 
hemoglobin.  Stable glycosylated hemoglobin A1 (HbA1) was originally measured in saline-
incubated samples by microcolumn cation exchange chromatography (Isolab, Akron, Ohio, 
USA).  On October 26, 1987, the method was changed to high-performance liquid 
chromatography (HPLC) (Diamat, Bio-Rad Laboratories, Hercules, CA, USA). The two methods 
were highly correlated (r = 0.95; Diamat HbA1 = 0.18±1.00 Isolab HbA1).  Beginning in 1998, 
HbA1c was measured using the DCA2000 analyzer.  Original HbA1 (1986 to 1998) and A1c 
(1998 to 2004) were converted to DCCT aligned HbA1c values using regression formulas derived 
from duplicate analyses (DCCT HbA1c = [0.83 * EDC HbA1] + 0.14; DCCT HbA1c = [EDC 
HbA1c − 1.13]/0.81).  Insulin dose was defined as the total daily units of insulin divided by the 
body weight in kilograms.  Intensive insulin therapy was defined as having three or more insulin 
injections per day or using an insulin pump.  A family history of type 2 diabetes was defined as 
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diabetes diagnosed after the age of 30 in a first degree relative without immediate insulin use.  
Physical activity was determined by number of flights climbed per day, city blocks or equivalent 
walked per day, and mets calculated from sports/exercise*minutes of participation*number of 
times per week.  Physical activity is expressed in kilocalories.   
 
                                               5.4      STATISTICAL ANALYSES 
The validity of the reported weight was assessed by conducting a Pearson’s correlation test 
between the measured and reported weight of all participants providing both.  Self-reported and 
measured BMI were highly correlated in both 2000-2004 (intraclass correlation=0.92, 0.10-
0.94), median difference=0.4 kg/m²) and 2004-2007 (intraclass correlation=0.82, 0.05-0.85), 
median difference 0.7 kg/m^2).   
Mixed models analyses were used to determine the association of age group cohort with 
average weight change.  Weight change was defined as BMI at last follow-up controlled for 
baseline BMI.  Generalized linear models were used to assess the determine predictors of weight 
change.  All analyses were adjusted for follow-up time.  Cox proportional hazards models were 
used to determine predictors of time to the first gain of 5 kg/m² or loss of 2 kg/m² loss, while 
controlling for baseline BMI.  Results are expressed as per standard deviation change in 
continuous independent variables.  Generalized linear models were used to determine differences 
in continuous variables by BMI category and to test for a linear trend across BMI category.  
Linear regression analysis with stepwise selection was used to determine the independent 
predictors of final BMI.  Chi square analyses were used to determine differences in dichotomous 
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variables by BMI category and to test for a linear trend across BMI category.  All analyses were 
conducted using SAS version 9.1 (Cary, North Carolina). 
               5.5      RESULTS 
Participants were followed for a median of 18 years (range: 1.5-20.6 years), with follow-up data 
for 95% of the original cohort.  Mean and median increase in BMI over the course of follow-up 
was 2.6 and 2.2 kg/m², respectively, ranging from a change of -6.7 to a change of 29.3 kg/m².  
This did not vary by sex (p=0.96).  One hundred and eighty-three participants gained five or 
more kg/m² over the course of follow-up.  Twenty-six participants had a gain of ten or more 
kg/m².  Seven percent of the population was on intensive insulin therapy (IIT) at baseline; by 
2004-2007, this had increased to 82% and median insulin injection frequency among non pump 
users increased from 2 to 3.7 per day. 
Overall 3.3 % of the participants aged 20 years and older were obese in 1986-1988.  By 
2004-2007 this had risen seven-fold to 22.7%.  The prevalence of being overweight, but not 
obese, rose from 28.6% in 1986-1988 to 42.0% in 2004-2007, a 47% increase. The combined 
prevalence of overweight and obesity increased by an average of 1.8% per year.   Figures 5-1 
and 5-2 show the time trends in the prevalences of being overweight and obese and the use of 
IIT.  As these data maybe influenced by the aging of the cohort and survivorship, age specific 
prevalences of underweight, normal weight, overweight, and obese were also examined 
(Appendix C) for age-specific groupings by time-period.   
As an example, Table 5-1 presents these data for the 40-49 year-old age group, 25% of 
whom were overweight or obese in 1986-1988.  By 2004-2007, 68.2 % in that age group were 
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overweight or obese.  Appendix C shows both full age and gender prevalences by time period.  
Time trends were similar in men and women.  Mixed models analyses of variance revealed no 
age related effect on average BMI over the eighteen years (p=0.51, 0.10, 0.32 for those aged 
<20. 20-29, 30-39 respectively, relative to those aged 40-49) (Appendix C). 
The incidence of overweight and obesity were also examined.  In those with a BMI <25 
in 1986-1988, the incidence of being overweight or obese was 49.1%, while the incidence of 
obesity, for those with a BMI <30 at baseline, was 20.9%, during the 18 years of follow-up.  
Twenty percent of the population gained at least 5 kg/m² over the course of follow-up; seven 
percent loss at least 2 kg/m². 
The baseline predictors (and subsequent use of intensive insulin therapy) of change in 
BMI from baseline to last follow-up are shown in Table 5-2.  A higher HbA1c at baseline and 
the subsequent use of intensive insulin therapy during follow-up were predictive of weight gain, 
while overt nephropathy and symptomatic autonomic neuropathy predicted weight loss.  In 
multivariable linear regression analyses with stepwise selection, intensive insulin therapy was 
reduced to marginal significance (p=0.07) and overt nephropathy was not selected as an 
independent predictor (Table 5-3).    
Baseline predictors of a 5 kg/m² gain or a 2 kg/m² loss are presented in Appendix C.  
After multivariable adjustment, independent predictors of a 5 kg/m² gain were low annual 
household income (HR=1.63, 1.08-2.47) and alcohol consumption (HR=0.53, 0.31-0.91).  
Independent predictors of a 2 kg/m² loss were female sex (HR=3.57, 1.57-8.14), HbA1c 
(HR=1.62, 1.13-2.32), overt nephropathy (HR=327, 1.58-6.75), symptomatic autonomic 
neuropathy (HR=5.80, 2.13-15.78), and smoking (HR=2.79, 1.28-6.06). 
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Tables 5-4 and 5-5 present selected cardiovascular and mortality risk factors by BMI 
category at baseline and the 18th year follow-up exam.  At baseline there was a significant linear 
trend by BMI category for use of intensive insulin therapy, systolic and diastolic blood pressures, 
HDL (inverse) and non-HDL cholesterol, and smoking (inverse).  These trends for intensive 
insulin therapy, systolic blood pressure, and smoking were no longer evident at the 18th year of 
follow-up, although it remained for diastolic blood pressure.  At the 18th year of follow-up, a 
trend for age emerged, although this appeared to be due to the significantly higher age in the 
underweight.  Additionally, although a significantly higher HDL and lower non-HDL cholesterol 
were observed in the overweight relative to the normal weight at baseline, this had disappeared 
by the 18th year of follow-up, although the obese were at increased at the 18th year of follow-up.  
Finally, at the 18th year of follow-up, systolic blood pressure in both the overweight and the 
obese were significantly higher than the normal weight, although no linear trend was observed as 
systolic blood pressure in the underweight was similar to that of the overweight and obese.   
5.6 DISCUSSION 
Several important findings emerge from these analyses of long-term time trends in weight 
change in type 1 diabetes.  First, the prevalence of being overweight or obese is increasing in 
type 1 diabetes.   Second, we have shown that the percentage on intensive insulin therapy 
increased nearly 10 fold during the course of follow-up, an increase which parallels that of being 
overweight or obese.  Finally, we have shown that traditional predictors of weight change, that 
is, smoking, and socioeconomic status appear to be less operant in type 1 diabetes while diabetes 
complications have a major impact on weight change. 
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We have previously shown a lower prevalence of overweight/obesity in the EDC study 
relative to the general population, although the incidence (12%) in both populations was similar 
after a mean of 7 years of follow-up (4).  The rise in adiposity in EDC appears to be independent 
of aging itself as our data have demonstrated similar increases in overweight and obesity in age-
specific strata (Table 5-1).  After 18 years of follow-up, the prevalence of overweight in type 1 
diabetes appears to have increased at a faster pace than in the general population.  At baseline 
(1986-1988), the combined prevalence of overweight and obesity in our population was much 
lower than the general population (31.9 vs. 55.9) (8); by 2004-2007 there was no difference in 
the two populations (64.6 vs. 66.3, EDC vs. NHANES 2003-2004).  Similarly, the prevalence of 
obesity in our population increased 7-fold, from 3.3 % to 22.7%.  In the DCCT, weight gain was 
also apparent, with mean BMI rising from approximately 23 kg/m² to approximately 26 kg/m² 
over nine years of follow-up (9).   
 There are several possible reasons for the rising prevalence of overweight and obesity 
observed in our population.  First of all, there is in the total cohort a healthy survivor effect.  By 
the end of follow-up, 22% of the population had died.  Thus, as overt nephropathy and 
symptomatic autonomic neuropathy are associated with weight loss, the survivors are biased 
toward weight gain.  It is likely that those remaining (n=379) in 2004-2007 represents a 
substantially survival biased cohort.   
Insulin itself promotes weight gain in that it stimulates lipogenesis, inhibits protein 
catabolism, and slows down basal metabolism.  This, in combination with the abnormal 
physiological route of insulin via its peripheral insulin administration in those with T1D, which 
is also associated with a reduced energy metabolism (10,11), is likely to relate to the well known 
weight gain with the advent of intensive insulin therapy.  This seems to be evidenced in our data 
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by the marked increase in obesity after 1996-1998 (Figure 5-1) reflecting a dramatic increase in 
intensive insulin therapy post DCCT results.  At baseline, only 7.2 % of our participants were on 
intensive insulin therapy, but by 2004-2007 82% were on intensive insulin therapy (Figure 5-2).  
The United Kingdom Prospective Diabetes Study (UKPDS), aimed at assessing the benefits of 
lowering glycemia in type 2 diabetes, also demonstrated that those in the intensive treatment arm 
gained an average of 3 kg more than those in the conventional treatment arm during the ten years 
of follow-up (12).   
Weight gain associated with insulin therapy in type 1 diabetes might be traditionally 
viewed as a normalization of weight, i.e. the correction of glucosuria, diuresis, and/or catabolism 
(wasting) with the initiation of insulin therapy.  Consistent with this, we found that a higher 
baseline HbA1c was predictive of a 2kg/m² weight loss, independent of complications associated 
with wasting and poor glycemic control, namely overt nephropathy and symptomatic autonomic 
neuropathy. However, the association of HbA1c with weight change in our population was also a 
positive predictor of weight gain, a finding consistent with the DCCT (5). We have also 
previously shown that those with the worst glycemic control at baseline showed the greatest 
glycemic improvement after an average of 7 years.  This group also gained the greatest amount 
of weight (4), indicating a reversal of the catabolism.  Nevertheless, the anabolic role of insulin 
itself appears to be quite strong as others have reported an association between weight gain and 
daily insulin dosage (13). 
Income, education, physical activity, and smoking, all inverse risk factors for obesity in 
the general population (14,15,16), were not associated with absolute weight change from 
baseline to last follow-up, although low income was predictive of gaining 5 kg/m² during follow-
up.  In type 1 diabetes, the advantages that income and education offer in reducing the risk of 
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overweight and obesity may be offset by the increased access they provide to insulin and 
intensive insulin therapy.  Likewise, the same may be operant in the relationship of smoking with 
weight change in type 1 diabetes.  Smokers may be more likely to be of a lower socioeconomic 
status and therefore affected by the same competing influences on weight change.  Although 
smoking was not predictive of absolute weight change from baseline to last follow-up, it was 
predictive of a 2kg/m² weight loss.  Physical activity, however, was protective against a 2kg/m² 
weight loss during follow-up.  In type 1 diabetes, physical activity may reflect both health and 
morbidity.  That is, it may reflect increased leisure time activity in sports or other types of 
exercise.  Conversely, it may reflect increased morbidity from complications that are part of its 
natural history, suggested its inverse relationship with a 2 kg/m² weight loss.  Finally, alcohol 
consumption, though not associated with absolute weight change from baseline to last follow-up, 
was protective against excessive (5 kg/m²) weight gain.  In the general population as well, 
inconsistent associations between alcohol consumption and weight gain are observed (17, 18, 
19). 
Weight change in type 1 diabetes is thus complex.  The increasing prevalence of 
overweight and obesity may reflect both the anabolic effects of insulin and the “normalization” 
of the population that intensive insulin therapy allows, i.e., allowing it to follow the temporal 
trend occurring in the background population.  This increasing prevalence occurred in the face of 
both overt nephropathy and symptomatic autonomic neuropathy at baseline, complications part 
of the natural history of type 1 diabetes and associated with subsequent weight loss.  Indeed, 
although twenty-two % of our population demonstrated a negative weight change, reflecting the 
negative impact that these complications have on weight change in type 1 diabetes, mean weight 
gain in this population was still 2.6 BMI units over an 18 year period.    
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Finally, we have shown, in every BMI category, an attenuation over time of the risk 
posed by some CVD and mortality risk factors and, with the exception of diastolic blood 
pressure, a loss of the trend in risk across BMI category.  This is suggestive of better health care 
overall, in every BMI category.  It is possible that the concomitant rise in overweight and obesity 
in intensive insulin therapy in type 1 diabetes is simply mirroring better health care in this 
population and that better health care is allowing a normalization of the type 1 diabetes 
population, such that the same phenomenon occurring in the background population, i.e. a rapid 
rise in overweight and obesity, is also occurring in type 1 diabetes.   However, as we have also 
shown linear trends in the use of intensive insulin therapy by BMI category and that although not 
significant at last follow-up, 90% of the obese were on intensive insulin therapy, the role of 
insulin itself still appears very strong.    
A limitation of these analyses was the inclusion of reported height and weight data in the 
determination of adiposity time trends during the last ten years of follow-up, representing 
approximately 20% of the data for this time period.  Although the R² for the reported and 
measured weight in this population was very high, BMI was underreported by about a half of a 
BMI unit.  Therefore, the prevalence of overweight and obesity for this time period was likely 
underestimated.  However, in the determination of weight change, only measured BMI was used.  
Another major limitation of this study is the substantial survival bias in the population during the 
last two examination periods, a time associated with a marked increase in the prevalence of 
overweight and obesity and the widespread adaptation of intensive insulin therapy.  However, as 
type 1 diabetes is characterized by a very early mortality, this could not be avoided and age 
specific analyses confirmed a major weight gain.   
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Taken as a whole, the results of this study may appear quite alarming as we have 
demonstrated a marked increase in the prevalence of overweight and obesity in type 1 diabetes, 
which is probably greater than in the general population.  However, as overweight and obesity 
increased with time, overweight and obesity may also be a marker of survival.  The effect of 
adiposity and weight gain on mortality, further explored in the accompanying paper, suggests 
that weight gain and the overweight state may not be harmful.  Thus despite the rise of 
overweight and obesity in type 1 diabetes, caution should be used in admonishing patients to lose 
weight or maintain an ideal body weight (BMI <25), particularly in light of the role that insulin 
plays in weight gain and the reduction of complication risk.  
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5.8 FIGURES AND TABLES 
        
 
      Figure 5-1.  Time trends in the prevalence of overweight and obesity in type 1 diabetes. 
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   Figure 5-2.  Time trends in the prevalence of intensive insulin therapy in type 1 diabetes. 
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Table 5-1.  Age-specific Prevalence of Underweight, Normal Weight, Overweight, and Obese for 
those Aged 40-49 Years at Each Time Period, n (%). 
 
 <20 20-24.9 25-25.9 ≥30 
1986-1988 4 (9.1) 29 (65.9) 10 (22.7) 1 (2.3) 
1988-1990 3 (5.8) 29 (55.8) 17 (32.7) 3 (5.8) 
1990-1992 6 (8.5) 43 (60.6) 18 (25.4) 4 (5.6) 
1992-1994 10 (12.2) 39 (47.6) 27 (32.9) 6 (7.3) 
1994-1996 14 (11.9) 58 (49.2) 35 (29.7) 11 (9.3) 
2004-2007 5 (2.9) 51 (30.0) 77 (45.3) 37 (21.8) 
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Table 5-2.  Predictors of Final Body Mass Index (BMI) Adjusted for Baseline BMI and Follow-up 
Time in Adults with Type 1 Diabetes 
 
 BMI change  
 β (SE)  p-value 
Age (years) -0.19 (0.15) 0.21 
Diabetes duration (years) -0.12 (0.15) 0.43 
HbA1c (%) 0.35 (0.15) 0.03 
Insulin dose (U/kg/dy) 0.10 (0.16)  0.54 
Insulin injections/day* -0.02 (0.15) 0.88 
Physical activity (kcal/week)* 0.15 (0.16)  0.35 
Sex (female) -0.16 (0.30) 0.58 
Coronary artery disease -0.21 (0.58) 0.72 
Overt nephropathy         -0.78 (0.35) 0.03 
Proliferative Retinopathy                     0.10 (0.33) 0.76 
Symptomatic autonomic neuropathy                -1.41 (0.61) 0.02 
Distal symmetrical polyneuropathy -0.55 (0.34) 0.11 
Lower extremity arterial disease -0.53 (0.55) 0.34 
Intensive insulin therapy:   
Incident during follow-up vs Never 0.77 (0.37) 0.04 
Family history of T2D                                            0.39 (0.43) 0.36 
Annual Household Income    
<$20,000 0.34 (0.34) 0.31 
Some college                                                         0.006 (0.33) 0.98 
Current smoker                                                       0.08 (0.36) 0.83 
Alcohol consumption:  3+gl/wk                                    -0.36 (0.36) 0.31 
   BMI units=kg/m²*Natural-logarithmically transformed before analysis.   
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Table 5-3.  Predictors of Final Body Mass Index in Adults with Type 1 Diabetes: Multivariable 
Adjusted Linear Regression Model. 
 
 Standardized regression 
coefficient (SE) 
P-value 
HbA1c, % 0.43 (0.18) 0.02 
Initiating intensive insulin therapy after 
baseline 
0.77 (0.42) 0.07 
Symptomatic autonomic neuropathy -1.49 (0.67) 0.03 
Baseline BMI 1.01 (0.06) <0.0001 
Follow-up time 0.16 (0.04) 0.0006 
Intercept -5.62 (2.91 0.05 
 Stepwise selection also allowed for age, insulin dose/kg of body weight, and overt nephropathy. 
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Table 5-4.  Characteristics by Body Mass Index (BMI) Category in Adults 18 Years and Older in 1986-1988, 
% (n), mean (SD), or median (IQR). 
 
Characteristics BMI <20 20≤BMI<25 25≤BMI<30 BMI ≥30 p-trend 
Sex (female), % 57.6 (34) 49.7 (171) 42.8 (71)  70.0 (14) 0.37 
Age (years) 30.2±6.2  29.1±7.1 28.8±6.5 28.8±6.9 0.39 
HbA1c (%) 8.8±1.7 8.8±1.5 8.4±1.3† 8.6±1.1 0.24 
Intensive insulin therapy (%) 0.0 (0) 6.8 (22) 9.4 (15) 10.5 (2) 0.02 
Systolic blood pressure (mm 
Hg) 
109.2 (17.7)† 114.5 (16.8) 117.4 (14.0) 118.6 (16.5) 0.01 
Diastolic blood pressure (mm 
Hg) 
70.1 (12.3) 72.7 (10.7) 76.6 (10.6)¶ 76.4 (12.0) 0.005 
Hypertension (%) 13.6 (8) 17.4 (60) 19.4 (32) 30.0 (6) 0.12 
HDL cholesterol (mg/dL) 55.9 (13.3) 54.8 (13.0) 51.1 (11.8)‡ 50.4 (8.4) 0.03 
Non-HDL cholesterol (mg/dL) 128.8 (35.0) 137.1 (40.8) 146.7 (47.2)† 162.2 (47.4)† 0.0007 
AER* (μg/min), median (IQR) 42.2 (5.6-423.8) 17.4 (7.3-241.4) 22.7 (9.4-297.9) 42.2 (5.8-423.8) 0.65 
Current Smoker (%) 28.8 (17) 27.0 (93) ‡ 15.1 (25) 10.0 (2) 0.001 
    AER=albumin excretion rate   HDL=high density lipoprotein   *Natural logarithmically transformed before analysis 
    significantly different than 20≤BMI<25 at p<0.05.    ‡ significantly different than 20≤BMI<25 at p<0.01. 
   ¶ significantly different than 20≤BMI<25 at p<0.001     § significantly different than 20≤BMI<25 at p<0.0001 
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Table 5-5.  Characteristics by Body Mass Index (BMI) Category in Adults 18 Years and Older in 
2004-2007, % (n), mean (SD), or median (IQR). 
 
Characteristics BMI <20 20≤BMI<25 25≤BMI<30 BMI ≥30 p-trend 
Sex (female), % 69.2 (9) 53.7 (65) 49.1 (78) 51.2 (44) 0.34 
Age (years) 50.4 (6.7) ‡ 44.6 (8.1) 44.6 (7.3) 44.9 (7.1) 0.02 
HbA1c (%) 7.9 (2.2) 7.7 (1.9) 8.0 (1.6) 7.8 (1.6) 0.93 
Intensive insulin therapy (%) 66.7 (8) 81.1 (86) 80.3 (118) 89.6 (69) 0.06 
Systolic blood pressure (mm Hg) 118.8 (14) 111.6 (16.5) 119.1 (15.1) ¶ 119.2 (17.6) ‡ 0.47 
Diastolic blood pressure (mm Hg) 62.4 (15.6) 62.6 (10.0) 68.1 (9.6)¶ 68.5 (12.0)¶ 0.02 
Hypertension (%) 40.0 (4) 26.5 (26) 37.1 (52) 45.7 (37) 0.02 
HDL cholesterol (mg/dL) 65.3 (20.8) 61.9 (16.1) 58.1 (15.8) 54.7 (16.1)‡ 0.03 
Non-HDL cholesterol (mg/dL) 106.0 (23.4) 108.1 (32.3) 117.4 (36.8) 128.4 (39.2) ¶ 0.04 
AER* (μg/min), median (IQR) 4.9 (4.4-7.1) 6.6 (3.8-26.5) 9.2 (4.8-75.7) 12.1 (5.1-57.5) 0.58 
Current Smoker (%) 23.1 (3) 10.0 (12) 12.0 (19) 5.9 (5) .16 
AER=albumin excretion rate   HDL=high density lipoprotein   *Natural logarithmically transformed before analysis 
 significantly different than 20≤BMI<25 at p<0.05.    ‡ significantly different than 20≤BMI<25 at p<0.01. 
¶ significantly different than 20≤BMI<25 at p<0.001     § significantly different than 20≤BMI<25 at p<0.0001 
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6.1 ABSTRACT 
Background: In the general population, adiposity exhibits a J- or U-shaped relationship with 
mortality; however, in catabolic states this relationship is often inversely linear.  We have 
recently documented an age-independent increase in overweight/obesity in the Pittsburgh 
Epidemiology of Diabetes Complications study (EDC) of type 1 diabetes (T1D).  As intensified 
insulin therapy (IIT) may promote weight gain, the impact of weight gain in T1D is critical to 
assess. We therefore assessed the association of adiposity with mortality in 655 EDC 
participants, followed for up to twenty years.   
Methods: Individuals were categorized as underweight (BMI <20), normal (20≤BMI<25), 
overweight (25≤BMI<30), or obese (BMI≥30).  Cox models were constructed using BMI and 
covariates at baseline, updated means during follow-up, time-varying (reflecting most recent 
status), and change during adulthood as predictors of mortality.   
Results: During follow-up, the prevalence of IIT (3+ insulin shots daily and/or pump) increased 
from 7% to 82%.  The prevalence of overweight increased by 47%, while the prevalence of 
obesity increased 7-fold.  There were 146 deaths.  In unadjusted models BMI (modeled 
continuously) demonstrated a quadratic relationship with mortality (p=0.002, <0.0001, <0.0001 
for baseline, updated mean, and time-varying models, respectively).  However, only in the time-
varying model were the obese significantly different from the normal weight.  In both the 
updated mean and time varying models, the underweight were at significantly greater risk than 
the normal weight (p<0.0001 both models), while the baseline model revealed no specific 
differences by BMI category.  The nonlinear relationship of adiposity with mortality remained 
even after adjustment for diabetes complications, biological, or socioeconomic/lifestyle risk 
factors, with the exception of baseline socioeconomic/lifestyle risk factors where a linear 
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association emerged.  Adjustment for waist circumference eliminated the risk in the obese.  
Finally, weight gain was inversely associated with mortality. 
Conclusion: The relationship of adiposity with mortality in T1D now appears to resemble that of 
the general population, albeit with a marked increased risk in those underweight.  While obesity 
shows some relationship with mortality, weight gain appears protective and BMI in the 
overweight, non-obese range does not predict death.  Further study is needed before optimal 
weight goals can be set in T1D. 
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6.2 INTRODUCTION 
Mortality in type 1 diabetes (T1D) is greatly accelerated, occurring several decades earlier than 
in the general population (1, 2, 3, 4, 5).  Although adiposity is associated with increased risk of 
many chronic diseases in the general population (6,7,8,9), there is some evidence that this 
relationship may not be so straightforward, particularly for mortality, where U- and J-shaped 
relationships are often observed (10,11,12,13,14).  Furthermore, within diseased populations, 
increased adiposity is often associated with longer survival (15, 16, 17).   
Within type 1 diabetes, coronary artery disease (CAD) is the leading cause of death 
overall, although renal disease, especially at shorter and medium term durations of diabetes, is 
also a major cause (1, 18, 19).  Chronic complications such as these are part of the natural history 
of type 1 diabetes and thus may confound the relationship of adiposity with mortality.  
Furthermore, in T1D the association of overweight and obesity with mortality may be further 
complicated, as intensive insulin therapy is associated with both weight gain and a reduction in 
complications. 
Few studies have fully investigated adiposity as a risk factor for mortality in T1D.  In the 
studies in which it was considered, adiposity has not been demonstrated to be a risk factor for 
mortality (19, 20, 21), with the exception of Roy et al (22) in which adiposity was associated 
with longer survival.  However, with the marked increase in overweight and obesity and 
therefore a much wider range in adiposity in T1D, this situation may be changing.  This paper 
investigates the association of adiposity with mortality above and beyond the known risk factors 
for mortality in T1D.  To both serve the needs of the practicing clinician and to account for 
confounding and address reverse causation, adiposity is investigated as both a baseline predictor 
and as a function of BMI change over an 18-20 year time period.   
 66 
 
6.3 METHODS 
The Pittsburgh Epidemiology of Diabetes Complications Study is a prospective study based on a 
well-defined cohort of individuals with childhood-onset (<17 years old) type 1 diabetes mellitus.  
There were 658 eligible subjects (325 women and 333 men; 98% Caucasian) diagnosed between 
January 1, 1950, and May 30, 1980, who were first seen between 1986 to 1988; 654 provided 
BMI and some mortality follow-up data.  Mortality follow-up was censored January 1, 2008. 
At biennial cycles of examinations, information was collected concerning demographic 
characteristics, medical history, and health care behaviors as previously described (23,24).  At 
each cycle, both a standardized medical history and clinical examination were performed by a 
trained internist to document complications of diabetes. 
Participants were weighed in light clothing and without shoes on a balance beam scale.  
Height was measured using a stadiometer.  Body mass index (BMI) was calculated as the weight 
in kilograms divided by the square of the height in meters.  For the first ten years of follow-up, 
all height and weight were measured.  Beginning in 1998, exams were limited to certain 
subgroups, so measured height and weight data were not fully available.  Between 2004 and 
2007, an eighteen year follow-up exam was again made available to all participants.  Self-
reported data from the medical history questionnaire were used when measured data were not 
available, representing 83%, 33%, and 19% of the data from the 14th, 16th, and 18th year follow-
up periods.  The validity of the reported height and weight has been reported (Paper 1).   
Underweight was defined as a BMI <20kg/m²; normal weight a BMI ≥ 20 kg/m² < 25 kg/m²; 
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overweight a BMI ≥25 kg/m² < 30 kg/m²; obesity a BMI ≥30 kg/m².  Weight change was defined 
as BMI at the 10-year follow-up exam minus baseline BMI.  
Fasting blood samples were assayed for lipids, lipoproteins, glycosylated hemoglobin 
(HbA1), creatinine, and HCT.  High-density lipoprotein (HDL) cholesterol was determined by a 
heparin and manganese procedure, a modification of the Lipid Research Clinics method.  
Cholesterol was measured enzymatically (25). Stable glycosylated hemoglobin A1 (HbA1) was 
originally measured in saline-incubated samples by microcolumn cation exchange 
chromatography (Isolab, Akron, Ohio, USA).  On October 26, 1987, the method was changed to 
high-performance liquid chromatography (HPLC) (Diamat, Bio-Rad Laboratories, Hercules, CA, 
USA). The two methods were highly correlated (r = 0.95).  Beginning in 1998, HbA1c was 
measured using the DCA2000 analyzer.  Original HbA1 (1986 to 1998) and A1c (1998 to 2004) 
were converted to Diabetes Control and Complications Trial (DCCT) aligned HbA1c values 
using regression formulas derived from duplicate analyses (DCCT HbA1c = [0.83 * EDC HbA1] 
+ 0.14; DCCT HbA1c = [EDC HbA1c − 1.13]/0.81).  Blood pressure was measured by a random-
zero sphygmomanometer according to a standardized protocol (26) after a 5-minute rest period.  
Blood pressure levels were analyzed, using the mean of the second and third readings.  Insulin 
dose/kg body weight was defined as the total daily units of insulin divided by the body weight in 
kilograms. 
  Intensive insulin therapy was defined as having three or more insulin injections per day 
or using an insulin pump.  Physical activity was determined by number of flights climbed per 
day, city blocks or equivalent walked per day, and mets calculated from sports/exercise*minutes 
of participation*number of times per week, and is expressed in kilocalories. Complications were 
assessed as previously described (23, 24) and overt nephropathy (ON) defined as albumin 
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excretion rate >200 µg/min in 2 or 3 timed urine samples (27) or a history of renal dialysis or 
transplant.  All procedures were approved by the Institutional Review Board of the University of 
Pittsburgh. 
 
Statistical analyses 
The student’s t test and chi-square tests were used to examine univariate associations of 
BMI category with mortality risk factors.  Cox proportional hazards modeling was used to 
determine the independent predictive ability of BMI category on mortality, with normal weight 
being used as the reference.  Risk factors were grouped into three categories (complications, 
biological risk factors, and socioeconomic/lifestyle risk factors) and models fitted separately for 
each group as predictors of mortality.  The number of participants included in different statistical 
models varied due to item nonresponse.  Preliminary analyses revealed that the relationship of 
BMI category with mortality was essentially similar in each sex; therefore sex-specific analyses 
were not conducted.  Children younger than 18 years old (n=66) were excluded from baseline 
analyses.  Cox models with baseline risk factors were used to determine the association of 
baseline BMI category on mortality.  Cox models with updated mean covariates were also used 
to determine the association of average BMI status during follow-up with mortality.  The 
updated mean was determined by taking the average value of a risk factor during follow-up.  For 
dichotomous variables, the updated variable was entered as the number of years with the given 
risk factor.  The forward selection procedure was used to identify the most predictive risk 
factors; BMI category was forced into all models.  Cox modeling was also used to determine the 
association of the residuals of weight change with mortality in adults at least 18 years old at 
baseline.  Variables are expressed as per standard deviation change in the continuous variable.  
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All tests were two-tailed and a p-value <0.05 was considered significant.  All analyses were 
conducted using SAS version 9.1 (Cary, North Carolina). 
 
6.4 RESULTS 
Body mass index data were available on 655 participants and 99.8% provided some follow-up 
data.  Participants (mean age and diabetes duration 28 and 19 years, respectively) were followed 
for a median of 18.2 years (range: 0.2-20.6 years).  There were 146 deaths (22%).   
Baseline characteristics of the participants (aged 18 years and older) by BMI category are 
described in Table 6-1.  At baseline, compared to normal weight participants, obese participants 
had a higher non-HDL cholesterol.  Overweight participants also had, compared to normal 
weight, a lower HbA1c, were on more insulin injections per day, had a higher diastolic blood 
pressure, a lower HDL cholesterol, a lower prevalence of symptomatic autonomic neuropathy, 
and were less likely to be current smokers.   
During follow-up, the prevalence of intensive insulin therapy (IIT-3+ insulin shots daily 
and/or pump) increased from 7% to 82% (Paper 1).  The prevalence of being overweight 
increased by from 28.6% to 42.0% while the prevalence of obesity increased 7-fold (from 3.4 to 
22.7%) over an average of 18 years of follow-up (Paper 1).  Figure 6-1 shows the unadjusted 
association of mortality with baseline BMI category (panel a), updated mean BMI status during 
follow-up (panel b), and most recent BMI status prior to event or censoring (panel c).  Baseline 
BMI demonstrated a slight U-shape relationship with mortality (p for quadratic term=0.002), 
such that there was a higher risk in the underweight relative to the normal weight and a more 
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marked higher level of risk in the obese.  However, average BMI during follow-up (updated 
means model), revealed a reverse J-shaped relationship with mortality, such that those with an 
average BMI in the obese category were at slightly increased risk of mortality relative to the 
normal weight, but the greatest risk was in those with an average BMI less than 20 kg/m² (p for 
quadratic term <0.0001).  The BMI nadir for mortality risk fell in the overweight category.  In 
the time-varying model, reflecting most recent BMI status prior to event or censoring, the risk in 
the underweight and obese appeared to be even stronger, compared to the baseline and updated 
means models, with the risk in the underweight being 3 times, and the risk in the obese twice, 
that of the normal weight (p for quadratic term<0.0001). 
The results of modeling baseline risk markers by type, namely, complications, biological 
risk factors, and socioeconomic/lifestyle risk factors are shown in Table 6-2.  As sample size 
with full data available varies for these three risk marker categories, the base models show the 
relationship of BMI category with mortality, specific for that population, adjusted only for age 
and sex.  The increased risk in the obese was attenuated after adjustment for chronic 
complications of diabetes, and eliminated after adjustment for biological and socioeconomic risk 
factors.  The multivariable baseline models showed weak U- and J-shaped relationships with 
mortality. 
Table 6-3 shows the relationship of updated mean BMI category with mortality.  In 
contrast to the baseline model, average BMI status during follow-up demonstrated a strong U-
shaped relationship with mortality after adjustment for the proportion of follow-up time spent 
with complications independently predictive of mortality during follow-up.  Adjusting for these 
complications did not account for the increased risk in the underweight or obese.  Similarly, 
compared to the base model, adjusting for updated mean biological risk factors had very little 
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effect on the BMI relationship with mortality.  However, adjusting for socioeconomic lifestyle 
risk factors, where intensive insulin therapy emerged as a protective factor, eliminated the risk in 
the underweight while no substantial change in risk of the obese was noted.  Comparing both the 
base and the adjusted updated mean models with baseline, the risk in the underweight appears to 
have increased while that in the obese to have been reduced, with the exception of the 
socioeconomic/lifestyle risk factors adjusted analyses, where no change in risk appeared to be 
observed in the obese.   
Table 6-4 shows the relationship of most recent BMI status with mortality.  Thus 
adjusting for time-varying complication status, appears to have attenuated the risk in the 
underweight compared to the base model, while adjusting for time-varying biological or 
socioeconomic/lifestyle risk factors did not appear to have substantial affect the relationship of 
BMI category with mortality.  Compared to the baseline and updated means models, whether 
adjusting for complications, biological risk factors, or socioeconomic/lifestyle risk factors, base 
and adjusted time-varying models show a stronger (larger effect size) adverse relationship with 
being underweight.  Base time-varying models show no substantial difference from updated 
mean base models in obesity’s relationship with mortality, but suggest an attenuation in risk 
compared to baseline base models.  This same pattern is not observed for the adjusted models 
where the time-varying adjusted models appear similar to the baseline adjusted models in the 
relationship of obesity with mortality.  
Figure 6-2 shows the relationship of baseline BMI category, updated means BMI 
category, and time-varying (most recent) BMI category with mortality after adjusting for waist 
circumference.  Controlling for waist circumference eliminated the relationship of obesity with 
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mortality in all three time models.  Being overweight was also protective in the baseline and 
updated means models.   
Figure 6-3 shows the association of change in BMI in adults during the first ten years of 
follow-up with mortality during years the subsequent 10 years.  BMI change ranged from -6.5 to 
11.0 kg/m².  There was a significant trend for a positive change in BMI to be associated with a 
lower mortality, such that for each tertile of change, risk was reduced by approximately one-third 
(p for trend=0.01).  In multivariable analysis in adults 18 years and older, after controlling for 
baseline BMI, age, and albumin excretion rate, and allowing for intensive insulin therapy and 
other univariate significant risk factors, each one unit positive change in the residuals of BMI 
change during the first 10 years of follow-up was associated with a 12% decreased risk of 
mortality during follow-up years 11-20 (HR=0.88, 0.80-0.97) (Table 6-5).   
 
6.5 DISCUSSION 
In this report, we have documented the association of both baseline BMI and BMI measured 
repeatedly during follow-up with mortality in type 1 diabetes.   To our knowledge, this is the first 
study to document the long term association of adiposity with mortality in type 1 diabetes, where 
adiposity was the predictor of interest.  We have shown that baseline BMI demonstrated a slight 
U-shaped relationship with 20-year mortality.  We have also shown during follow-up the role of 
underweight as a predictor increases and conversely, we have shown that weight gain in adults 
with type 1 diabetes is protective against mortality.  Finally, we have shown that the role of 
overweight and obesity in increasing mortality appears to be mediated by waist circumference. 
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The relationship of BMI with mortality in this population was not linear, neither at 
baseline nor throughout follow-up.  Although Roy et al (22), found BMI to be inversely 
associated with mortality (HR=0.94, 0.91-0.97) in a large African American population with type 
1 diabetes, in general in type 1 diabetes the relationship of BMI with mortality has been reported 
to be nonsignificant, although apart from the present study, no study has specifically looked at 
mortality in this population with adiposity as the explanatory variable of interest.  The 
association of BMI with mortality in the general population is usually found to exhibit a U-or J-
shaped curve, although some argue that this may be due to failure to exclude for pre-existing 
disease, smoking, or recent weight loss (28, 29, 30).  Against this, others have shown that even 
after excluding for pre-existing disease, smoking, or recent weight loss, this non-linear 
relationship persists (13, 31, 32).  Excluding for pre-existing disease in type 1 diabetes may be 
debatable, as type 1 diabetes itself is a pre-existing disease.  Furthermore, 55% of our adult 
population at baseline, with a mean age of 29, had at least one of the long-term diabetes 
complications at study entry and 23% of our adult population at baseline were smokers; 
therefore, exclusion of smokers and those with pre-existing disease would not be representative 
of the type 1 diabetes population.   However, we have attempted to account for weight loss, 
smoking, and long-term complications by looking at them biennially in updated means and time-
dependent survival analyses.  In our population, after examining the association of BMI on 
mortality with up to twenty-years of follow-up, BMI failed to show a linear relationship with 
mortality, demonstrating a similar relationship observed in the general population, with the 
exception of a much increased risk in those whose average or most recent BMI was in the 
underweight category. 
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The issue as to whether complications (or comorbidities) should be adjusted for in 
analyses of overweight and obesity is complex.  It might be argued that it is inappropriate to 
control for complications such as coronary artery disease or kidney disease as they may be 
intermediates in the causal pathway between obesity and mortality.  However, complications 
such as these are a part of the natural history of type 1 diabetes.  Coronary artery disease risk 
factors such as hypertension and dyslipidemia also tend to increase with adiposity and as we do 
not know to what extent they are part of the natural history of obesity within type 1 diabetes, i.e. 
risk additive to the underlying risk these complications already pose in type 1 diabetes, it is also 
appropriate to control for them in order to determine the residual or independent effect of 
adiposity on mortality.  In our analyses we have therefore presented multivariate data on all three 
levels-comorbidities, biological risk factors/mediators, socioeconomic/lifestyle factors in order to 
serve the multiple objectives of those interested in this use. 
A major biologic risk factor for mortality in our population was HbA1c.  HbA1c has been 
shown previously to be a risk factor for mortality in type 1 diabetes (1, 33) and Shankar et al (33) 
noted that the mortality risk associated with HbA1c was greater at a higher BMI although this 
was not noticed by Stadler et al (1).  Intensive insulin therapy has been shown to reduce the risk 
of long term diabetes complications, the major causes of death in type 1 diabetes; however 
intensive insulin therapy is also associated with weight gain and its association with weight gain 
both in this population and in others raises concern that the gains made in the reduction of 
microvascular disease may be lost with the increased risk of obesity related complications such 
as CAD, particularly as this increased weight gain associated with intensive insulin therapy is 
accompanied by a deterioration in the CAD risk profile, although this has not always been 
observed (34).  In this population, both HbA1c and intensive insulin therapy were positive 
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predictors of weight gain (Paper 1); however, in the prediction of mortality, while HbA1c was 
directly predictive, average amount of time spent on intensive insulin therapy during follow-up 
was protective.  After accounting for age and sex, further adjusting for time on intensive insulin 
therapy during follow-up in the updated means socioeconomic/lifestyle risk factors model 
appeared to eliminate the risk in the underweight while having no effect on the overweight or 
obese.  Thus it appears the elimination of risk in the underweight after adjustment for intensive 
insulin therapy may due to treatment by indication where thinner participants in poorer control 
may have been advised to intensify their insulin therapy due to comorbid conditions.   
Other socioeconomic lifestyle risk factors associated with adiposity and mortality are also 
complex in type 1 diabetes.  In our analyses of predictors of weight change from baseline to last 
follow-up in this population, neither smoking, education, nor income were predictive; however, 
physical activity was an inverse predictor of a 2 kg/m² loss, i.e. the more physically active, the 
less likely they were to lose weight (Paper 1).  In the current analyses of mortality, physical 
activity was a consistent protective factor against mortality in all three of the time to event 
models looking at BMI category.  In type 1 diabetes, increased physical activity may be 
intentional and related to a healthier lifestyle; conversely, decreased physical activity may be 
largely a marker of morbidity associated with the long term complications of the disease.  
Smoking, associated with lower socioeconomic status, leanness, and mortality in the general 
population, was a strong predictor of mortality in our population only in the baseline model; 
however, at baseline in the population with full data on socioeconomic/lifestyle risk factors, the 
underweight were never different from the normal weight in mortality risk, whether adjusting 
only for sex and age or for socioeconomic/lifestyle risk factors.  Income also was an independent 
predictor of mortality at baseline and in the time-varying analysis, i.e. analysis assessing BMI 
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near to the time of event.  However, only at baseline was the effect of obesity accounted for by 
socioeconomic /lifestyle risk factors, suggesting that the closer to the time of event, the more 
important obesity is as a risk factor itself than as a marker of socioeconomic status.    
The effect of change in weight over time is yet another dimension of the complex 
association of adiposity with mortality in type 1 diabetes.  In adults eighteen years and older, we 
observed a protective effect of weight gain, as assessed by BMI, and mortality, such that with 
each increasing tertile of change, mortality was reduced by approximately thirty-three percent.  
While it is not unexpected for weight loss to predict mortality in a population with pre-existing 
disease, i.e. type 1 diabetes itself, we found that weight gain had beneficial survival effects 
beyond that of even the relatively weight stable, an observation that should be underscored as 
average baseline BMI in this population was 23.8 kg/m², a value well within the normal weight 
range.  Weight change modeled as a continuous variable was inversely associated with mortality 
even after adjustment for other factors associated with mortality.  Although weight gain in 
adulthood has been reported to be a positive predictor of mortality (32) and that weight loss is 
beneficial if volition is taken into account (35, 36), in the main, general population studies have 
demonstrated an inverse or U-shaped relationship between weight change and mortality (37, 38, 
39), even when pre-existing illness and smoking have been taken into account (40, 41).  In our 
population with type 1 diabetes, with a mean age of 28 years at baseline, weight gain appeared to 
be protective against mortality in middle-age.    
A major observation of this study was that waist circumference accounted for the U-
shaped relationship of BMI with mortality.  Some have hypothesized that, contrary to being a 
failure to adequately control for smoking, subclinical, or occult disease, the non-linear 
relationship observed between BMI and mortality may be a consequence of BMI being a 
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composite of both fat and fat-free mass (42,43,44), not simply a surrogate for overall adiposity.  
Bigaard et al (44) demonstrated that the U-shaped relationship between BMI and mortality was 
due to the J-shaped relationship of fat mass and the reverse J-shaped relationship of fat-free mass 
with mortality.  Several studies have shown that adjustment for waist circumference, a surrogate 
for abdominal adiposity (45, 46, 47, 48), eliminates or attenuates BMI’s nonlinear relationship of 
with mortality (49, 50).  In our type 1 diabetes population as well, adjustment for waist 
circumference also eliminated the U-shaped relationship between BMI and mortality such that 
both overweight and obesity were protective while the risk in the underweight appeared to be 
even greater.  Beyond suggesting that the effect of obesity on mortality is mediated through 
central adiposity, this is suggestive of a protective effect for both peripheral body fat and for lean 
body mass. Consistent findings have also been reported in the literature (51, 52, 42).   
 
Strengths and Limitations 
Major strengths of our study include the prospective nature of the design, measured 
height and weight, repeated assessment of height and weight as well other risk factors over time, 
and a long follow-up period.  As BMI was assessed every two years, we were able to assess the 
affects of weight change on mortality, demonstrating an increased risk in those who lost weight 
and a decreased risk in those who gained the most weight, a weight gain well beyond a 
normalization of weight.   
A major strength of this paper could also be one of its limitations.  As this study tracked 
mortality over 20 years, changes in both diabetes treatment and risk factor management 
associated with obesity may have affected mortality results.  However, we have attempted to 
account for this, as well as weight change, in the time-varying covariate models.  Results from 
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these models did not reveal a major change in the association of obesity with mortality, but a 
they did reveal a much stronger relationship with being underweight and a reversal of the 
relationship of being overweight with mortality, even after long-term diabetes complications and 
intensive insulin therapy were taken into account.  This would seem to suggest that with 
improved diabetes treatment and risk factor management, a modest increased adiposity is 
actually beneficial, as also suggested by our analysis of weight change.    
 
Conclusion 
With the rise in overweight and obesity in type 1 diabetes, and the rise in intensive 
insulin therapy, the traditional view of type 1 diabetes as a starvation state is clearly outdated.  
Nevertheless, an interaction between catabolic and anabolic imbalances is evidenced by the 
increased risk in the obese and the greatly increased risk in the underweight.  Although an 
understanding of the risk associated with obesity is of interest, in terms of a disease traditionally 
characterized by relative thinness and enhanced catabolism, of greater concern maybe the excess 
mortality risk due to leanness.  Given the wide BMI range associated with minimal mortality 
(20-29 kg/m²), weight gain is not necessarily a bad occurrence in type 1 diabetes.  Though frank 
obesity should be avoided, risk factor management may be better focused on glycemia, blood 
pressure and lipids, and other complication specific risk factors, than on overweight per se.  
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6.7 FIGURES AND TABLES 
 
            
             Figure 6-1.  Risk of mortality by body mass index (BMI) category. 
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Figure 6-2.  Risk of mortality by body mass index (BMI) category, unadjusted and adjusted for waist 
circumference. 
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Figure 6-3.  Mortality in adults in years 11-20 of follow-up by change in body mass index (BMI) during the         
                                                                       first 10 years of follow-up. 
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Table 6-1.  Baseline (1986-1988) Characteristics by Body Mass Index (BMI) Category in Adults 18 
Years and Older, mean±SD, % (n), or median (IQR). 
 
Characteristics BMI <20 20≤BMI<25 25≤BMI<30 BMI ≥30 p-trend 
Sex (female), % 57.6 (34) 49.7 (171) 42.8 (71)  70.0 (14) 0.37 
Age (years) 30.2±6.2 29.1±7.1 28.8±6.5 28.8±6.9 0.39 
Diabetes Duration (years) 21.3±6.2 20.3±7.4 20.3±6.9 21.3±7.3 0.99 
BMI (kg/m2) 19.1±0.81§ 22.7±1.3 26.9±1.4§ 31.6±1.7§ <0.0001 
Biological risk factors     
HbA1 (%) 8.8±1.7 8.8±1.5 8.4±1.3‡ 8.6±1.1 0.24 
Daily insulin dose/kg body weight 0.82 (0.59-0.99) 0.75 (0.58-0.91) 0.77 (0.63-0.93) 0.74 (0.63-0.90) 0.11 
 Insulin injections per day 1.5 ±0.50 1.6 ± 0.83 1.8± 1.0† 1.9 ± 0.85 0.01 
 Intensive insulin therapy (%) 0.0 (0) 6.8 (22) 9.4 (15) 10.5 (2) 0.02 
 Systolic blood pressure (mm Hg) 109.2 ± 17.7 114.5 ± 16.8 117.4 ± 14.0 118.6 ± 16.5 0.01 
 Diastolic blood pressure (mm Hg) 70.1 ± 12.3 72.7 ± 10.7 76.6 ± 10.6¶ 76.4 ± 12.0 0.005 
 Hypertension (%) 13.6 (8)  17.4 (60) 19.4 (32) 30.0 (6) 0.12 
 HDL cholesterol (mg/dL) 55.9 ± 13.3 54.8 ± 13.0 51.1 ± 11.6‡ 50.4± 8.4  0.03 
 Non-HDL cholesterol (mg/dL) 128.8 ± 35.0 137.1 ± 40.8 146.7 ± 47.2 162.2 ± 47.4† 0.0007 
AER* (μg/min), median (IQR) 31.6 (11.9-178.5) 17.4 (7.3-241.4) 22.7 (9.4-297.9) 42.2 (5.8-423.8) 0.65 
 WBC (x 10³/mm²) 6.7 ± 2.2 6.6 ± 1.9 6.7 ± 1.9 7.7 ± 2.3 0.05 
Complication, %     
Coronary Artery Disease 8.5 (5) 8.5 (29) 8.4 (14) 5.0 (1) 0.78 
Overt Nephropathy 27.8 (15) 29.9 (96) 33.3 (50) 42.1 (8) 0.20 
Proliferative Retinopathy 39.0 (23) 32.1 (106) 41.1 (65) 42.1 (8) 0.24 
Symptomatic Autonomic Neuropathy 10.9 (5) 11.3 (31)  3.7 (5)† 6.3 (1) 0.04 
Distal Symmetrical Polyneuropathy 46.4 (26) 32.6 (104) 32.4 (48) 36.8 (7) 0.26 
Lower Extremity Arterial Disease 15.3 (9) 8.2 (28) 6.0 (10) 15 (3) 0.23 
Sociodemographic/lifestyle risk factors     
Household Income:  <$20,000/yr 47.9 (23) 45.7 (122) 36.6 (52) 53.3 (8) 0.23 
Education:  any college 63.0 (34) 63.4 (203) 65.8 (104) 63.2 (12) 0.69 
Physical activity*, median (IQR)  1316 (560-2236) 1414 (616-2752) 1428 (616-2912) 1295(224-2484) 0.40 
Alcohol consumption (3+ gl/wk) 23.6 (13) 26.2 (85) 24.2 (38) 5.3 (1) 0.27 
Current Smoker (%) 28.8 (17) 27.0 (93) 15.1 (25) ‡ 10.0 (2) 0.001 
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AER=albumin excretion rate   WBC=white blood cell count   *Natural log transformed before analysis   
† significantly different than 20≤BMI<25 at p<0.05   ‡ significantly different than 20≤BMI<25 at p<0.01   
¶ significantly different than 20≤BMI<25 at p<0.001    § significantly different than 20≤BMI<25 at p<0.0001    
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Table 6-2.  Independent Baseline Predictors of Mortality in Type 1 Diabetes by Risk Factor 
Groupings in Adults ≥ 18 Years, Cox Regression Analyses. 
 
 Complications, base and adjusted 
models (n=465) 
Biological Risk Factors, base and 
adjusted models (n=478) 
SES/Lifestyle Risk Factors, base and 
adjusted models (n=441) 
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Normal weight Ref Ref Ref Ref Ref Ref 
Underweight 1.44(0.79-2.63) 1.60 (0.88-2.91) 1.27(0.73-2.21) 1.04(0.58-1.86) 1.15(0.61-2.16) 0.87 (0.45-1.67) 
Overweight 1.13 (0.70-1.81) 1.43 (0.86-2.38) 0.99(0.65-1.52) 0.83 (0.54-1.28) 1.15(0.74-1.80) 1.29 (0.83-2.02) 
Obese 2.87 (1.21-6.80) 3.37 (1.42-7.98) 2.62(1.12-6.13) 1.70 (0.72-3.98) 3.18(1.42-7.11) 2.25 (0.99-5.13) 
Sex (female) 0.69 (0.46-1.05)  0.60(0.42-0.88)  0.58(0.38-0.88) 0.46 (0.30-0.70) 
Age (years) 2.15 (1.71-2.72) 1.54 (1.16-2.04) 2.16(1.75-2.66) 1.85 (1.49-2.31) 2.34(1.86-2.94) 2.23 (1.75-2.84) 
       
Overt nephropathy  2.43 (1.52-3.74)     
Symptomatic AN  2.74 (1.66-4.52)     
Distal symmetrical PN  2.28 (1.42-3.66)     
Proliferative retinopathy  1.68 (1.02-2.77)     
       
HbA1c (%)    1.31 (1.08-1.59)   
AER (μg/min)*    1.48 (1.19-1.84)   
Serum creatinine 
(mg/dl) 
   1.40 (1.17-1.67)   
Non-HDLc (mg/dl)    1.26 (1.06-1.49)   
WBC (x 10³/mm²)    1.31 (1.12-1.53)   
Pulse (beats/min)     1.34 (1.15-1.56)   
       
Physical activity (kcal)      0.74 (0.62-0.88) 
Current smoker      1.81 (1.20-2.73) 
Low income      2.02 (1.33-3.06) 
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AN=autonomic neuropathy  PN= polyneuropathy  AER=albumin excretion rate WBC=white blood cell count *natural logarithmically 
transformed before analyses  Low income= household income <$20,000/yr  
 Complications model also allowed for coronary artery disease and peripheral vascular disease.   
Biological risk factors model also allowed for sex, daily insulin dose/kg of body weight, high density lipoprotein cholesterol, diastolic blood 
pressure, use of hypertension medications, and hematocrit. 
SES/Lifestyle risk factors model also allowed for having some college education, consumption of alcohol ≥3x/wk, and intensive insulin therapy.
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Table 6-3.  Independent Updated Mean Predictors of Mortality in Type 1 Diabetes by Risk Factor 
Groupings, Cox Regression Analyses. 
 
 Complications, base and adjusted 
models (n=519) 
Biological Risk Factors, base and 
adjusted models (n=632) 
SES/Lifestyle Risk Factors, base 
and adjusted models (n=598) 
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Normal weight Ref Ref Ref Ref Ref Ref 
Underweight 2.90 (1.60-5.28) 2.66 (1.46-4.85) 2.55 (1.55-4.20) 2.19 (1.30-3.68) 2.07 (1.15-3.72) 1.41(0.78-2.54) 
Overweight 0.93 (0.57-1.49) 1.19 (0.73-1.94) 0.72 (0.48-1.08) 0.70 (0.46-1.05) 0.80 (0.53-1.20) 0.82(0.55-1.24) 
Obese 2.00 (1.03-3.89) 2.41 (1.22-4.76) 1.73 (0.99-3.02) 1.43 (0.81-2.53) 1.92 (1.07-3.44) 2.18(1.19-4.01) 
Sex (female) 0.64 (0.42-0.97)  0.58 (0.41-0.81)  0.56 (0.39-0.80) 0.54 (0.37-0.79) 
Age (years) 2.14 (1.73-2.64) 1.43 (1.10-1.87) 2.10 (1.76-2.50) 1.76 (1.45-2.14) 2.16 (1.80-2.60) 1.78 (1.46-2.17) 
       
Overt nephropathy*   3.03 (1.86-4.95)     
Distal symmetrical PN*  3.33 (1.68-6.57)     
Proliferative 
Retinopathy 
 2.32 (1.28-4.20)     
Peripheral vascular 
disease 
 0.95 (0.90-1.00)     
       
HbA1c (%)    1.40 (1.16-1.70)   
Serum creatinine 
(mg/dl)** 
   1.30 (1.10-1.54)   
AER (μg/min)**    1.67 (1.32-2.13)   
Non-HDLc (mg/dl)**    1.54 (1.28-1.84)   
DBP (mm Hg)**    1.33 (1.09-1.62)   
Hypertension 
medication*  
   0.81 (0.74-0.88)   
       
Physical activity (kcal)      0.64 (0.51-0.80) 
Intensive insulin 
therapy*  
     0.77 (0.72-0.83) 
Alcohol consumption      0.93 (0.89-0.98) 
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*% of time with this condition  AN=autonomic neuropathy  PN= polyneuropathy  AER=albumin excretion rate DBP=diastolic blood pressure 
**natural logarithmically transformed before analyses  Alcohol consumption=3+ beverages/wk   Low income= household income <$20,000/yr 
Complications model also allowed for coronary artery disease, proliferative retinopathy, and peripheral vascular disease. 
Biological risk factors model also allowed for sex, daily insulin dose/kg of body weight, high density lipoprotein cholesterol, heart rate, and 
hematocrit. 
SES/Lifestyle risk factors model also allowed for having some college education and years of current smoking. 
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Table 6-4.  Independent Time-Varying Predictors of Mortality in Type 1 Diabetes by Risk Factor 
Groupings, Cox Regression Analyses. 
 
 Complications, base and adjusted 
models (n=519) 
Biological Risk Factors, base and 
adjusted models (n=632) 
SES/Lifestyle Risk Factors, base 
and adjusted models (n=598) 
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Normal weight Ref Ref Ref Ref Ref Ref 
Underweight 4.28 (2.46-7.46) 2.96 (1.78-4.91) 3.40 (2.14-5.42) 3.26 (2.06-5.17) 3.01 (1.78-5.08) 2.49 (1.42-4.16) 
Overweight 0.81 (0.47-1.38) 0.89 (0.55-1.42) 0.72 (0.46-1.12) 0.74 (0.47-1.15) 0.85 (0.55-1.33) 0.94  (0.60-1.47) 
Obese 2.21 (1.26-3.88) 2.10 (1.26-3.52) 2.01 (1.25-3.24) 1.92 (1.18-3.14) 2.19 (1.33-3.61) 1.92  (1.14-3.23) 
Sex (female) 0.59 (0.39-0.89) 0.61 (0.42-0.88) 0.56 (0.39-0.79)  0.55 (0.38-0.79) 0.57 (0.40-0.83) 
Age (years) 2.09 (1.69-2.58)  2.10 (1.76-2.50) 1.71 (1.41-2.07) 2.16 (1.79-2.59) 1.99 (1.64-2.42) 
       
Coronary artery 
disease 
 2.86 (1.91-4.29)     
Overt nephropathy  2.08 (1.39-3.12)     
Symptomatic AN  2.11 (1.41-3.14)     
Proliferative 
retinopathy 
 2.33 (1.37-3.95)     
Peripheral vascular 
disease 
 1.57 (1.03-2.38)     
       
HbA1c (%)    1.32 (1.14-1.53)   
AER (μg/min)*    1.55 (1.28-1.88)   
Serum creatinine 
(mg/dl) 
   1.48 (1.31-1.66)   
Non-HDLc (mg/dl)    1.23 (1.08-1.41)   
WBC (x 10³/mm²)    1.16 (1.01-1.35)   
       
Physical activity (kcal)      0.79 (0.73-0.86) 
Alcohol consumption      1.87 (1.28-2.75) 
Low Income       3.28  (2.24-4.80) 
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AN=autonomic neuropathy  AER=albumin excretion rate DBP=diastolic blood pressure *natural logarithmically transformed before analyses  
Alcohol consumption=3+ beverages/wk   Low income= household income <$20,000/yr.   
Complications model also allowed for distal symmetrical polyneuropathy.   
Biological risk factors model also allowed for daily insulin dose/kg of body weight, hematocrit, high density lipoprotein cholesterol, diastolic 
blood pressure, use of hypertension medications, and heart rate. 
SES/Lifestyle risk factors model also allowed for having some college education, low income, smoking, and consumption of alcohol ≥3x/wk.
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Table 6-5.  Change in Body Mass Index (BMI) in Adults with Type 1 Diabetes in Follow-up Years 1-10 and 
Risk  of Mortality in Years 11-20. 
 
 HR (95% CI) 
BMI CHANGE (RESIDUALS) 0.88 (0.80-0.97) 
BASELINE BMI 1.10 (1.00-1.21) 
AGE (YEARS) 2.10 (1.53-2.87) 
ALBUMIN EXCRETION RATE* 2.32 (1.74-3.09) 
*Natural logarithmically transformed before analysis. 
Forward selection model also allowed for sex, hypertension, HbA1c, intensive insulin therapy, 
HDL cholesterol, and non-HDL cholesterol. 
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7.1 ABSTRACT 
Background: Coronary artery disease (CAD), a leading cause of death in type 1 diabetes (T1D), 
often occurs two or more decades earlier in this population.  Although CAD generally increases 
with adiposity, this association is unclear in T1D.  We thus examined the associations of 
adiposity with Coronary Artery Calcium (CAC-a subclinical marker of CAD) in 315 individuals 
with T1D.   
Methods: Mean age and diabetes duration were 42 and 34 yrs, respectively at the time of 
assessment of CAC, visceral adiposity (VAT) and subcutaneous adiposity (SAT) by electron 
beam tomography and when BMI and waist circumference (WC) were measured.  Chi-square 
frequencies and generalized linear models were used to compare the presence of any CAC and 
age-adjusted mean CAC total score, respectively, by tertiles of adiposity.   
Results:  There was a positive relationship between the presence of CAC and tertiles of VAT, 
SAT, BMI, and WC in both genders (p trend<0.05).  The presence of CAC was positively 
associated with VAT, SAT, and BMI in men (p<0.05) and with all four adiposity measures in 
women (p<0.05).  However, the degree of CAC was not associated with any adiposity measure, 
with the exception of SAT in women.  Women in the lowest tertile of SAT had more CAC than 
those in the second tertile (p<0.016).  
 Conclusion:  Adiposity was positively associated with the presence of CAC, but the relationship 
with its severity was either inverse or nonexistent.  This double-edged association, which appears 
to be more pronounced in women, emphasizes the complex relationship between adiposity and 
cardiovascular risk in diabetes.  
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7.2 INTRODUCTION 
Coronary artery disease (CAD) is the leading cause of death in type 1 diabetes (1) and often 
occurs two or more decades earlier than in the general population.  Although the risk of CAD 
tends to increase with increasing BMI in the general population, this association in type 1 
diabetes is unclear.  Coronary artery calcification (CAC) is a subclinical marker of coronary 
vascular disease (2) and has been shown to be predictive of future clinical cardiac events (3). The 
few studies that have investigated CAC in T1D are inconsistent in terms of the relationship 
between CAC and adiposity.  All five studies investigated the association of BMI with CAC.  
Both Dabelea et al (4) and Colhoun et al (5) reported a positive association between BMI and the 
prevalence of CAC; in contrast, in the Epidemiology of Diabetes Complications Study (6), the 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) Study (7), and in Starkman et al (8), no association was found 
between BMI and CAC prevalence.  Olson et al (6) and Cleary et al (7) also failed to show an 
association with CAC severity.  Additionally, in a subgroup of the CACTI population reported 
on by Dabelea et al (4), Snell-Bergeon et al (9) failed to find a difference in BMI when 
investigating progression of CAC.   
Markers of visceral adiposity, thought by many to independently relate to cardiovascular 
disease risk, have also been studied.  Unlike BMI, the association of waist-to hip ratio (WHR) 
and/or waist circumference (WC) with CAC has been more consistent.  With the exception of 
Colhoun et al (5), who failed to show an association in men, and Starkman et al (8), who did not 
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investigate WHR /WC, all of the studies found CAC to be positively associated with WHR/WC.  
Additionally, Dabelea et al (4) using a direct measurement of visceral obesity, also found 
intraabdominal fat to be positively associated with the prevalence of CAC, although this was not 
investigated sex-specifically.  They also found men to be at higher risk for CAC.  As sex 
differences in adiposity also exist, even for BMI, and not all of the above mentioned studies 
looked at adiposity sex-specifically (4,7,8), sex specific analyses are warranted.  Furthermore, 
none of the studies investigated subcutaneous abdominal fat (SAT). This is important as SAT has 
also been suggested to be a major contributor of free fatty acids into both the portal and systemic 
circulation and thus insulin resistance (10, 11, 12, 13).   
Given the above conflicts in the literature and the evidence that being overweight and 
obese is rising in type 1 diabetes (T1D) (14), concern and further evaluation of the association of 
adiposity with CAD in this population already at increased risk is warranted.  This study 
therefore sought to determine the following: a) which measure of adiposity best identifies CAC 
(testing the hypothesis that measures of central obesity will be more strongly associated with 
CAC), b) whether any associations of adiposity with CAC vary by sex and c) whether any 
associations differ for the prevalence as opposed to the severity of CAC.   Four different indices 
of body fat, i.e. BMI, WC, VAT, and SAT were investigated.  
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7.3 METHODS 
7.3.1 Subjects 
The EDC study is an ongoing cohort study examining the long term complications of T1D in 658 
individuals diagnosed before the age of 17 years with T1D at Children’s Hospital of Pittsburgh 
between 1950 and 1980.  This current report is based on a subset (n=315) who underwent 
electron beam tomography (EBT) for CAC between 2000 and 2007.  These participants were 
also scanned for VAT and SAT via EBT scanning.   
 
7.3.2 Clinical Evaluation Procedures 
Before attending the clinic, participants completed a questionnaire concerning demographic 
information, lifestyle, and medical history.  An ever smoker was defined as having smoked at 
least 100 cigarettes in a lifetime.  Participants were weighed in light clothing on a balance beam 
scale.  Height was measured using a wall-mounted stadiometer.  BMI was calculated as the 
weight in kilograms divided by the square of the height in meters.  Two waist measurements 
were taken by a standard medical measuring tape, measuring from the mid-point of the iliac crest 
and the lower costal margin in the mid-axillary line.  The average was used for data analysis.   
Fasting blood samples were assayed for lipids, lipoproteins, and glycosylated hemoglobin 
(HbA1c).  High-density lipoprotein (HDL) cholesterol was determined by a heparin and 
manganese procedure, a modification of the Lipid Research Clinics method (15).  Cholesterol 
and triglycerides were measured enzymatically.  Glomerular filtration rate (GFR) was estimated 
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using the Modification of Diet in Renal Disease (MDRD) formula (16).  Sitting blood pressures 
were measured according to the Hypertension Detection and Follow-up Program protocol (17) 
using a random zero sphygmomanometer.  The mean of the second and third readings was used.  
Estimated glucose disposal rate (eGDR) was calculated using the equation: eGDR=24.395-
12.971 (waist-to-hip ratio)-3.388 [hypertension status (140/90 mm Hg or on hypertension 
medication)]-0.601 (HbA1c).  This formula was derived from a substudy of 24 EDC participants 
(12 men and 12 women drawn from low, middle, and high age-specific tertiles of insulin 
resistance risk factors) who underwent euglycemic clamp studies (18).   
CAC was measured using EBT (Imatron C-150, Imatron, South San Francisco, CA).  
Threshold calcium determination was set using a density of 130 Hounsfield units in a minimum 
of 2 contiguous sections of the heart.  Scans were triggered by ECG signals at 80% of the R-R 
interval.  The entire epicardial system was scanned.  CAC volume scores were calculated based 
on isotropic interpolation (19).  Direct measurements of abdominal adiposity (visceral and 
subcutaneous abdominal adipose tissue surface area) were also taken by EBT scanning.  Scans of 
abdominal adipose tissue were taken between the fourth and fifth lumbar regions, which were 
located by counting from the first vertebra below the ribs.   Two 10 mm thick scans were taken 
during suspended respiration.  The images were then analyzed using commercially available 
software for all pixels corresponding to fat density in Hounsfield units in the appropriate 
anatomical distribution (subcutaneous or visceral). 
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7.3.3 Statistical Analyses   
Pearson’s correlations were used to assess the association between each of the four adiposity 
measures.  Two stage analyses were performed given the large number of subjects with no 
calcification and the resulting non-normal distribution. The first analysis evaluated the 
presence/absence of CAC. The second analysis evaluated the degree of CAC by volume scores 
in individuals with any CAC.  This approach also allows assessment of the third objective, i.e. 
whether relationships were different for prevalence versus severity. 
Differences between groups with and without CAC were evaluated using the Student’s t 
test for continuous variables and χ2 for dichotomous variables.  Logistic regression analysis was 
used to determine the association of adiposity with the presence of CAC.  Spearman’s 
correlations were used to determine how well the different adiposity measures correlated with 
CAC volume scores, given the presence of any CAC.   Generalized linear models (GLMs), 
which are fairly robust in analyses of non-normally distributed data, were used to compare CAC 
volume scores (CACs) across tertiles of the four adiposity measures.   
In order determine whether any adiposity associations with CAC vary by sex, BMI, WC, 
VAT, and SAT were examined by sex-specific tertiles; sex interactions were also explored.  
Analyses were performed on the entire cohort and within only those positive for calcification.  
All non-normally distributed variables were transformed using an appropriate transformation or 
were tested nonparametrically with the Kruskal Wallis test.  One was added to all values of CAC 
before log-transformation.  All odds ratios and parameter coefficients are reported as per one 
standard deviation change in the continuous variables.  Akaike’s Information Criterion (AIC) 
and Pearson’s r were used to determine which adiposity measurement best accounted for the 
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prevalence and severity of CAC, respectively. The criterion for statistical significance was P < 
0.05.  Analyses were conducted using SAS version 9.1 (Cary, North Carolina). 
 
7.4 RESULTS 
7.4.1 Adiposity and the Presence or Absence of CAC 
Baseline characteristics revealed that although men (n=152) had significantly higher VAT, WC, 
non-HDLc, and lower HDLc than women (n=161), there was no difference in percent with CAC 
or median CAC levels (Table 7-1).  Figure 7-1 shows the prevalence of CAC by sex-specific 
tertiles of adiposity.  There was a significant direct linear trend between tertile of each adiposity 
measure and prevalence of CAC in both sexes (p<0.05) (data not shown).  When the measures of 
adiposity were analyzed as continuous variables and adjusted for age, the presence of CAC was 
positively associated with VAT, SAT and BMI in both sexes, and WC in females (effect 
modification by gender was not observed, p=0.53).  Further adjustment for other clinically and/or 
statistically significant risk factors did not alter these associations (ORs range from 1.2 to 3.2), 
including menopausal status.   Model comparisons suggest that BMI was marginally better at 
accounting for CAC prevalence in both sexes. 
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7.4.2 Correlation between the Adiposity Measures and CAC 
Age-adjusted CACs showed low order positive correlations with each adiposity measure overall 
in both sexes, which reached statistical significance only for SAT in men (Table 7-2).  However, 
when restricted to only those with some measurable CAC, i.e. excluding those with ‘0’ values, 
correlations were surprisingly in the inverse direction, but none approached statistical 
significance (Table 7-3).   
 
7.4.3 Adiposity and the Degree of CAC 
Graphical examination of tertiles of adiposity in those with calcification revealed that there was a 
tendency for an inverse relationship of CACs with each of the adiposity measures in both men 
and women (p for trend <0.05 for each measure) (Figure 7-2).  With the exception of VAT in 
men, in both sexes and for all measures, the lowest tertile of adiposity had the highest median 
CAC scores.  Comparing the first tertile with second and third combined did not change the 
results, with the exception of significantly higher CACs in the lowest tertile of BMI for men 
(data not shown).  In order to explore whether other confounding variables may explain this 
finding, other risk factors were examined by tertile of SAT, where this observation was most 
striking.  No excess of major risk factors were identified in the lowest tertile; however, age, 
diabetes duration, and smoking were higher in both men and women, albeit nonsignificantly 
while eGFR was significantly lower and overt nephropathy was significantly higher in women 
(Table 7-4).   
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Generalized linear modeling revealed that given the presence of any CAC, there was no 
significant association of age-adjusted CAC with any of the four adiposity measures, with the 
exception of SAT in women.  Women in the lowest tertile of SAT had more CAC than those in 
the second tertile (p<0.016).  After adjustment for age, glomerular filtration rate, having ever 
smoked, and a history of a renal transplant, being in the lowest tertile of SAT remained 
significantly associated with CAC in women (Table 7-5) and after further adjustment for 
menopausal status which was not a strong independent predictor (p=0.8).  Model comparisons 
show R² ranging from 35 to 42%, suggesting that all four models generally explain variance in 
CAC to a similar degree.   
 
7.5 DISCUSSION 
In this cross-sectional study in which we investigated the association of adiposity with CAC in 
T1D several important findings are of note.  First, we demonstrated that the four different 
measures of adiposity investigated are similarly associated with CAC, both within and between 
sexes.   We also showed that the direction of the associations differed when looking at the 
presence of CAC as opposed to the degree of CAC, i.e. a lower level of adiposity had a higher 
CACs.   
 Contrary to expectations, central adiposity measures, e.g. VAT and WC, were not better 
able to identify CAC than the other body morphology parameters.  A major hypothesized 
mechanism by which adiposity is associated with CAD is via increased lipolysis of metabolically 
active VAT with its consequent release of inflammatory cytokines into the systemic circulation 
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and excess free fatty acids into the portal vein (20).  Cytokines such as Il-6 and CRP are 
associated with atherosclerosis while increased free fatty acid flux to the liver will increase 
triglyceride and LDLc and small dense LDLc synthesis and are postulated to be in the causal 
pathway of insulin resistance (21, 13).  The small dense LDL phenotype, associated with insulin 
resistance, is very atherogenic in high concentrations.  Despite these characteristics of visceral 
adiposity and our previous reports of CAD events being related to WHR (22; 23) and small 
dense LDL (24), in these current analyses CAC was not preferentially linked with visceral 
compared to general obesity, suggesting possible differences in these measures in T1D.  
However, other investigators state that it is elevated SAT, which is correlated with VAT, that is 
primarily responsible for the elevated systemic levels of FFA associated with VAT (13).  
Nevertheless, most of the studies investigating CAC in type 1 diabetes have found WHR or WC 
to be associated with CAC (6, 7, 9), although BMI has been less consistent (4, 5, 6, 7).  
Biological plausibility notwithstanding, no adiposity parameter appears strikingly better than 
another in detecting CAC.   
That BMI was marginally better able to detect the presence of CAC in both men and 
women may support the argument that BMI is not so much a measure of overall adiposity as it is 
a marker/predictor of health status (25).  In investigating the relationship of obesity with CAD in 
type 1 diabetes, it must be borne in mind that adiposity associations observed in non-diseased 
populations may be very different than that observed in populations with pre-existing disease, 
such as type 1 diabetes.  The inverse relationship of adiposity with severity of CAC in this 
population appears to lend support to this postulate. 
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That increasing adiposity was positively associated with the presence of CAC, while it 
was inversely associated with severity, albeit non-significantly for most parameters, seems to 
suggest at least two divergent disease processes.  A search for confounding by adiposity tertile 
within those with any CAC revealed that estimated glucose disposal rate (eGDR) in men, age, 
lipids, and kidney function/disease in women, and blood pressure in both sexes were 
significantly different for those in the lowest adiposity tertile and who had measurable CAC.  As 
alluded to earlier, obesity correlates such as hypertension, dyslipidemia, inflammation, and 
insulin resistance, i.e. features of the metabolic syndrome, may be responsible for the increased 
CAC observed.  Our marker for insulin sensitivity in this population, eGDR, was inversely 
associated with CAC severity and thus consistent with this hypothesis, though the correlation 
was not significant in women.  Despite identifying these potential confounders, the significant 
SAT difference in women (Table 7-5) remained significant. 
The CAC detected, at least in some of the participants, may not be from atherosclerotic 
plaque, i.e. intimal, as is generally associated with CAD,  but rather partially medial (4,5).  This 
cannot be determined by EBCT. In a recent analysis demonstrating medial wall calcification in 
the EDC population (26), some six years prior to EBT scanning for CAC, a strong association 
was seen between earlier medial wall calcification, determined six years earlier by ankle x-rays, 
and CAC, which remained in multivariable analyses unless neuropathy was included as a 
variable.  Thus both processes may be at work in this population. 
The majority of the studies looking at CAC in T1D have found age and diabetes duration 
to be the strongest correlates of CAC.  Residual confounding due to factors related to long-term 
exposure to hyperglycemia, such as advanced glycated end products (AGEs), may also be apart 
of the pathogenesis of CAC.   Long-term exposure to hyperglycemia may result in AGEs 
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depositing into the extracellular matrix of the arterial wall.  These AGES have the ability to 
stimulate osteoblastic differentiation, leading to vascular calcification.  Sakata et al (27) reported 
increased CML, an AGEs, in the medial wall of the inter-thoracic artery of individuals with type 
1 diabetes, while very little of this was noted in those with type 2 diabetes.  Although there was 
no age-adjusted association between glycemic control and CAC in our population, this does not 
negate the possibility that long duration of hyperglycemia, i.e. diabetes, may be responsible for 
the more severe CAC, particularly in the older participants, who also happened to be the thinnest.  
However, increased levels of AGEs are also found in kidney disease.  
CAC is a well known to be associated with kidney disease, possibly due to abnormal 
calcium and phosphorus metabolism (28).  Extensive calcification is observed in those in renal 
failure, even in the young, and CAC is an important predictor of overall mortality in the kidney 
disease population.  Colhoun et al (5) found AER to be associated with the presence of CAC in 
men with T1D, but not women.  Thilo et al (29) observed no association between 
microalbiminuria and CAC in 71 participants with T1D with a mean age of 48 and disease 
duration of 26 years.  In our population, kidney function was associated with CAC.  We 
observed that GFR tended to increase and overt nephropathy tended to decrease with adiposity in 
women, suggesting that the more severe CAC observed in women with less body fat might be 
partially explained by kidney disease.  However, this association was not observed in men.  
Additionally, although renal transplant recipients had the highest levels of CAC, i.e. most severe 
CAC, they were not more likely to be in the lowest adiposity tertile.  Nevertheless, where 
adiposity failed to be a strong predictor, renal function, as measured by GFR and renal failure 
were significantly related to CAC severity in this population.   
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Consistent with the literature in type 1 diabetes, there were no significant differences in 
CAC prevalence, severity (5,6) or its association of body fat by sex; though the association in 
men for waist circumference was not significant, there was no gender interaction (p=0.53).  
However, contrary to expectations, VAT, albeit nonsignificantly, appeared to be better at 
detecting CAC severity in women than in men.   In the general population, men have an average 
of about twice as much visceral fat as premenopausal women when matched for total body fat 
(30).  We did not observe such a large sex difference in our population.  Visceral fat levels were 
50% higher in males than premenopausal women in our T1D population (data not shown).  This 
attenuation in the sex difference in VAT in T1D has been observed elsewhere.  In the CACTI 
study, Dabelea et al (4) observed that men with T1D had lower WHRs and much lower levels of 
VAT, although similar BMI levels, than nondiabetic men.  Women with T1D had higher waist-
to-hip ratios, WCs, and BMIs, but similar levels of VAT.  Dabelea noted that women with T1D 
“had a more android disposition of adipose tissue” while this was attenuated in men.  It appears 
that VAT is not stored to the same extent in T1D, indicating a more functional role of VAT in 
T1D.  Although many CAD risk factors increase with adiposity in this population, traditional 
CAD risk factors appear (including menopausal status) to be less operant in the pathogenesis of 
severe atherosclerosis, particularly in women, an observation noted elsewhere (31). 
 
Study Limitations 
Obesity may lead to false CAC detection, that is, the higher prevalence in the more obese 
could be artifactual; however, our major findings were not different when being positive for 
CAC was defined as having a CAC score ≥10.  A major limitation of this study is that we were 
unable to follow participants from an earlier time point when participants were free of CAC to 
 113 
determine if the adiposity measures predict the incidence or severity of CAC.  In a population 
such as this, in which it is defined by its pre-existing disease, complications that are part of the 
natural history of the disease may be well underway after 16-18 years of follow-up.  As CAC, 
VAT, and SAT were not available in this population at earlier time periods, the adiposity indices 
measured at the time of EBT may not reflect the adiposity level prior to the development of 
severe calcification.  It is thus not possible to determine the exact causal pathways given the 
cross-sectional nature of our study.  Survival bias may also be at issue in the current study.  It is 
possible that the more obese died before current follow-up. However, being overweight is not a 
mortality risk factor in this population (14) so disruption of the natural obesity/CAC association 
by premature loss of the more obese is unlikely.  It is also possible that longer exposure to 
kidney disease may result in weight loss or that increased body fat is merely a marker of better 
health.   
In conclusion, we found that adiposity was related to the presence of calcification 
irrespective of the measure used.  Age, which in this population is also a proxy for diabetes 
duration, remained, as in many studies, the strongest correlate for both the prevalence and 
severity of CAC.  Although the presence of CAC increased with adiposity, more severe disease, 
i.e. greater CAC, was inversely associated with body fat, albeit only significantly for SAT in 
women.  This was only partially explained by other risk factors, e.g. renal disease and age.  At 
least two distinct disease processes (atherosclerosis and medial wall calcification) may be 
operant in the CAC seen in T1D, underscoring the complex relationship of obesity with CAC in 
T1D.  This double-edged association, the association of CAC with both fat and thin, which 
appears to vary by sex, further highlights that factors other than the standard risk factors are at 
work in the development of CAD in T1D. 
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7.7 FIGURES AND TABLES    
 
 
Figure 7-1.  The prevalence of coronary artery calcification by sex-specific tertiles of adiposity. 
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Figure 7-2.  Median coronary artery calcification score by sex-specific tertiles of adiposity in those 
with a calcification score>0. 
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   Table 7-1.  Characteristics by Gender.  The Pittsburgh Epidemiology of Diabetes Complications Study. 
 
Characteristics Males (152) Females (161) p-value 
Age (years) 42.7 ± 6.7 43.2 ± 7.0 0.61 
Duration (years) 34.6 ± 7.3 34.6 ± 7.7 0.54 
CAC+ (%) 67.1 65.0 0.73 
CACs (median)* 22.2  (0-313.3) 8.9 (0-287.3) 0.47 
Hba1c (%) 7.8 ± 1.5 7.6 ± 1.3 0.10 
Hypertension (%) 37.7 30.2 0.22 
Ever Smoker (%) 36.2 36.9 0.82 
HDLc (mg/dL) 50.2 ± 11.8 63.9 ± 14.4 0.01 
NonHDLc (mg/dL) 132.0 ± 35.0 125.6 ± 28.9 0.02 
VAT cm²* 124.3 ± 68.9 82.0 ± 48.6 <0.0001 
SAT cm²* 224.9 ± 275.9 307.1 ± 446.9 0.0002 
BMI 26.8 ± 3.6 26.9 ± 5.6 0.96 
WC (cm) 92.8 ± 12.0 84.7 ± 11.8 <0.0001 
Menopause* *  39 (24.7)  
    *Non-parametrically tested.  **n=158 
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Table 7-2.  Age-adjusted Correlations of Adiposity with Coronary Artery Calcification (CAC) in 
Type 1 Diabetes (R, r), 2000-2007. 
 
Men, n=152       
 SAT BMI Waist 
Circumference 
eGDR Age CACs 
VAT** 0.67  
<0.0001 
0.67 
<0.0001 
0.69 
<0.0001 
-0.42 
 <0.0001 
0.25 
 0.002 
0.12 
 0.14 
SAT**  0.67 
<0.0001 
0.67 
<0.0001 
-0.39 
 <0.0001 
-0.03 
 0.75 
0.17 
 0.04 
BMI   0.76 
<0.0001 
-0.28 
 <0.0001 
-0.07 
 0.40 
0.11 
 0.19 
Waist 
Circumference 
   -0.46 
 <0.0001 
0.07 
0.42 
0.10 
 0.32 
eGDR     -0.07 
 0.59 
-0.24 
 0.006 
Age      0.59 
 <0.0001 
Women, n=161       
VAT* 0.58 
<0.0001 
0.63 
<0.0001 
0.77 
<0.0001 
-0.36 
 <0.0001 
0.17 
 0.03 
0.12 
 0.12 
SAT**  0.64 
<0.0001 
0.67 
<0.0001 
-0.15 
 0.08 
0.03 
 0.66 
0.06 
 0.42 
BMI   0.74 
<0.0001 
-0.22 
 0.01 
-0.06 
 0.39 
0.15 
 0.07 
Waist 
Circumference 
   -0.35 
 <0.0001 
-0.05 
 0.39 
0.15 
0.08 
eGDR     -0.09 
 0.26 
-0.09 
 0.31 
Age      0.59 
 <0.0001 
         *Pearson for adiposity measures with each other; Spearman for correlations with CAC  **Natural-logarithmically transformed 
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Table 7-3.  Age-adjusted Correlations* of Adiposity with Coronary Artery Calcification (CAC) in 
those with CAC (R, r), 2000-2007. 
 
Men, n=102      
 SAT BMI Waist Circumference eGDR Age CACs 
VAT** 0.54 
<0.0001 
0.66 
<0.0001 
0.67 
<0.0001 
-0.45 
  <0.0001 
0.13 
 0.18 
0.07 
0.46 
SAT**  0.63 
<0.0001 
0.61 
<0.0001 
-0.39 
 <0.0001 
-0.19 
 0.06 
-0.08 
0.40 
BMI   0.73 
<0.0001 
-0.24 
 0.02 
-0.25 
 0.01 
-0.14 
0.15 
Waist Circumference    -0.49 
    <0.0001 
-0.12 
 0.25 
-0.16 
0.12 
eGDR     0.01 
 0.90 
-0.22 
 0.04 
Age      0.59   
<0.0001 
Women, n=104      
VAT** 0.58 
<0.0001 
0.63 
<0.0001 
0.77 
<0.0001 
-0.37 
 0.0003 
-0.08 
 0.42 
-0.08 
0.37 
SAT**  0.64 
<0.0001 
0.67 
<0.0001 
-0.12 
 0.26 
-0.17 
 0.09 
0.18 
0.07 
BMI   0.74 
<0.0001 
-0.19 
 0.07 
-0.29 
0.08 
-0.05 
0.64 
Waist Circumference    -0.37 
 0.0003 
-0.09 
0.40 
-0.06 
0.59 
eGDR     -0.09 
0.40 
0.05 
0.61 
Age      0.54   
<0.0001 
*Pearson for adiposity measures with each other; Spearman for correlations with CAC.  **Natural-logarithmically transformed  
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Table 7-4.  Characteristics of Participants with Coronary Artery Calcification by Tertiles of 
Subcutaneous Abdominal Adiposity and Gender. 
 
Variable, mean 
(SD) 
Tertile 1 Tertile 2 Tertile 3 p-value Variable, mean 
(SD) 
Tertile 1 Tertile 2 Tertile 3 p-value 
Men Women   
Age (yrs) 47.0 
(8.0) 
44.0 
(6.1) 
44.3 
(7.4) 
0.23 Age (yrs) 48.2 (6.4) 45.2 (7.8) 44.4 (6.6) 0.06 
Diabetes 
Duration (yrs) 
38.1 
(8.5) 
34.8 
(6.2) 
34.4 
(7.2) 
0.32 Diabetes 
Duration (yrs) 
38.0 (7.1) 36.0 (8.0) 34.5 (7.0) 0.43 
HbA1c (%) 7.5 (1.3) 7.3 (1.6) 7.9 (1.3) 0.17 HbA1c (%) 7.7 (1.4) 7.2 (1.4) 7.4 (1.1) 0.30 
eGDR 
(mg/kg/min) 
7.2 
(1.8)‡ 
7.5 (1.8) 
‡ 
5.6 (2.1) 0.0001 eGDR 
(mg/kg/min) 
8.0 (2.5) 8.5 (2.0) 8.1 (1.6) 0.51 
HDL (mg/dl) 53.7 
(15.2) 
48.3 
(9.2) 
46.9 
(11.2) 
0.08 HDL (mg/dl) 63.5 (15.0) 63.2 
(14.1) 
61.7 
(12.7) 
0.85 
Non-HDLc 
(mg/dL) 
123.5 
(35.2) 
127.6 
(35.0) 
140.7 
(40.7) 
0.15 Non-HDLc 
(mg/dl) 
123.2 
(31.8) 
125.0 
(20.2) 
138.4 
(28.5) 
0.04 
SBP (mm/Hg) 121.7 
(19.9) 
125.5 
(16.1) 
130.5 
(16.0) 
0.08 SBP (mm/Hg) 120.8 
(17.8) 
113.5 
(14.4) 
121.2 
(15.4) 
0.09 
DBP (mm/Hg) 68.9  
(9.1) ‡ 
71.9 
(9.9) 
75.3 
(8.2) 
0.03 DBP (mm/Hg) 63.9 (7.7) 63.4 (8.7) 68.8 (9.5) 0.02 
eGFR (mg/min)γ 81.7 
(22.8) 
81.2 
(28.3) 
80.7 
(28.9) 
0.87 eGFR (mg/min)γ 62.0 (23.4) 
‡ 
75.0 
(19.5) 
78.6 
(27.6) 
0.02 
Overt 
Nephropathy (%) 
34.8 43.6 32.5 0.61 Overt 
Nephropathy (%) 
48.4 ‡ 29.0 22.0 0.05 
Transplant 
recipient (%) 
8.3 15.4 7.3 0.52 Transplant 
recipient (%) 
12.5 12.9 4.7 0.38 
Ever Smoker (%) 50.0 36.8 36.6 0.54 Ever Smoker (%) 48.4 32.3 40.5 0.45 
CAC, median 
(IQR) ***  
297.5 
(48.4-
1153.0) 
162.6 
(19.3-
605.3) 
135.5 
(20.5-
492.6) 
0.32 CAC, median 
(IQR) *** 
317.1 
(124.9-
868.8) 
73.5 (5.5-
376.9) 
90.4 (7.5-
510.4) 
0.0006 
*Significantly different from (sdf) Tertile (T) 1, †sdf T2, ‡ sdf T3 at p<0.017  **Natural logarithmically transformed before analysis 
***Nonparametrically tested  γTransplant recipients excluded    
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Table 7-5.  Generalized Linear Models for the Association of Visceral Abdominal Adiposity (VAT), 
Subcutaneous Abdominal Adiposity (SAT), Body Mass Index (BMI), and Waist Circumference (WC) with 
Coronary Artery Calcification by Gender. 
 
 
Characteristics 
VAT 
ß± ( p) 
SAT 
ß± ( p) 
BMI 
ß± ( p) 
WC 
ß± ( p) 
Men     
Adiposity*     
  2nd tertile -0.70 ± 0.44 (0.12) -0.25 ± 0.46 (0.59) -0.44 ± 0.45 (0.34) -0.26 ± 0.52 (0.62) 
  3rd tertile -0.08 ± 0.43 (0.85) -0.32 ± 0.45 (0.48) -0.37 ± 0.46 (0.43) -0.45 ± 0.53 (0.40) 
  1st tertile N/A N/A N/A N/A 
AGE 1.0 ± 0.18 (<0.0001) 1.0 ± 0.19 (<0.0001) 1.0 ± 0.19 (<0.0001) 0.90 ± 0.23 (0.0002) 
MDRD -0.01 ± 0.01 (0.12) -0.01 ± 0.01 (0.08) -0.01 ± 0.19 (0.09) -0.01 ± 0.01 (0.06) 
Ever Smoker 0.27 ± 0.18 (0.13) 0.32 ± 0.17 (0.07) 0.32 ± 0.18 (0.07) 0.31 ± 0.19 (0.10) 
Transplant 1.6 ± 0.60 (0.01) 1.5 ± 0.61 (0.01) 1.3± 0.64 (0.05) 1.6± 0.78 (0.04) 
R² 0.42 0.41 0.41 0.35 
Women     
 
Characteristics 
VAT 
ß± ( p) 
SAT 
ß± ( p) 
BMI 
ß± ( p) 
WC 
ß± ( p) 
Adiposity*     
   2nd tertile 0.32 ± 0.54 (0.55) -1.2 ± 0.50 (0.02) -0.17 ± 0.52 (0.76) 0.06 ± 0.53 (0.91) 
   3rd tertile 0.19 ± 0.41 (0.71) -0.76 ± 0.48 (0.12)† -0.16 ± 0.51 (0.74) -0.24 ± 0.53 (0.65) 
   1st tertile N/A N/A N/A N/A 
AGE 1.4 ± 0.23 (<0.0001) 1.3 ± 0.2.2 (<0.0001) 1.4 ± 0.23 (<0.0001) 1.4 ± 0.25 (<0.0001) 
MDRD -0. 01 ± 0.01 (0.18) -0.01 ± 0.01 (0.39) -0.01 ± 0.22 (0.18) -0.01 ± 0.01 (0.27) 
Ever Smoker 0.02 ± 0.15 (0.91) -0.02 ± 0.15 (0.91) 0.03 ± 0.15 (0.85) -0.04 ± 0.20 (0.83) 
Transplant 0.76 ± 0.71 (0.29) 0.79± 0.68 (0.25) 0.71 ± 0.70 (0.31) 0.56 ± 0.70 (0.43) 
R² 0.36 0.40 0.36 0.40 
*VAT, SAT, BMI, and WC, respectively  †Significantly different (lower) from the first tertile at p<0.016. 
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8.0  DISCUSSION 
In 1832, Adolf Quetlet described an index of relative body weight for height in adults with stable 
weight (122).  This index, the weight divided by the square of the height, was later termed the 
body mass index (BMI) by Alan Keyes (123) and has been found to be one of the best indices of 
relative adiposity or excess body weight in the association of body composition with mortality.  
Major putative complications of obesity include cardiovascular disease, hypertension, kidney 
disease, and type 2 diabetes.  Nevertheless, most epidemiological studies have found the 
relationship of body mass index to be U-shaped (30, 124), J-shaped (125, 126), or reverse J-
shaped (127) and, within populations with pre-existing disease, the relationship of adiposity on 
adverse outcomes, particularly mortality, is often found to be inverse (128-130).   
The prevalence of obesity was relatively stable in the U.S. until the 1960s and only rose 
slightly from the late 1960 to 1980, from 13.3 to 15.1% (131).  From 1980 to 1988 it rose from 
15.1% to 23% and has continued to rise, reaching a prevalence of 32.2% in 2004 (132).  
Although secular trends in overweight and obesity in the general population have been well 
documented (132-134), time trends in populations with pre-existing disease, such as type 1 
diabetes, have not been as thoroughly investigated, nor the relationship of adiposity with the long 
term complications of type 1 diabetes.   
At its essence type 1 diabetes is a wasting disease, characterized by severe deficiency or 
absolute absence of the anabolic hormone, insulin, essential to ensuring intake of energy into 
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cells and the prevention of muscle and fat catabolism.  Without this hormone, the natural history 
of the disease would be a progressive wasting to death.  Upon correction, or relative correction, 
of wasting via exogenous insulin, an alternate natural history of the disease commences.  This 
alternate natural history includes progressive kidney disease, with its sequelae of hypertension 
leading to further progression of kidney disease leading to an atherogenic lipid profile, anorexia, 
and wasting in its final stages.  This alternate natural history also includes very early 
cardiovascular disease, still largely unexplained, particularly in women, autonomic neuropathy 
with its dysphagia, anorexia, and early satiety, other neuropathies causing muscle wasting or 
limited mobility via pain, bone deformities, or amputations.  It also includes blindness with its 
limitation on mobility and peripheral vascular disease, the latter also causing limited mobility 
due to pain or amputations.  Finally, this natural history ends with very early mortality, with its 
obvious limit on the time in which weight gain can occur and its implications for adiposity as in 
populations with limited longevity increased adiposity tends to be protective.  Any effects of or 
on adiposity within type 1 diabetes must take place within this environment and to the extent that 
these effects mirror the general population, whether good or bad, represents a major 
accomplishment in type 1 diabetes.   
Within this hostile environment, we observed a 47% increase in the prevalence of being 
overweight and a 700% increase in the prevalence of obesity over 18 years of follow-up in the 
Pittsburgh Epidemiology of Diabetes Complications Study adult cohort.  Mean weight increased 
by 2.6 kg/m² over the course of follow-up, with weight gain observed in over two-thirds of the 
cohort at last follow-up.  Although more than one-fifth of the population had died by the end of 
follow-up, the mean age at death was the same as the mean age of the living at last follow-up, 
indicating an extension of the lifespan within this population.  Adiposity was not however 
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independently predictive of coronary artery disease (Appendix C), the leading cause of death 
within this population.  Body mass index was not predictive of overt nephropathy (Appendix C), 
nor complications of overt nephropathy (135), the second leading cause of death within this 
population.  Adiposity demonstrated divergent associations with the prevalence as opposed to the 
severity of coronary artery calcification, a process associated with both coronary artery disease 
and overt nephropathy.  Adiposity was positively associated with the presence of any coronary 
artery calcification, but, given calcification was present, inversely associated with the severity of 
coronary artery calcification.  Free fatty acids, a major putative factor in the relationship of 
adiposity with insulin resistance and cardiovascular disease, and posited to increase with 
increasing visceral fat, demonstrated no relationship with visceral adiposity or estimated insulin 
resistance and showed no relationship with coronary artery calcification; however, it was 
associated with subcutaneous abdominal adiposity, at low levels in men and at both low and high 
levels in women.  In women, free fatty acids were also associated with brachial pulse pressure, a 
measure of arterial stiffness.  Finally, adiposity demonstrated a complex relationship with 
mortality in this population, with increased risk at both ends of the BMI spectrum and 
demonstrated an inverse relationship with mortality when accounting for waist circumference, 
whether looking at baseline BMI, average BMI during follow-up, or BMI closer to the end of 
follow-up.   Weight gain in adulthood was associated with decreased mortality. 
Although traditionally viewed as a starvation state, after the discovery of Banting and 
Best and the subsequent availability of exogenous insulin (136, 137), type 1 diabetes can now be 
better described as a tug of war between excess peripheral insulin and insulin deficiency.  
Indeed, studies of mean amplitude of glycemic excursions indicate that even in relatively well 
controlled individuals with type 1 diabetes this is an ongoing process (138-140).  Insulin, the 
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primary anabolic hormone of nutrient metabolism, suppresses lipolysis, proteolysis, and 
gluconeogensis, facilitates glucose uptake into muscle and adipose tissue, increases glycogenesis 
and lipogenesis, and stimulates general protein anabolism, and thus weight gain (141).  While 
acute excess of this hormone in peripheral tissues can result in mild to severe hypoglycemia 
resulting in increased secretion of counterregulatory hormones and free fatty acids, and in very 
severe cases permanent brain damage or death, insulin deficiency results in hyperglycemia, and 
in more severe cases polyuria, dehydration, electrolyte imbalance, again increased free fatty 
acids, ketoacidosis, and weight loss.  Very severe cases of acute insulin deficiency can result in 
death.  Thus, although the anabolic effects of insulin promote adipose and muscle tissue build up 
and its deficiency promotes weight loss, both extremes of the insulin homeostasis spectrum result 
in increased FFA production and death. 
In this population, we have shown a complex interaction between catabolic and anabolic 
factors over the approximate two decades of follow-up.  Intensification of insulin therapy 
increased dramatically while HbA1c, a marker of glycemic control, showed a substantial 
reduction, both factors directly associated with weight gain via a reduction in catabolic tissue 
breakdown and glycosuria and an increase in adipose tissue storage.  They are also indirectly 
associated with weight gain via a reduction in complications associated with wasting, i.e.  
nephropathy and autonomic neuropathy (3).  Nevertheless, although the progression of the 
natural history of the disease has slowed, it has not halted, and for coronary artery disease, no 
improvement has been made (104) (some would argue that cardiac events may have even 
increased after the institution of intensive insulin therapy (142), and after 18 years of follow-up, 
the EDC population is considerably older with considerably more complications and thus the 
wasting process may still be operant.  Furthermore, although there was a reduction in many risk 
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factors associated with complications of diabetes, for blood pressure there was not.  Blood 
pressure, increased overtime and, particularly for systolic blood pressure, across BMI categories.  
This has important implications for mortality since in the general population hypertension is 
postulated to be a primary mediator of obesity’s impact on mortality (143). 
Despite the marked increase in overweight and obesity observed in this population, risk 
factors for weight gain were largely indeterminate.  There is strong biological plausibility for 
weight gain with intensive insulin therapy use (5, 144) and in our population, with a time lag of 
approximately 2 years, the increase in overweight an obesity paralleled that of intensive insulin 
therapy use.  Thus, intensive insulin therapy appeared to demonstrate a strong relationship with 
weight gain and the increasing prevalence of overweight and obesity; nevertheless, this was 
difficult to demonstrate in our statistical models and therefore ecological fallacy cannot be ruled 
out.  To the extent that increased longevity represents a normalization of the type 1 diabetes 
population, our observation may simply reflect secular trends in the general population.  It is 
possible that intensification of insulin therapy is allowing for greater dietary freedom and greater 
ability to simulate the background population in eating habits.  It is also possible that better risk 
factor management overall in those on intensive therapy as well as the reduction in or delayed 
progression to chronic diabetes complications as a result of intensification of insulin therapy is 
allowing for normalization of the population and subsequently the ability to mirror the secular 
trend observed in the general population.  This appears to be partially substantiated by our 
results, as the strongest predictors of weight gain were diabetes complications and smoking, all 
inverse predictors, while many risk factors for wasting associated complications demonstrated an 
improvement after 18 years of follow-up, despite the aging of the cohort.  However, intensive 
insulin therapy itself, being a more physiological method of insulin delivery, may itself result in 
 130 
a relative normalization of the type 1 diabetes population.  All of this notwithstanding, direct 
anabolic effects of insulin appear to be operant; although delayed, the increase in the prevalence 
of overweight and obesity in our population appeared to be occurring at a faster rate than in the 
general population.   
Intensive insulin therapy, associated with both weight gain (4, 145) and reduction in 
HbA1c (2, 146) and diabetes complications, loomed large but was relatively silent, statistically 
speaking, in our population.  Nonetheless, for the most important complication of all, mortality, 
intensive insulin therapy showed a strong protective effect.  But this was only when looking at 
the average duration on intensive insulin therapy and this did not account for the strong 
relationship of obesity with mortality.  Average duration of time on blood pressure medication 
was also protective of mortality, and in this model average amount of time spent in the obesity 
BMI range was not predictive, but average blood pressure during follow-up was, as was being 
underweight for the majority of follow-up.  Just as hypertension when defined by both absolute 
blood pressure cut points and use of hypertension medication can be misleading in its 
relationship with outcomes, e.g. hypertension is protective of mortality when modeled in place of 
blood pressure and hypertension medication, similarly it is possible that the assumed relationship 
of intensive insulin therapy with outcomes can be confounded by its individual components.  We 
(Appendix C) have shown that the reduction in HbA1c with intensive insulin therapy use was 
actually due to self monitoring of blood glucose and not to intensification of insulin therapy. 
Type 1 diabetes is not only an (absolute) insulin deficiency state; it is also an amylin 
deficiency state as amylin is cosecreted with insulin (100, 147, 148).  Thus another possible 
reason for weight gain with intensification of insulin therapy is that in tight glycemic control, 
although exogenous insulin may compensate for the glucoregulatory effect of amylin, it cannot 
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compensate for its satiety inducing effect, i.e. slowing of gastric emptying and reduction of food 
intake, and thus, knowing when to stop eating.  Conversely, in relatively low insulin states it may 
also result in wasted calories, without necessarily clinically evident wasting, due to its satiety and 
postprandial glucose regulatory effects, and thus increased postprandial glucose levels which 
may exceed the renal threshold (~180 mg/dl) (100), resulting in polyuria and thus the traditional 
lean phenotype in type 1 diabetes.  Nevertheless, intensification of insulin therapy may have 
effects on complications of diabetes beyond that of any effects on adiposity, as our updated 
means mortality model appeared to demonstrate. 
Not only does insulin suppress endogenous glucose output and facilitate glucose uptake, 
it also suppresses lipolysis.  In our population, a low insulin dose at baseline was an independent 
predictor of the eighteen year incidence of non-fatal coronary artery disease, while HbA1c, body 
mass index, and waist circumference were not (Appendix C).  It is possible that this low insulin 
dose resulted in increased levels of free fatty acids, shown to be related to adverse cardiac 
outcomes, such as arrhythmias(149, 150), ischemia (151), and sudden cardiac death (152).  
While we did not have free fatty acid measurements at baseline, for this thesis they were 
measured in the sixteen-year follow-up exam population and found to be predictive of pulse 
pressure in women, a measure of arterial stiffness also associated with arrhythmias (153), 
ischemic heart disease (154), and sudden cardiac death (1). 
The major putative mediator of obesity’s relationship with coronary artery disease is 
abdominal adiposity induced insulin resistance, primarily through free fatty acids.  Free fatty 
acids induce hepatic insulin resistance by inhibiting glycogenolysis, reducing peripheral tissue 
glucose uptake, and increasing hepatic glucose production.  Lipolytically active visceral 
adiposity, with its direct route to the portal vein, has generally been put forth as the primary 
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source of insulin resistance inducing free fatty acids.  However, it has also been argued that 
subcutaneous abdominal fat is the major source of both plasma and hepatic free fatty acids, and 
thus the insulin resistance associated with elevated abdominal adiposity.  Although free fatty 
acids are elevated with obesity in the general population, in our population, free fatty acids did 
not appear to increase with increasing adiposity overall.  They did, however, show a strong 
relationship with fasting glucose level and in type 1 diabetes, both ends of the glucose 
homeostasis spectrum may result in insulin resistance due to increased catecholamine and free 
fatty acid secretion, and in severe hyperglycemia, glucose toxicity.   
Although we did not observe a relationship of free fatty acids with pulse pressure in men, 
in men both visceral and subcutaneous abdominal adiposity were related to aortic pulse pressure.  
These abdominal fat measures were also associated with pulse pressure in women, although in 
women this relationship interacted with free fatty acids.  However, in both men and women, 
visceral and subcutaneous abdominal adiposity was associated with coronary artery calcification, 
a positive relationship with the presence of any coronary artery calcification and, particularly in 
women, an inverse relationship with its severity given any calcification.  In men, there was a 
suggestion of a U-shaped relationship of visceral adiposity with the severity of coronary.  Thus 
in men, high levels of visceral fat appear to be associated with both pulse pressure and insulin 
resistance (Appendix A, Paper 3).  Just as there is a sexual dimorphism in lipid metabolism and 
adiposity distribution (155-157), there also appears to be sexual dimorphism in lipid and adipose 
tissue function.  The free fatty acid relationship with insulin resistance in the non-diabetes 
population appears to be just in men.  Nevertheless, we did not observe a relationship of free 
fatty acids with coronary artery calcification, presence or severity, in either sex.  Then again, we 
did not observe the expected difference in free fatty acids by fasting status in men, although it 
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was observed in women with no difference in ambient glucose levels either by sex or fasting 
status. 
The divergent relationship of our adiposity measures, whether visceral abdominal fat, 
subcutaneous abdominal fat, body mass index, or waist circumference, with coronary artery 
calcification may help to explain our failure to show a relationship of either body mass index or 
waist circumference with the 18-year incidence of coronary artery disease, whether fatal or non-
fatal (Appendix C).  In contrast, both of these adiposity indices were associated with overall 
mortality and appeared to provide independent information.  It appears that abdominal adiposity 
and body mass index, although providing independent information, are better predictors of all-
cause mortality than of coronary artery disease mortality or non-fatal coronary artery disease, an 
interesting finding given that coronary artery disease is posited to be in the biological pathway 
between obesity and mortality.   
We found that after adjustment for waist circumference, any adverse obesity relationship 
with mortality disappeared and an inversely linear relationship between body mass index and 
mortality emerged.  This was true whether looking at baseline body mass index, average body 
mass index, or body mass index closer to the time of event.  In contrast, the relationship between 
waist circumference and mortality remained positive in baseline and time-varying models.  In the 
updated means model, the relationship between waist circumference and mortality changed from 
a U-shaped relationship to a positively linear relationship after adjustment for body mass index.  
It appears that abdominal adiposity accounted for any adverse effect of a higher BMI and any 
protective effect of a lower BMI, while lower lean body mass and/or peripheral adiposity 
accounted for any adverse effect of low abdominal fat.  So here we see divergent effects of 
abdominal adipose tissue and lean/peripheral adipose tissue on mortality.   Given that weight loss 
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shows a stronger association with lean body mass than fat mass in general and the very strong 
inverse association between weight change and mortality in our population, our finding of an 
inverse relationship between body mass index and mortality once accounting for abdominal fat is 
not surprising.  More difficult to explain is the relationship of abdominal fat with mortality after 
accounting for body mass index since we did not find waist circumference to  account for the 18-
year incidence of coronary artery disease.  Closer examination of the pulse pressure data 
revealed that although free fatty acids were associated with pulse pressure at low levels of 
subcutaneous adiposity in men and at high levels of subcutaneous adiposity in women, in both 
men and women, pulse pressure was associated with visceral abdominal fat.  Estimated insulin 
resistance was strongly associated with pulse pressure in both sexes (r=0.37, p=0.002 in men; 
r=0.41, p=0.0004 in women, after age-adjustment) and after adjustment for estimated insulin 
resistance, the relationship of free fatty acids with pulse pressure was even stronger in women 
(r=0.30, p=0.01), with no effect on men (r=0.05, p=0.71).   Thus it is possible that insulin 
resistance in men and both insulin resistance and free fatty acids in women may account for the 
relationship of abdominal adiposity with mortality.  The increased stress imposed by 
complications of diabetes, as well as any acute illness, on the individual with type 1 diabetes may 
cause both an increase in catecholamines and a rise in free fatty acids and subsequently in insulin 
resistance.   
Our finding of divergent relationships of adiposity for the presence versus the severity of 
coronary artery calcification suggested that two different processes were operant in the 
calcification process in type 1 diabetes.   One is the atherosclerotic process of the intimal arterial 
wall, the other the advanced glycation end products (AGEs) driven calcification of the medial 
arterial wall.  Our positive association of adiposity with both the presence and progression of 
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coronary artery calcification (158), but it’s inverse, albeit non-significant association with the 
severity of coronary artery calcification lends support to this.  We have recently shown a cross-
sectional association of AGEs with coronary artery calcification and overt nephropathy, but not 
coronary artery disease (159).  We were also able to demonstrate a relationship with distal-
symmetrical polyneuropathy, but not lower arterial extremity disease.  Since both overt 
nephropathy and coronary artery calcification show a strong relationship with coronary artery 
disease (160) and likewise distal-symmetrical polyneuropathy shows a strong association with 
lower extremity arterial disease, it is possible that any large vessel disease not accounted for by 
AGEs may be largely due to adiposity driven atherosclerosis.  Finally, poorer glycemic control 
was predictive of mortality in all three of the biological risk factors time models and, in the 
prediction of weight change, it was associated with both weight gain and weight loss.  With its 
constant struggle between catabolism and anabolism, lipolysis/proteolysis and 
lipogenesis/proteogenesis,  and chronically elevated free fatty acid levels, the single most 
important mediator of weight change in type 1 diabetes is not  any of is long-term complications, 
but the disease itself and duration of disease is the single most important risk factor for mortality. 
 
8.1 LIMITATIONS 
A major limitation of this study was that at a mean of 19 years duration, our population, although 
young, was already long duration cohort at baseline.  Furthermore, with a mean age of eight 
years at diabetes diagnosis, effects of age could not be truly separated from those of the disease 
itself.  The non-linear relationship between BMI and mortality observed in the general 
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population has been reported by some to be mainly in the elderly and that in the middle-aged or 
young this relationship tends to be linear.  With a maximum age of 48 years at baseline, we were 
not able to investigate this, nevertheless, even in this young cohort the U-shaped association of 
baseline BMI with mortality was observed.  It could be argued that type 1 diabetes is an 
accelerated aging disease in which diabetes complications, termed chronic diseases in the general 
population, occur at a very early age and life expectancy is reduced by several decades, and in 
this population with only an average of eight years separating birth and diagnosis of type 1 
diabetes, age appears to be synonymous with the disease itself.  This seems to be supported by 
our finding of a very strong association between surrogate measures of AGEs and the severity of 
coronary artery calcification (159), where an inverse relationship with adiposity was observed 
(VAT/calcification paper).  Although both coronary artery calcification and AGEs are associated 
with age, AGEs increase naturally with age, and are elevated further in type 1 diabetes perhaps 
as a result of their formation being accelerated with chronic hyperglycemia and oxidative stress 
(161).  Indeed, AGEs have been found to be associated with almost all long-term complications 
of diabetes. 
Our long-duration cohort with its very strong association between age and diabetes 
duration also made it difficult to stratify by “pre-existing disease”.  It has been argued that in 
estimating the association of BMI with mortality, pre-existing illness should be excluded, 
however, it should be noted that in this population, type 1 diabetes itself is probably the most 
important pre-existing disease.  At study baseline, nearly half of this population had a pre-
existing long-term complication of type 1 diabetes.  However, the increased mortality among the 
lean was not due to “pre-existing disease”, i.e. complications of diabetes, as exclusion of this 
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subgroup did not alter the shape of the association.  But this same observation has been 
repeatedly shown in the general population (162, 163). 
In addition, after approximately twenty years of follow-up in which nearly one-fourth of 
the population has died, our long-duration cohort is now a survival cohort, and substantial 
survival bias in our results may be operant.  While it is possible that due to the cross-sectional 
nature of the study design of the investigation of adiposity with coronary artery calcification, the 
inverse association observed between adiposity and severity of calcification resulting from left 
truncation of the more corpulent 16-18-year follow-up exam pre-deceased, due to the very nature 
of type 1 diabetes it appears more likely that those with increased adiposity near the end of our 
follow-up period represent those better able to fight the catabolic process of the disease.  This 
seems to be supported by the very strong relationship we observed between weight change in 
mortality, and that in analyses that excluded the pediatric population.  Furthermore, although a 
net weight gain was observed in the majority of this population at last follow-up, perhaps more 
importantly net weight gain, far exceeded weight loss very likely due to the competing risk of 
mortality.  And while we tried to control for follow-up time, perhaps this too, like age, could not 
be truly controlled for. 
Another limitation of this study is that baseline measurements of visceral and 
subcutaneous adiposity, coronary artery calcification, and free fatty acids were not available.  
These measurements were not made available until the 16-year follow-up exam, with the 
exception of coronary artery calcification which was first made available at the 12-year follow-
up exam.  In addition to the bias that this may present in the interpretation of our results as at the 
16-18-year follow-up when these variables were investigated this was a survival cohort, only 
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cross-sectional associations coronary artery calcification with abdominal fat and free fatty acids 
could be determined and as such reverse causality cannot be ruled out.    
Given the importance of insulin and glucose homeostasis on weight change and free fatty 
acids, the lack of data on mean amplitude of glucose excursions is another limitation of this 
study.  Similarly, although hyperinsulinemic euglycemic clamp data was available on a sub-
sample of our population, it would have been useful to have hyperinsulinemic hypoglycemic 
clamp data as well since free fatty acids provide a substantial part of the counterregulatory 
response to hypoglycemia (164, 165) and elevated free fatty acids from antecedent hypoglycemia 
also induce insulin resistance as a defense mechanism against subsequent hypoglycemia (166).  
However, as this was a long duration cohort even at baseline it may have been unethical to 
perform this type of clamp study as hypoglycemia and the free fatty acid response to 
hypoglycemia are hypothesized to trigger dangerous ischemia, arrhythmias, and even myocardial 
infarctions in those with an already compromised vasculature, even if subclinical, and is one of 
the hypothesized causes of dead (167) in bed syndrome and sudden death too frequently 
observed in type 1 diabetes (168). 
Finally, this was a 98% Caucasian (2% African American) population and as such is 
limited in its generalizability to non-White type 1 diabetes populations.  Although the prevalence 
of type 1 diabetes was low among African Americans relative to Caucasian Americans in the 
diagnosis years of EDC eligibility, it was not that low. Type 1 diabetes is one of the leading 
chronic diseases in African American children and African Americans account for approximately 
6% of type 1 diabetes cases in the United States overall.  To the extent that race has any impact 
on the effects of or on adiposity in type 1 diabetes above and beyond the type 1 diabetes disease 
process itself, our results are limited in their generalizability.   However, considering the inverse 
 139 
association of BMI with three-year mortality in the New Jersey 725 Cohort (169), an exclusively 
African American type 1 diabetes cohort, this does not appear to be the case, at least not for 
African Americans.  Perhaps of greater concern is the overgeneralization that may be caused by 
the under-representation in type 1 diabetes studies of racial/ethnic groups at increased risk of 
type 2 diabetes relative to non-Whites.  Indeed, overgeneralization of type 2 to type 1 diabetes, 
whether in White or non-White populations, is perhaps the biggest public health concern that 
adiposity poses for type 1 diabetes. 
 
8.2 PUBLIC HEALTH AND CLINICAL IMPLICATIONS 
Caution should be taken not to generalize risk factors for adverse outcomes in the general 
population to outcomes within diseased populations.  Considering the complex relationship of 
adiposity in type 1 diabetes, the general lack of a relationship with long-term complications, the 
protective effect of weight gain on mortality and the wide BMI range associated with minimal 
mortality, risk factor management should focus on risk factors shown to be associated with 
mortality in type 1 diabetes.  Although obesity itself should be avoided, it should not be at the 
expense of improved metabolic control and may be better focused on abdominal adiposity and 
risk factors correlated with obesity, such as increased blood pressure and an adverse lipid profile.  
Accounting for these appears to abolish any increased risk associated with obesity with mortality 
in type 1 diabetes.  Although overweight and obesity are increasing in type 1 diabetes, the 
clinician should bear in mind that type 1 diabetes is the pre-existing disease.  With an average 
disease duration of 33 years and age at death of 43 years, mortality is still occurring several 
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decades earlier than in the general population.  Considering the years of life lost, the protective 
effect of weight gain may have a strong public health impact. 
Future directions should focus on strategies/product development to maximize glucose 
control while minimizing obesity and without substantially negatively influencing quality of life.   
This may also be a better way of reducing chronically elevated free fatty acid levels as direct 
pharmacological lowering of free fatty acids may have adverse outcomes in this population 
strongly dependent on them as an alternative fuel source and substrate for glucose 
counterregulation.  Finally these data raise the possibility that weight gain reflecting lean body 
mass and general health, may also be a positive benefit if peripheral in location.  This is an area 
that merits further research. 
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A.1 ABSTRACT 
Background: Cardiovascular disease is the leading cause of death in type 1 diabetes.  Pulse 
pressure, a measure of arterial stiffness, is also elevated in type 1 diabetes, and associated with 
arrhythmias, ischemic and sudden cardiac death.  Free fatty acids, elevated in type 1 diabetes, 
females, and abdominal obesity, have associations.  We therefore examined whether free fatty 
acids were associated with pulse pressure in an adult population (n=150) of childhood onset type 
1 diabetes and whether any such association appeared to be mediated by abdominal adiposity and 
gender.   We also investigated the relationship of free fatty acids with coronary artery 
calcification.   
Methods: Mean age and diabetes duration were 42 and 33 yrs, respectively when CAC, visceral 
adiposity (VAT), and subcutaneous abdominal adiposity (SAT) were determined by electron 
beam tomography. Free fatty acids were determined by in vitro colorimetry.  Pulse pressure was 
calculated as the systolic blood pressure minus diastolic blood pressure.  Free fatty acids were 
log-transformed before analyses and all analyses were controlled for serum albumin.   
Results: Free fatty acids were associated with pulse pressure in women (r=24, p=0.04), but not in 
men (r=0.07, p=0.55).  An interaction for the prediction of pulse pressure was noted between free 
fatty acids and both VAT (p=0.03) and SAT (p=0.008) in women, but only a marginal 
interaction with SAT (p=0.09) and no interaction for VAT with free fatty acids observed 
(p=0.40) in men.  In multivariable linear regression analysis allowing for serum albumin, age, 
height, heart rate, albumin excretion rate, HbA1c, HDLc, free fatty acids, SAT, and the 
interaction between free fatty acids and SAT, the interaction between free fatty acids and SAT 
remained significantly associated with pulse pressure in women (p=0.03), but not men (p=0.32).  
Free fatty acids showed no association with log-transformed coronary artery calcification.   
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Conclusion: Free fatty acids are associated with in women, but not men, with type 1 diabetes.  
This finding might help to explain the lost of the gender difference in cardiovascular disease in 
type 1 diabetes.   
  
 144 
A.2 INTRODUCTION 
Free fatty acids (FFAs) are known to be elevated in type 1 diabetes and obesity, 
particularly abdominal obesity (1, 2), and to be associated with insulin resistance (3).  Insulin 
resistance in type 2 diabetes and in the general population is associated with a markedly 
increased risk of coronary artery disease (4, 5).   However, T1D is a disease characterized by an 
abnormality in fuel utilization.   Both intermittent insulin deficiency/absence and excess are 
characteristic of this disease, and both contribute to excess free fatty acid production; therefore, 
the adiposity FFA/relationship observed in the general population may be very different in T1D.   
Coronary artery calcification is a subclinical marker of coronary artery disease.  In the 
Epidemiology of Diabetes Complications (EDC) Study, inverse and non-existent relationships 
were observed between the severity of coronary artery calcification and abdominal fat (6).  In 
type 1 diabetes it is uncertain to what extent calcification of the coronary arteries is due to 
atherosclerosis of the intima layer of the arterial wall (which may in part relate to obesity and 
other cardiovascular risk factors) or calcification of the medial layer, partially renal driven.  
Another subclinical measure of cardiovascular disease is arterial stiffness.  All these measures 
are likely strongly interrelated, for example Sutton-Tyrrell (7) observed a direct relationship 
between visceral abdominal fat with arterial stiffness in a non-diabetes population; however, 
little is known about this association in type 1 diabetes.   As FFAs have been postulated to be a 
mediator of insulin resistance and are predictive of ischemic heart disease (8), cardiac 
arrhythmias (9,10) and sudden cardiac death (11) in the general population, the elevated levels of 
free fatty acids observed in type 1 diabetes may also help to explain the greatly increased risk of 
CAD in this population.   
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The purpose of this study was to assess the association of free fatty acids with coronary 
artery calcification and arterial stiffness (pulse pressure) in an adult population of childhood 
onset type 1 diabetes and to determine whether any such association appeared to be mediated by 
body fat.  As abdominal body fat and free fatty acids are known to vary by gender, these analyses 
are investigated sex-specifically.  To our knowledge, this has not been investigated in type 1 
diabetes. 
 
A.3 METHODS 
The EDC study is an ongoing study examining the long term complications of T1D in 
658 individuals diagnosed before the age of 17 years with T1D at Children’s Hospital of 
Pittsburgh between 1950 and 1980.  This current report is based on a subset (n=150) of this 
population who underwent electron beam tomography (EBT) VAT and subcutaneous abdominal 
fat (SAT) via EBT scanning as part of the Insulin Resistance Study, a substudy of the 16-year 
follow-up.   
Fasting blood samples were assayed for lipids, lipoproteins, and hemoglobin A1c.  High-
density lipoprotein (HDL) cholesterol was determined by a heparin and manganese procedure, a 
modification of the Lipid Research Clinics method (12).  Cholesterol was measured 
enzymatically (13).  FFA were measured using the colorimetric method (Wako Pure Chemical 
Industries, Ltd).  Only fasting samples were used.  Urinary albumin was determined immuno-
nephelometrically (14).   
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CAC was measured using EBT (Imatron C-150, Imatron, South San Francisco, CA).  
Threshold calcium determination was set using a density of 130 Hounsfield units in a minimum 
of 2 contiguous sections of the heart.  Scans were triggered by ECG signals at 80% of the R-R 
interval.  The entire epicardial system was scanned.  CAC volume scores were calculated based 
on isotropic interpolation (15).  Direct measurements of abdominal adiposity (visceral and 
subcutaneous abdominal adipose tissue surface area) were also taken by EBT scanning.  Scans of 
abdominal adipose tissue were taken between the fourth and fifth lumbar regions, which were 
located by counting from the first vertebra below the ribs.   Two 10 mm thick scans were taken 
during suspended respiration.  The images were then analyzed using commercially available 
software for all pixels corresponding to fat density in Hounsfield units in the appropriate 
anatomical distribution (subcutaneous or visceral).  Height was measured using a stadiometer.   
Blood pressure was measured by a random-zero sphygmomanometer according to a 
standardized protocol (16) after a 5-minute rest period.  Blood pressure levels were analyzed, 
using the mean of the second and third readings.  Brachial pulse pressure was calculated (systolic 
blood pressure-diastolic blood pressure).   
The student’s t test was used to compare characteristics of study participants by fasting 
status.  Further analyses were limited to participants providing fasting blood samples.  Pearson 
correlations were used to assess the relationship between FFA, brachial pulse pressure, and 
coronary artery calcification, adiposity indices, height, heart rate, glycemia indices, and albumin 
excretion rate.  FFA, VAT, SAT, BMI, coronary artery calcification, and albumin excretion rate 
were log-transformed before analyses.  Multiple linear regression analyses with backward 
elimination was used to determine independent predictors of pulse pressure and coronary artery 
calcification.  All analyses with FFA were adjusted for serum albumin as FFA travel in serum 
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bound to albumin.  FFA and serum albumin were forced into all multivariable models.  Analyses 
were conducted using SAS version 9.1.3 (Cary, North Carolina).  All procedures were approved 
by the Institutional Review Board of the University of Pittsburgh. 
 
 
 
A.4 RESULTS 
Twenty-nine percent of the sixteenth-year follow-up exam study participants provided non-
fasting blood samples.  Table A-1 shows the characteristics of the study participants by fasting 
status.  Overall, there were no differences by fasting status, with the exception of age and FFA 
levels (41.7 vs. 44.5 years, p=0.02, 0.99 vs. 0.84 mmol/l, p=0.04 in fasters vs. non-fasters, 
respectively, data not shown).  However, upon sex-specific examination, this age difference was 
found to be only in men.  Fasting men were approximately five years younger than non-fasters 
(41.0 vs. 45.8, p=0.004).  By contrast, there was no difference in age in women able or willing to 
come in for the exam fasting (42.5 vs. 43.5, p=0.56); however, fasting women, but not men, had 
significantly higher free fatty acid levels than non-fasters.  There were no other differences by 
fasting status in men and women.  The remaining analyses are restricted to the 150 fasting 
participants. 
Table A-2 shows the sex-specific Pearson correlations between free fatty acids, pulse 
pressure, coronary artery calcification, adiposity and glycemia indices, height, heart rate, and 
albumin excretion rate.  Free fatty acids were positively correlated with pulse pressure in women 
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(r=0.24, p=0.04) but not men (r=0.07, p=0.55), but showed no association with coronary artery 
calcification in either sex.  Free fatty acids were associated with fasting glucose in both men and 
women, but showed no association with HbA1c, albumin excretion rate, heart rate, height, or any 
of the adiposity indices.  Correlates of pulse pressure and coronary artery calcification are also 
presented in Table A-2. 
Figures A-1 and A-2 show the Pearson’s correlation of free fatty acids with pulse 
pressure by tertiles of sex-specific subcutaneous and visceral abdominal adiposity, respectively.   
An interaction was observed between free fatty acids and subcutaneous adiposity for pulse 
pressure in both men (p=0.09) and women (p=0.008), although only marginal in men.  An 
interaction was also seen between free fatty acids and visceral abdominal adiposity in women 
(p=0.03), but not in men (p=0.40).  Interactions between free fatty acids and adiposity were not 
observed for coronary artery calcification. 
 After multivariable linear regression analyses with backward selection, free fatty acids 
remained significantly associated with pulse pressure in women, but not in men.  After adding 
the interaction term between free fatty acids and subcutaneous adiposity to the final model,  the 
interaction term was significant in women (p=0.03), but not in men (p=0.32) (Table A-3).   
Table A-4 shows the multivariable linear regression analyses, with backward selection, of 
free fatty acids with coronary artery calcification.  Free fatty acids were not associated with 
coronary artery calcification in either sex.   
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A.5 DISCUSSION 
The major finding of this study was that free fatty acids are associated with pulse pressure in 
women, but not coronary artery calcification in either gender in type 1 diabetes.  We also 
observed that the relationship of free fatty acids with pulse pressure varied by level of 
subcutaneous and visceral abdominal adiposity.  Finally we note that although abdominal fat is 
not associated with free fatty acids in type 1 diabetes it does appear to modify the relationship 
between free fatty acids and arterial stiffness in women with type 1 diabetes.   
Pulse pressure, the difference between the systolic and diastolic blood pressure, is a 
measure of arterial distensibility, or stiffness.  We found that free fatty acids were associated 
with an increase in brachial pulse pressure.  Although little is known about the relationship of 
free fatty acids and arterial stiffness, Steinberg et al (17) found that free fatty acids caused 
endothelial dysfunction in healthy individuals.   Nakayama et al (18) found that abnormal free 
fatty acid metabolism was associated with diastolic, but not systolic, dysfunction in individuals 
with essential hypertension.  Free fatty acids account for a substantial proportion of the 
counterregulatory defense against hypoglycemia (19), a known player in endothelial dysfunction 
and cardiac ischemia.  Acute hypoglycemia causes an increase in systolic blood pressure and a 
decrease in diastolic blood pressure, and therefore an increase in pulse pressure (20, 21).  
Although mean fasting glucose levels in our study were well out of the hypoglycemia range, 
preclinic nocturnal hypoglycemia and subsequent counterregulation cannot be ruled out. 
The free fatty acid associated increase in pulse pressure may lead to cardiac arrhythmias, 
ischemia, and sudden cardiac death.  In the Framingham Heart Study, pulse pressure, but not 
mean arterial pressure, significantly predicted atrial fribillation (22). In patients with type 2 
diabetes, Paolisso et al (9) observed ventricular premature complexes to increase with increasing 
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free fatty acid concentration and to decrease when free fatty acids were directly lowered.  The 
increased free fatty acids accompanying hypoglycemia counterregulation or very low to absent 
insulin levels in type 1 diabetes may also increase tissue ischemia.  In nondiabetic men, elevated 
levels of free fatty acids were associated with ischemic heart disease (8).  Elevated levels of free 
fatty acids have also been associated with sudden cardiac death (11, 23).  Free fatty acid 
inundation of the myocardium is observed in Acute Coronary Syndromes and the better 
outcomes in patients in the first DIGAMI study (24, 25) randomized to insulin treatment may be 
due to insulin’s suppression of free fatty acid release into the circulation.   In the EDC 
population, low daily insulin dose at baseline, but not HbA1c, was independently predictive of 
the 18 year incidence of non-fatal coronary artery disease (Appendix C3).  
In our population, the adiposity relationship of pulse pressure with free fatty acids varied 
by sex.  In the general population as well, a sexual dimorphism exists in adiposity, particularly 
visceral adiposity, and insulin resistance.  Visceral adiposity and insulin resistance are both 
higher in men; nevertheless, free fatty acids tend to be slightly increased in women (26).  A 
sexual dimorphism in lipid metabolism is also observed (26) in the general population.  Women 
have an increased free fatty acid response to fasting (27), while fasting glucose levels tend to be 
lower.  Hojlund et al (28) observed during 72 hours of fasting mean plasma free fatty acids were 
higher in women while mean glucose levels were lower in women throughout the duration of the 
fast.  After approximately 36 hours of fasting, mean glucose levels were approximately 3.5 
mmol/l (~63mg/dl) in women, while they remained at approximately 4 mmol/l (~72gm/dl) or 
above in men.  Similar findings were noted by Soeters et al (29).  A sex difference in the 
counterregulatory response to hypoglycemia also exists both in the non-diabetic population (30; 
31, 32) and in type 1 diabetes (33).  Women have a reduced sympathetic nervous system 
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response to hypoglycemia (34).  This decreased epinephrine, norepinephine, growth hormone, 
and subsequent endogenous glucose production response to declining glucose levels would be 
expected to produce a greater frequency of hypoglycemia in women with type 1 diabetes.  
However, men experience a greater blunting of the autonomic nervous system counterregulatory 
responses to hypoglycemia following antecedent hypoglycemia (34). Although the tightened 
glycemic control achieved in the intensive arm of the Diabetes Control and Complications Trial 
(DCCT) came at the expense of a three-fold increase in severe hypoglycemic events, there was 
no difference in the prevalence of hypoglycemia between men and women (35).  Enhanced free 
fatty acid response to hypoglycemia in women (27) may account for the resistance women 
exhibit to the blunting effects of antecedent hypoglycemia.  Nevertheless, this may come at the 
expense of the increased stiffness observed in women with type 1 diabetes (36, 37) and may 
partially account for the loss of the gender difference in coronary artery disease in type 1 
diabetes. 
Free fatty acids themselves, although showing a relationship with pulse pressure, failed to 
show a relationship with coronary artery calcification.  We have previously suggested that the 
coronary artery calcification in type 1 diabetes might not be the obesity/lipid driven 
atherosclerosis, but advanced glycation end products (AGEs) driven, as we failed to show an 
association of adiposity with the severity of coronary artery calcification in the EDC population 
(with the exception of an inverse relationship if subcutaneous abdominal fat in women) (6).  
These findings suggest two divergent pathways to coronary artery disease unrelated to obesity 
driven insulin resistance in type 1 diabetes.  Nevertheless, as we have previously shown BMI to 
predict progression of calcification (38), the obesity driven atherosclerotic pathway cannot be 
completely ruled out. 
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In conclusion, free fatty acids predict arterial stiffness, but not coronary artery 
calcification in type 1 diabetes.  Although neither coronary artery calcification nor arterial 
stiffness appear to be mediated by obesity driven insulin resistance, arterial stiffness does appear 
to mediate in part by free fatty acid driven insulin resistance.  As both low insulin dose and 
hypoglycemia increase the free fatty acid flux in type 1 diabetes, these findings may help to 
explain the inconsistent, and generally null, findings of a relationship of HbA1c and coronary 
artery disease in type 1 diabetes (39).  Given the recent failure clinical trials to show a 
cardiovascular benefit, and in one study, an adverse association, of intensive glycemic control in 
diabetes (40), the results of our study have important clinical implications.  Both hypoglycemia 
and hyperglycemia need to be monitored, not just HbA1c, in order to avoid elevated free fatty 
acid flux to the myocardium and kidney and the subsequent myocardial damage.  
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Figure A-1.  Association of free fatty acids (FFA) with pulse pressure by tertiles of subcutaneous abdominal 
adiposity (SAT). 
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Figure A-2. Association of free fatty acids (FFA) with pulse pressure by tertiles of visceral abdominal 
adiposity (VAT). 
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       Table A-1.  Characteristics of Study Participants by Fasting Status at the 16th Year Follow-up Exam,  
                                                                                      mean (SD). 
 
 Men (n=101) Women (n=109) 
 Fasting Non-fasting Fasting Non-fasting 
Age, years 41.2 (6.9) 46.0 (7.4)‡ 42.5 (8.0) 44.4 (8.8) 
VAT*, cm² 113.8 (66.5) 136.6 (67.8) 75.2 (52.4) 75.2 (43.9) 
SAT*, cm² 239.1 (387.5) 203.1 (76.2) 255.1 (138.6) 300.5 (434.9) 
BMI*, kg/m² 26.8  (3.9) 26.8 (3.4) 26.1 (26.2) 25.6 (25.5) 
FFA*, mmol/l 0.95 (0.49) 0.90 (0.42) 1.02 (0.48) 0.82 (0.47)† 
HbA1c, % 7.9 (1.4) 8.2 (1.6) 7.9 (1.3) 7.3 (1.2)† 
Glucose, mg/dl 156.2 (84.5) 187.7 (96.8) 158.1 (83.4) 162.3 (81.9) 
Dose, U/kg/dy 0.67 (0.61) 0.68 (0.23) 0.57 (0.18) 0.57 (0.20) 
AER, μg/min 205.3 (693.7) 91.0 (179.6) 99.0 (397.5) 119.4 (420.1) 
Height, meters 174.6 (6.19) 174.9 (7.42) 162.5 (6.8) 161.1 (8.3) 
Heart rate, beats/min 73.1 (11.5) 75.8 (9.6) 76.6 (11.7) 76.5 (13.3) 
CAC score* 176.0 (374.8) 286.5 (523.1) 207.0 (498.1) 146.2 (244.3) 
Pulse Pressure, mm HG 50.7 (14.7) 54.2 (15.0) 50.3 (14.2) 52.9 (14.4) 
    *Natural logarithmically transformed before analyses   †p<0.05   ‡p<0.01 
    VAT=visceral abdominal adiposity, SAT=subcutaneous abdominal adiposity,  
    BMI=body mass index, FFA=free fatty acids, AER=albumin excretion rate, CAC=coronary artery calcification 
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Table A-2.  Association of Free Fatty Acids (FFA) with Pulse Pressure (PP), Coronary Artery Calcification 
                                       (CAC), Adiposity Indices, and Glycemia, Pearson's r (p-value). 
 
 Men (n=75) Women (n=76) 
 NEFA PP CAC NEFA PP CAC 
Pulse Pressure, mmHg 0.07    0.24 (0.04)   
CAC score* 0.12 (0.32) 0.32 
(0.005) 
 0.06 (0.66) 0.40 (0.0003)  
VAT*, cm² 0.15 (0.22) 0.40 
(0.0005) 
0.37 (0.001) 0.10 (0.38) 0.20 (0.09) 0.37 (0.001) 
SAT*, cm² 0.17 (0.15) 0.26 (0.03) 0.22 (0.06) 0.06 (0.63) 0.14 (0.23) 0.22 (0.06) 
BMI*, kg/m² 0.19 (0.10) 0.17 (0.13) 0.20 (0.09) 0.10 (0.41) 0.17  
(0.13) 
0.19 (0.09) 
HbA1c, % 0.14 (0.24) -0.01 (0.92) -0.05 (0.68) 0.02 (0.89) 0.19 (0.10) -0.02 (0.90) 
Insulin dose, U/kg/dy** 0.24 (0.07) 0.24 (0.07) 0.08 (0.54) -0.14 (0.35) -0.39 
(0.006) 
-0.26 (0.08) 
Glucose, mg/dl 0.33 (0.005) 0.05 (0.66) -0.07 (0.57) 0.49 
(<0.0001) 
0.23 (0.05) 0.16 (0.17) 
Triglycerides, mg/dl* 0.39 
(0.0007) 
0.15 (0.19) 0.32 (0.006) 0.04 (0.74) 0.13 (0.26) 0.18 (0.13) 
HDLc, mg/dl -0.02 (0.92) -0.03 (0.81) 0.21 (0.07) 0.09 (0.42) 0.16 (0.17) 0.05 (0.65) 
eGDR, mg/kg/min -0.17 (0.17) -0.38 
(0.002) 
-0.15 (0.21) 0.10 (0.40) -0.41 (0.0004) -0.13 (0.28) 
AER, μg/min * 0.14 (0.24) 0.29 (0.01) 0.17 (0.16) -0.11 (0.34) 0.35 (0.002) 0.18 (0.11) 
Height, meters 0.07 (0.73) 0.32 
(0.006) 
0.22 (0.05) 0.01 (0.90) 0.13 (0.25) -0.06 (0.60) 
Heart rate, beats/min 0.13 (0.27) 0.04 (0.75 -0.15 (0.20) -0.11 (0.37) 0.22 (0.05) 0.0008 
(0.99) 
Analyses with NEFA are controlled for serum albumin  HDLc=high density lipoprotein cholesterol AER=albumin excretion rate     
**n=55 for men and 47 for women  
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    Table A-3.  Multivariable Adjusted Association of Free Fatty Acids (FFA) with Pulse Pressure in Type 1 
                                                                                   Diabetes. 
 
 Males (n=70) Females (n=74) 
 Β ± SE (p-value) Β ± SE (p-value) 
Interaction between FFA *and 
SAT* 
-5.49 ± 5.63 (0.33) 8.80 ± 4.15 (0.04) 
Serum albumin, g/dl  -0.48  ± 2.97 (0.87) -4.16 ± 2.33 (0.08) 
Age, years 0.93 ± 0.25 (0.0004) 0.64 ± 0.18 (0.005) 
Height, meters NS 0.41 ± 0.19 (0.04) 
Albumin excretion rate, μg/min* 1.51  ± 0.74 (0.05) 2.54 ± 0.73 (0.0009) 
   
Model R-square 0.32 0.45 
     *Natural logarithmically transformed before analysis  NS=not selected   
     FFA=free fatty acids SAT=subcutaneous abdominal adiposity 
     Backward selection model controlled for free fatty acids and subcutaneous abdominal adiposity and also allowed      
     for heart rate, HbA1c, and high density lipoprotein cholesterol 
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 Table A-4.  Multivariable Adjusted Association of Free Fatty Acids with Coronary Artery Calcification in 
                                                                              Type 1 Diabetes. 
 
 Males (n=70) Females (n=74) 
 Β ± SE (p-value) Β ± SE (p-value) 
Free fatty Acids (mmol/l) 0.43 ± 0.48 (0.37) -0.54 ± 0.52 (0.30) 
Serum albumin, g/dl  -0.65 ± 0.49 (0.19) -0.25 ± 0.41 (0.54) 
Age, years 0.22 ± 0.04 (<0.0001) 0.23 ± 0.04 (<0.0001) 
High density lipoprotein 
cholesterol, mg/dl 
-0.07 ± 0.02 (0.002) NS 
   
Model R-square 0.36 0.45 
      *Natural logarithmically transformed before analysis  NS=not selected 
      Backward selection model also allowed for HbA1c and high density lipoprotein cholesterol log-transformed    
      subcutaneous adiposity, log-transformed albumin excretion rate, HbA1c, daily insulin dose/kg of body weight,     
      heart rate, and a history of unconsciousness due to hypoglycemia.  Results did not vary in log-transformed   
      visceral adiposity was used in place of log-transformed subcutaneous adiposity. 
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APPENDIX B: UPDATED PAPER 3 
The following version of paper 3 differs marginally from the published version due to updates in 
the data and corresponds to the data set turned in with this dissertation. 
 
B.1 ABSTRACT 
Background: Coronary artery disease (CAD), a leading cause of death in type 1 diabetes (T1D), 
often occurs two or more decades earlier in this population.  Although CAD generally increases 
with adiposity, this association is unclear in T1D.  We thus examined the associations of 
adiposity with Coronary Artery Calcium (CAC-a subclinical marker of CAD) in 315 individuals 
with T1D.   
Methods: Mean age and diabetes duration were 42 and 35 yrs, respectively at the time of 
assessment of CAC, visceral adiposity (VAT) and subcutaneous adiposity (SAT) by electron 
beam tomography and when BMI and waist circumference (WC) were measured.  Chi-square 
frequencies and generalized linear models were used to compare the presence of any CAC and 
age-adjusted mean CAC total score, respectively, by tertiles of adiposity.   
Results:  There was a positive relationship between the presence of CAC and tertiles of VAT, 
SAT, BMI, and WC in both genders (p trend<0.05).  The presence of CAC was also positively 
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associated with all four adiposity measures modeled continuously in both men (p<0.05) and 
women (p<0.05).  However, the degree of CAC was not associated with any adiposity measure, 
with the exception of SAT in women.  Women in the lowest tertile of SAT had more CAC than 
those in the second tertile (p<0.016).   
Conclusion:  Adiposity was positively associated with the presence of CAC, but the relationship 
with its severity tended to be inverse or reverse J-shaped.  This double-edged association, which 
appears to be more pronounced in women, emphasizes the complex relationship between 
adiposity and cardiovascular risk in diabetes.  
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B.2 INTRODUCTION 
Coronary artery disease (CAD) is the leading cause of death in type 1 diabetes (1) and often 
occurs two or more decades earlier than in the general population.  Although the risk of CAD 
tends to increase with increasing BMI in the general population, this association in type 1 
diabetes is unclear.  Coronary artery calcification (CAC) is a subclinical marker of coronary 
vascular disease (2) and has been shown to be predictive of future clinical cardiac events (3). The 
few studies that have investigated CAC in T1D are inconsistent in terms of the relationship 
between CAC and adiposity.  All five studies investigated the association of BMI with CAC.  
Both Dabelea et al (4) and Colhoun et al (5) reported a positive association between BMI and the 
prevalence of CAC; in contrast, in the Epidemiology of Diabetes Complications Study (6), the 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) Study (7), and in Starkman et al (8), no association was found 
between BMI and CAC prevalence.  Olson et al (6) and Cleary et al (7) also failed to show an 
association with CAC severity.  Additionally, in a subgroup of the CACTI population reported 
on by Dabelea et al (4), Snell-Bergeon et al (9) failed to find a difference in BMI when 
investigating progression of CAC.   
Markers of visceral adiposity, thought by many to independently relate to cardiovascular 
disease risk, have also been studied.  Unlike BMI, the association of waist-to hip ratio (WHR) 
and/or waist circumference (WC) with CAC has been more consistent.  With the exception of 
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Colhoun et al (5), who failed to show an association in men, and Starkman et al (8), who did not 
investigate WHR /WC, all of the studies found CAC to be positively associated with WHR/WC.  
Additionally, Dabelea et al (4) using a direct measurement of visceral obesity, also found 
intraabdominal fat to be positively associated with the prevalence of CAC, although this was not 
investigated sex-specifically.  They also found men to be at higher risk for CAC.  As sex 
differences in adiposity also exist, even for BMI, and not all of the above mentioned studies 
looked at adiposity sex-specifically (4, 7, 8), sex specific analyses are warranted.  Furthermore, 
none of the studies investigated subcutaneous abdominal fat (SAT). This is important as SAT has 
also been suggested to be a major contributor of free fatty acids into both the portal and systemic 
circulation and thus insulin resistance (10, 11, 12, 13).   
Given the above conflicts in the literature and the evidence that being overweight and 
obese is rising in type 1 diabetes (T1D) (14), concern and further evaluation of the association of 
adiposity with CAD in this population already at increased risk is warranted.  This study 
therefore sought to determine the following: a) which measure of adiposity best identifies CAC 
(testing the hypothesis that measures of central obesity will be more strongly associated with 
CAC), b) whether any associations of adiposity with CAC vary by sex and c) whether any 
associations differ for the prevalence as opposed to the severity of CAC.   Four different indices 
of body fat, i.e. BMI, WC, VAT, and SAT were investigated.  
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B.3 METHODS 
Subjects 
The EDC study is an ongoing cohort study examining the long term complications of T1D in 658 
individuals diagnosed before the age of 17 years with T1D at Children’s Hospital of Pittsburgh 
between 1950 and 1980.  This current report is based on a subset (n=316) who underwent 
electron beam tomography (EBT) for CAC between 2000 and 2007.  These participants were 
also scanned for VAT and SAT via EBT scanning.   
 
Clinical Evaluation Procedures 
Before attending the clinic, participants completed a questionnaire concerning 
demographic information, lifestyle, and medical history.  An ever smoker was defined as having 
smoked at least 100 cigarettes in a lifetime.  Participants were weighed in light clothing on a 
balance beam scale.  Height was measured using a wall-mounted stadiometer.  BMI was 
calculated as the weight in kilograms divided by the square of the height in meters.  Two waist 
measurements were taken by a standard medical measuring tape, measuring from the mid-point 
of the iliac crest and the lower costal margin in the mid-axillary line.  The average was used for 
data analysis.   
Fasting blood samples were assayed for lipids, lipoproteins, and glycosylated hemoglobin 
(HbA1c).  High-density lipoprotein (HDL) cholesterol was determined by a heparin and 
manganese procedure, a modification of the Lipid Research Clinics method (15).  Cholesterol 
and triglycerides were measured enzymatically.  Glomerular filtration rate (GFR) was estimated 
using the Modification of Diet in Renal Disease (MDRD) formula (16).  Sitting blood pressures 
were measured according to the Hypertension Detection and Follow-up Program protocol (17) 
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using a random zero sphygmomanometer.  The mean of the second and third readings was used.  
Estimated glucose disposal rate (eGDR) was calculated using the equation: eGDR=24.395-
12.971 (waist-to-hip ratio)-3.388 [hypertension status (140/90 mm Hg or on hypertension 
medication)]-0.601 (HbA1c).  This formula was derived from a substudy of 24 EDC participants 
(12 men and 12 women drawn from low, middle, and high age-specific tertiles of insulin 
resistance risk factors) who underwent euglycemic clamp studies (18).   
CAC was measured using EBT (Imatron C-150, Imatron, South San Francisco, CA).  
Threshold calcium determination was set using a density of 130 Hounsfield units in a minimum 
of 2 contiguous sections of the heart.  Scans were triggered by ECG signals at 80% of the R-R 
interval.  The entire epicardial system was scanned.  CAC volume scores were calculated based 
on isotropic interpolation (19).  Direct measurements of abdominal adiposity (visceral and 
subcutaneous abdominal adipose tissue surface area) were also taken by EBT scanning.  Scans of 
abdominal adipose tissue were taken between the fourth and fifth lumbar regions, which were 
located by counting from the first vertebra below the ribs.   Two 10 mm thick scans were taken 
during suspended respiration.  The images were then analyzed using commercially available 
software for all pixels corresponding to fat density in Hounsfield units in the appropriate 
anatomical distribution (subcutaneous or visceral). 
 
 
Statistical analyses   
Pearson’s correlations were used to assess the association between each of the four 
adiposity measures.  Two stage analyses were performed given the large number of subjects with 
no calcification and the resulting non-normal distribution. The first analysis evaluated the 
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presence/absence of CAC. The second analysis evaluated the degree of CAC by volume scores 
in individuals with any CAC.  This approach also allows assessment of the third objective, i.e. 
whether relationships were different for prevalence versus severity. 
 Differences between groups with and without CAC were evaluated using the 
Student’s t test for continuous variables and χ2 for dichotomous variables.  Logistic regression 
analysis was used to determine the association of adiposity with the presence of CAC.  
Spearman’s correlations were used to determine how well the different adiposity measures 
correlated with CAC volume scores, given the presence of any CAC.   Generalized linear models 
(GLMs), which are fairly robust in analyses of non-normally distributed data, were used to 
compare CAC volume scores (CACs) across tertiles of the four adiposity measures.   
In order determine whether any adiposity associations with CAC vary by sex, BMI, WC, 
VAT, and SAT were examined by sex-specific tertiles; sex interactions were also explored.  
Analyses were performed on the entire cohort and within only those positive for calcification.  
All non-normally distributed variables were transformed using an appropriate transformation or 
were tested nonparametrically with the Kruskal Wallis test.  One was added to all values of CAC 
before log-transformation.  All odds ratios and parameter coefficients are reported as per one 
standard deviation change in the continuous variables.  Akaike’s Information Criterion (AIC) 
and Pearson’s r were used to determine which adiposity measurement best accounted for the 
prevalence and severity of CAC, respectively. The criterion for statistical significance was P < 
0.05.  Analyses were conducted using SAS version 9.1 (Cary, North Carolina). 
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Results 
Adiposity and the Presence or Absence of CAC 
Baseline characteristics revealed that although men (n=152) had significantly higher 
VAT and WC, non-HDLc, and lower HDLc than women (n=164), there was no difference in 
percent with CAC or median CAC levels (Table B-1).  Figure 1 shows the prevalence of CAC by 
sex-specific tertiles of adiposity.  There was a significant direct linear trend between tertile of 
each adiposity measure and prevalence of CAC in both sexes (p<0.05) (data not shown).  When 
the measures of adiposity were analyzed as continuous variables and adjusted for age, the 
presence of CAC was positively associated with each adiposity indice in both sexes.  Further 
adjustment for other clinically and/or statistically significant risk factors did not alter these 
associations (ORs range from 1.9 to 3.8), including menopausal status.   Model comparisons 
suggest that BMI was marginally better at accounting for CAC prevalence in both sexes. 
 
Correlation between the Adiposity Measures and CAC 
Age-adjusted CACs showed low order positive correlations with each adiposity measure 
overall in both sexes, which reached statistical significance only for SAT in men (Table B-2a).  
However, when restricted to only those with some measurable CAC, i.e. excluding those with ‘0’ 
values, correlations were surprisingly in the inverse direction, but none reached statistical 
significance (Table B-2b).   
 
Adiposity and the degree of CAC 
Graphical examination of tertiles of adiposity in those with calcification revealed a 
reverse J-shaped relationship between CACs and VAT in both men and women, for SAT in 
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women, and an inverse relationship between CACs and BMI and WC in both sexes (Figure B2).  
With the exception of SAT in men, in both sexes and for all measures, the lowest tertile of 
adiposity had the highest median CAC scores.  In order to explore whether other confounding 
variables may explain this finding, other risk factors were examined by tertile of SAT, where this 
observation was most striking.  No excess of major risk factors were identified in the lowest 
tertile; however, age, diabetes duration, and smoking were higher in both men and women, albeit 
nonsignificantly while eGFR was significantly lower and overt nephropathy was higher in 
women (Table B-3).   
Generalized linear modeling revealed that given the presence of any CAC, there was no 
significant association of age-adjusted CAC with any of the four adiposity measures, with the 
exception of SAT in women.  Women in the lowest tertile of SAT had more CAC than those in 
the second tertile (p<0.016).  After adjustment for age, glomerular filtration rate, having ever 
smoked, and a history of a renal transplant, being in the lowest tertile of SAT remained 
significantly associated with CAC in women (Table B-4) and after further adjustment for 
menopausal status which was not a strong independent predictor (p=0.96). Model comparisons 
show R² ranging from 39 to 45%, suggesting that all four models generally explain variance in 
CAC to a similar degree.   
 
B.4 DISCUSSION 
In this cross-sectional study in which we investigated the association of adiposity with CAC in 
T1D several important findings are of note.  First, we demonstrated that the four different 
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measures of adiposity investigated are similarly associated with CAC, both within and between 
sexes.   We also showed that the direction of the associations differed when looking at the 
presence of CAC as opposed to the degree of CAC, i.e. a lower level of adiposity was associated 
with higher CACs.   
 Contrary to expectations, central adiposity measures, e.g. VAT and WC, were not better 
able to identify CAC than the other body morphology parameters.  A major hypothesized 
mechanism by which adiposity is associated with CAD is via increased lipolysis of metabolically 
active VAT with its consequent release of inflammatory cytokines into the systemic circulation 
and excess free fatty acids into the portal vein (20).  Cytokines such as Il-6 and CRP are 
associated with atherosclerosis while increased free fatty acid flux to the liver will increase 
triglyceride and LDLc and small dense LDLc synthesis and are postulated to be in the causal 
pathway of insulin resistance (21, 13).  The small dense LDL phenotype, associated with insulin 
resistance, is very atherogenic in high concentrations.  Despite these characteristics of visceral 
adiposity and our previous reports of CAD events being related to WHR (22, 23) and small 
dense LDL (24), in these current analyses CAC was not preferentially linked with visceral 
compared to general obesity, suggesting possible differences in these measures in T1D.  
However, other investigators state that it is elevated SAT, which is correlated with VAT, which 
is primarily responsible for the elevated systemic levels of FFA associated with VAT (13).  
Nevertheless, most of the studies investigating CAC in type 1 diabetes have found WHR or WC 
to be associated with CAC (6, 7, 9), although BMI has been less consistent (4, 5, 6, 7).  
Biological plausibility notwithstanding, no adiposity parameter appears strikingly better than 
another in detecting CAC.   
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That BMI was marginally better able to detect the presence of CAC in both men and 
women may support the argument that BMI is not so much a measure of overall adiposity as it is 
a marker/predictor of health status (25).  In investigating the relationship of obesity with CAD in 
type 1 diabetes, it must be borne in mind that adiposity associations observed in non-diseased 
populations may be very different than that observed in populations with pre-existing disease, 
such as type 1 diabetes.  The inverse relationship of adiposity with severity of CAC in this 
population appears to lend support to this postulate. 
That increasing adiposity was positively associated with the presence of CAC, while it 
was inversely associated with severity, albeit non-significantly for most parameters, seems to 
suggest at least two divergent disease processes.  A search for confounding by adiposity tertile 
within those with any CAC revealed that estimated glucose disposal rate (eGDR) and blood 
pressure in men, and lipids and kidney function in women were significantly different for those 
in the lowest adiposity tertile and who had measurable CAC.  As alluded to earlier, obesity 
correlates such as hypertension, dyslipidemia, inflammation, and insulin resistance, i.e. features 
of the metabolic syndrome, may be responsible for the increased CAC observed.  Our marker for 
insulin sensitivity in this population, eGDR, was inversely associated with CAC severity and 
thus consistent with this hypothesis, though the correlation was not signifcant in women.  
Despite identifying these potential confounders, the significant SAT difference in women (Table 
B-4) remained significant. 
The CAC detected, at least in some of the participants, may not be from atherosclerotic 
plaque, i.e. intimal, as is generally associated with CAD,  but rather partially medial (4,5).  This 
cannot be determined by EBCT. In a recent analysis demonstrating medial wall calcification in 
the EDC population (26), some six years prior to EBT scanning for CAC, a strong association 
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was seen between earlier medial wall calcification, determined six years earlier by ankle x-rays, 
and CAC, which remained in multivariable analyses unless neuropathy was included as a 
variable.  Thus both processes may be at work in this population. 
The majority of the studies looking at CAC in T1D have found age and diabetes duration 
to be the strongest correlates of CAC.  Residual confounding due to factors related to long-term 
exposure to hyperglycemia, such as advanced glycated end products (AGEs), may also be apart 
of the pathogenesis of CAC.   Long-term exposure to hyperglycemia may result in AGEs 
depositing into the extracellular matrix of the arterial wall.  These AGES have the ability to 
stimulate osteoblastic differentiation, leading to vascular calcification.  Sakata et al (27) reported 
increased CML, an AGEs, in the medial wall of the inter-thoracic artery of individuals with type 
1 diabetes, while very little of this was noted in those with type 2 diabetes.  Although there was 
no age-adjusted association between glycemic control and CAC in our population, this does not 
negate the possibility that long duration of hyperglycemia, i.e. diabetes, may be responsible for 
the more severe CAC, particularly in the older participants, who also happened to be the thinnest.  
However, increased levels of AGEs are also found in kidney disease.  
CAC is a well known to be associated with kidney disease, possibly due to abnormal 
calcium and phosphorus metabolism (28).  Extensive calcification is observed in those in renal 
failure, even in the young, and CAC is an important predictor of overall mortality in the kidney 
disease population.  Colhoun et al (5) found AER to be associated with the presence of CAC in 
men with T1D, but not women.  Thilo et al (29) observed no association between 
microalbiminuria and CAC in 71 participants with T1D with a mean age of 48 and disease 
duration of 26 years.  In our population, kidney function was associated with CAC.  We 
observed that GFR tended to increase and overt nephropathy tended to decrease with adiposity in 
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women, suggesting that the more severe CAC observed in women with less body fat might be 
partially explained by kidney disease.  However, this association was not observed in men.  
Additionally, although renal transplant recipients had the highest levels of CAC, i.e. most severe 
CAC, they were not more likely to be in the lowest adiposity tertile.  Nevertheless, where 
adiposity failed to be a strong predictor, renal function, as measured by GFR and renal failure 
were significantly related to CAC severity in this population.   
Consistent with the literature in type 1 diabetes, there were no significant differences in 
CAC prevalence, severity (5, 6) or its association of body fat by sex.  However, contrary to 
expectations, VAT, albeit nonsignificantly, appeared to be better at detecting CAC severity in 
women than in men.   In the general population, men have an average of about twice as much 
visceral fat as premenopausal women when matched for total body fat (30).  We did not observe 
such a large sex difference in our population.  Visceral fat levels were 53% higher in males than 
premenopausal women in our T1D population (data not shown).  This attenuation in the sex 
difference in VAT in T1D has been observed elsewhere.  In the CACTI study, Dabelea et al (4) 
observed that men with T1D had lower WHRs and much lower levels of VAT, although similar 
BMI levels, than nondiabetic men.  Women with T1D had higher waist-to-hip ratios, WCs, and 
BMIs, but similar levels of VAT.  Dabelea noted that women with T1D “had a more android 
disposition of adipose tissue” while this was attenuated in men.  It appears that VAT is not stored 
to the same extent in T1D, indicating a more functional role of VAT in T1D.  Although many 
CAD risk factors increase with adiposity in this population, traditional CAD risk factors appear 
(including menopausal status) to be less operant in the pathogenesis of severe atherosclerosis, 
particularly in women, an observation noted elsewhere (31). 
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Study Limitations 
A major limitation of this study is that we were unable to follow participants from an 
earlier time point when participants were free of CAC to determine if the adiposity measures 
predict the incidence or severity of CAC.  In a population such as this, in which it is defined by 
its pre-existing disease, complications that are part of the natural history of the disease may be 
well underway after 16-18 years of follow-up.  As CAC, VAT, and SAT were not available in 
this population at earlier time periods, the adiposity indices measured at the time of EBT may not 
reflect the adiposity level prior to the development of severe calcification.  It is thus not possible 
to determine the exact causal pathways given the cross-sectional nature of our study.  Survival 
bias may also be at issue in the current study.  It is possible that the more obese died before 
current follow-up. However, being overweight is not a mortality risk factor in this population 
(14) so disruption of the natural obesity/CAC association by premature loss of the more obese is 
unlikely.  It is also possible that longer exposure to kidney disease may result in weight loss or 
that increased body fat is merely a marker of better health.   
In conclusion, we found that adiposity was related to the presence of calcification 
irrespective of the measure used.  Age, which in this population is also a proxy for diabetes 
duration, remained, as in many studies, the strongest correlate for both the prevalence and 
severity of CAC.  Although the presence of CAC increased with adiposity, more severe disease, 
i.e. greater CAC, was inversely associated with body fat, albeit only significantly for SAT in 
women.  This was only partially explained by other risk factors, e.g. renal disease and age.  At 
least two distinct disease processes (atherosclerosis and medial wall calcification) may be 
operant in the CAC seen in T1D, underscoring the complex relationship of obesity with CAC in 
T1D.  This double-edged association, the association of CAC with both fat and thin, which 
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appears to vary by sex, further highlights that factors other than the standard risk factors are at 
work in the development of CAD in T1D.  
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      Figure B-1.  The prevalence of coronary artery calcification by tertiles of adiposity.                    
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  Figure B-2.   Median total coronary artery calcification scores in those with some measureable  
                                                       calcification by tertiles of adiposity. 
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     Table B-1.  Characteristics by Gender.  The Pittsburgh Epidemiology of Diabetes Complications Study. 
 
Characteristics Males (n=152) Females (n=164) p-value 
Age (years) 42.8 (7.4) 43.3 (7.8) 0.55 
Duration (years) 34.8 (7.3) 34.7 (7.8) 0.90 
CAC+ (%)  68.2 (104) 65.2 (107) 0.54 
CACs (median)* 22.1 (0-313.3) 8.8 (0-279.0) 0.34 
HbA1c (%) 7.8 (1.5) 7.5 (1.3) 0.12 
Hypertension (%) 36.6 (53) 26.4 (43) 0.05 
Ever smoker (%) 38.6 (56) 37.1 (59) 0.79 
HDL-C (mg/dl) 50.3 (12.2) 64.4 (14.6) <0.0001 
Non-HDL-C (mg/dl) 132.5 (35.9) 125.8 (28.4) 0.07 
VAT (cm²)* 121.7 (64.3) 82.3 (48.9) <0.0001 
SAT (cm²)* 226.7 (276.4) 282.2 (232.4) 0.0006 
BMI (kg/m²) 26.8 (3.6) 26.7 (5.2) 0.88 
WC (cm) 93.7 (9.6) 84.8 (11.7) <0.0001 
Menopause**  25.0 (40)  
*Natural logarithmically transformed before analysis.   **n=160  
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                 Table B-2a.  Age-Adjusted Correlations* of Adiposity with Calcification (R, p). 2000-2007. 
 
Men, n=152       
 SAT BMI Waist 
Circumference 
eGDR Age CACs 
VAT** 0.65 
<0.0001 
0.66 
<0.0001 
0.77 
<0.0001 
-0.36 
     <0.0001 
0.28 
   0.0004 
0.09 
    0.25 
SAT**  0.69 
<0.0001 
0.76 
<0.0001 
-0.27 
    0.002 
0.11 
    0.17 
0.20 
 0.01 
BMI   0.88 
<0.0001 
-0.24 
     0.005 
-0.03 
    0.67 
0.13 
 0.10 
Waist Circumference    -0.44 
 <0.0001 
0.08 
 0.38 
0.12 
 0.16 
eGDR     -0.11 
 0.22 
-0.23 
 0.007 
Age      0.57 
 <0.0001 
Women, n=164       
VAT* 0.62 
<0.0001 
0.70 
<0.0001 
0.79 
<0.0001 
-0.31 
 <0.0001 
0.23 
 0.003 
0.13 
 0.06 
SAT**  0.75 
<0.0001 
0.73 
<0.0001 
-0.08 
 0.31 
0.03 
 0.68 
0.09 
 0.28 
BMI   0.85 
<0.0001 
-0.19 
 0.02 
-0.03 
0.67 
0.12 
 0.13 
Waist Circumference    -0.34 
 <0.0001 
0.08 
 0.36 
0.14 
 0.09 
eGDR     -0.10 
 0.22 
-0.13 
 0.13 
Age      0.60 
 <0.0001 
*Pearson for adiposity measures with each other; Spearman for correlations with CAC  **Natural-logarithmically transformed  
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Table B-2b.  Age-Adjusted Correlations* of Adiposity with Calcification (R, p) in those with Coronary Artery   
                                                                        Calcification. 2000-2007. 
 
Men, n=112       
 SAT BMI Waist 
Circumference 
eGDR Age CACs 
VAT** 0.50 
<0.0001 
0.65 
<0.0001 
0.76 
<0.0001 
-0.43 
 <0.0001 
0.09 
 0.37 
-0.14 
 0.15 
SAT**  0.64 
<0.0001 
0.69 
<0.0001 
-0.20 
 0.05 
-0.14 
 0.14 
-0.10 
 0.32 
BMI   0.84 
<0.0001 
-0.19 
 0.07 
-0.28 
 0.004 
-0.14 
 0.15 
Waist Circumference    -0.46 
 <0.0001 
-0.23 
 0.02 
-0.20 
 0.05 
eGDR     -0.02 
 0.83 
-0.14 
 0.19 
Age      0.60 
 <0.0001 
Women, n=104       
VAT* 0.57 
<0.0001 
0.68 
<0.0001 
0.78 
<0.0001 
-0.34 
 0.0006 
-0.006 
 0.95 
-0.06 
 0.53 
SAT**  0.76 
<0.0001 
0.72 
<0.0001 
-0.04 
 0.73 
-0.16 
 0.10 
-0.15 
 0.13 
BMI   0.84 
<0.0001 
-0.16 
 0.11 
-0.24 
 0.01 
-0.09 
 0.34 
Waist Circumference    -0.34 
 0.001 
-0.09 
 0.40 
-0.08 
0.43 
eGDR     -0.11 
 0.27 
-0.06 
 0.58 
Age      0.55 
 <0.0001 
*Pearson for adiposity measures with each other; Spearman for correlations with CAC  **Natural-logarithmically transformed  
 188 
Table B-3.  Characteristics of Participants with CAC by Tertiles of Subcutaneous Abdominal Adiposity and 
                                                                                    Gender. 
 
Variable, mean 
(SD) 
Tertile 1 Tertile 2 Tertile 3 p-value Variable, mean 
(SD) 
Tertile 1 Tertile 2 Tertile 3 p-value 
Men     Women     
Age (yrs) 46.2 (7.2) 43.8 (6.8) 44.0 (7.4) 0.20 Age (yrs) 48.0 (5.9) 45.6 (8.3) 44.1 
(6.2) 
0.02 
Diabetes 
Duration (yrs) 
37.9 (7.9) 35.7 (7.1) 35.3 (6.9) 0.14 Diabetes 
Duration (yrs) 
38.5 (6.5) 37.4 (7.8) 35.7 
(7.4) 
0.11 
HbA1c (%) 7.5 (1.5) 7.5 (1.7) 8.0 (1.2) 0.15 HbA1c (%) 7.7 (1.4) 7.4 (1.3) 7.2 (1.2) 0.16 
eGDR 
(mg/kg/min) 
6.7 (1.9) ‡ 6.4 (2.2)  4.9 (2.0) 0.0008 eGDR 
(mg/kg/min) 
8.0 (2.5) 7.9 (1.9) 7.7 (2.2) 0.60 
HDL (mg/dl) 51.5 (12.1) 48.4 (10.9) 47.6 
(13.3) 
0.19 HDL (mg/dl) 64.8 
(16.3) 
63.0 
(13.1) 
62.1 
(14.1) 
0.46 
Non-HDLc 
(mg/dl) 
125.7 
(32.4) 
133.7 
(45.4) 
137.6 
(38.2) 
0.21 Non-HDLc 
(mg/dl) 
124.0 
(30.9) ‡ 
126.0 
(19.9) 
140.5 
(28.7) 
0.01 
SBP (mm/Hg) 120.8 
(18.4) ‡ 
125.3 
(16.6) 
132.2 
(16.1) 
0.007 SBP (mm/Hg) 120.3 
(16.8) 
113.8 
(13.3) 
121.9 
(16.6) 
0.67 
DBP (mm/Hg) 70.4 (10.2)  72.5 (9.6) 74.9 (8.0) 0.05 DBP (mm/Hg) 63.0 (7.6) 64.8 (9.0) 67.6 
(9.7) 
0.04 
MDRD 
(mg/min)γ 
83.6 (22.7) 83.1 (25.5) 85.1 
(25.7) 
0.81 MDRD 
(mg/min)γ 
63.4 
(21.9) †‡ 
80.5 
(19.5) 
79.2 
(28.4) 
0.01 
Overt 
Nephropathy (%) 
41.2 (14) 41.9 (13) 31.6 (12) 0.39 Overt 
Nephropathy (%) 
48.5 (16)  24.3 (9) 25.0 (9) 0.04 
Transplant 
recipient (%) 
14.7 (5) 12.5 (4) 5.3 (2) 0.19 Transplant 
recipient (%) 
15.2 (5) 10.8 (4) 8.1 (3) 0.35 
Ever Smoker (%) 44.1 (15) 40.0 (12) 35.1 (13) 0.44 Ever Smoker (%) 45.5 (15) 35.3 (12) 35.1 (13) 0.38 
CAC, median 
(IQR) ***  
143.9 
(31.8-
762.4) 
16.27 
(16.4-
582.2) 
69.2 
(17.5-
492.6) 
0.39 CAC, median 
(IQR) *** 
304.9 
(94.2-
799.7) 
37.6 (3.1-
273.9) 
118.4 
(9.3-
410.0) 
0.009 
*Significantly different from (sdf) Tertile (T) 1, †sdf T2, ‡ sdf T3 at p<0.017  **Natural logarithmically transformed before analysis 
***Nonparametrically tested  γTransplant recipients excluded    
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      Table B-4.  Generalized Linear Models for the Association of Visceral Adiposity (VAT), Subcutaneous 
Abdominal Adiposity (SAT), Body Mass Index (BMI), and Waist Circumference (WC) with Coronary Artery 
                           Calcification by Gender.  The Epidemiology of Diabetes Complications Study. 
 
 
Characteristics 
VAT 
ß± ( p) 
 SAT 
ß± ( p) 
 BMI 
ß± ( p) 
 WC 
ß± ( p)  
Men        
Adiposity*        
   2nd tertile -0.50 ± 0.41 (0.23)  -0.03 ± 0.42 (0.94)  -0.29 ± 0.43 (0.50)  -0.53 ± 0.46 (0.25) 
   3rd tertile -0.08 ± 0.40 (0.85)  0.13 ± 0.40 (0.75)  -0.20 ± 0.44 (0.66)  -0.59 ± 0.46 (0.21) 
   1st tertile N/A  N/A  N/A  N/A 
AGE 0.97 ± 0.19 (<0.0001)  0.95 ± 0.19 (<0.0001))  0.93 ± 0.19 (<0.0001)  0.86 ± 0.21 (0.0001) 
MDRD -0.20 ± 0.19 (0.29)  -0.24 ± 0.18 (0.20)  -0.26 ± 0.19 (0.17)  -0.31 ± 0.19 (0.11) 
Ever Smoker 0.46 ± 0.34 (0.17)  0.50 ± 0.34 (0.14)  0.49 ± 0.35 (0.16)  0.31 ± 0.37 (0.41) 
Transplant 1.59 ± 0.59 (0.008)  1.60 ± 0.59 (0.009)  1.48± 0.61 (0.02)  1.42± 0.62 (0.03) 
R² 0.42  0.41  0.41  0.41 
Women        
 
Characteristics 
VAT 
ß± ( p) 
 SAT 
ß± ( p) 
 BMI 
ß± ( p) 
 WC 
ß± ( p) 
Adiposity*        
   2nd tertile -0.38 ± 0.43 (0.38)  -1.32 ± 0.43 (0.003)†  -0.26 ± 0.45 (0.57)  -0.16 ± 0.43 (0.71) 
   3rd tertile -0.57 ± 0.44 (0.20)  -0.54 ± 0.43 (0.21)  -0.05 ± 0.45 (0.91)  -0.55 ± 0.44 (0.21) 
   1st tertile N/A  N/A  N/A  N/A 
AGE 1.07 ± 0.18 (<0.0001)  1.08 ± 0.18 (<0.0001)  1.08 ± 0.19 (<0.0001)  1.08 ± 0.19 (<0.0001) 
MDRD -0.29 ± 0.20 (0.14)  -0.15 ± 0.19 (0.43)  -0.27 ± 0.20 (0.17)  -0.31 ± 0.20 (0.12) 
Ever Smoker 0.66 ± 0.36 (0.07)  0.56 ± 0.34 (0.11)  0.65 ± 0.37 (0.08)  0.61 ± 0.36 (0.09) 
Transplant 0.84 ± 0.59 (0.16)  0.90± 0.57 (0.11)  0.88 ± 0.60 (0.14)  0.86 ± 0.57 (0.14) 
R² 0.40  0.45  0.39  0.45 
  *VAT, SAT, BMI, and WC, respectively  †Different (lower) from the first tertile at p<0.0167. 
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APPENDIX C: SUPPLEMENTARY ANALYSES 
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C.1 SUPPLEMENTARY ANALYSES FOR PAPER 1 
                         Table C1-1.  Time Trends in BMI in Men with Type 1 Diabetes. 
  
   BMI   
 N (%) <20 20-<25 25-<30 ≥30 
1986-1988 Overall 23 (8.3) 157 (56.5) 92 (33.1) 6 (1.8) 
 Age group     
 20-<30 11 (3.4) 85 (30.6) 51 (18.4) 4 (1.4) 
 30-<40 12 (4.3) 59 (21.2) 34 (12.2) 2(0.7) 
 40-<50 0 (0) 13 (4.7) 7 (2.5) 0 (0) 
      
1988-1990 Overall 10 (4.3) 129 (54.9) 90 (38.3) 6 (2.6) 
 Age group     
 20-<30 1 (0.9) 66 (60.6) 39 (35.8) 3 (2.8) 
 30-<40 9 (9.0) 50 (50.0) 39 (39.0) 2 (2.0) 
 40-<50 0 (0) 13 (50.0) 12 (46.2) 1 (3.9) 
   1990-1992 Overall 8 (3.9) 107 (51.9) 81 (39.3) 10 (4.9) 
 Age group     
 20-<30 1 (1.3) 43 (53.8) 32 (40.0) 4 (5.0) 
 30-<40 5 (5.4) 47 (51.1) 36 (39.1) 4 (4.4) 
 40-<50 2 (5.9) 17 (50.0) 13 (38.2) 2 (5.9) 
      
1992-1994 Overall 9 (4.6) 94 (47.7) 77 (39.1) 17 (8.6) 
 Age group     
 20-<30 2 (3.6) 26 (46.4) 23 (41.1) 5 (8.9) 
 30-<40 4 (4.1) 49 (49.5) 38 (38.4) 8 (8.1) 
 40-<50 3 (7.3) 19 (46.3) 15 (36.6) 4 (9.8) 
 ≥50 0 (0) 0 (0) 1 (100) 0 (0) 
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   Table C1-1 continued 
 
1994-1996 Overall 7 (3.3) 102 (47.4) 87 (40.5) 19 (8.8) 
 Age group     
 20-<30 2 (3.9) 23 (45.1) 22 (43.1) 4 (7.8) 
 30-<40 0 (0) 48 (48.0) 44 (44.0) 8 (8.0) 
 40-<50 5 (9.1) 28 (50.9) 15 (27.3) 7 (12.7) 
 ≥50 0 (0) 3 (33.3) 6 (66.7) 0 (0) 
      
1996-1998 Overall 9 (3.4) 126 (47.2) 108 (40.2) 24 (9.0) 
 Age group     
 20-<30 3 (6.7) 26 (57.8) 13 (28.9) 3 (6.7) 
 30-<40 1 (0.8) 58 (45.7) 58 (45.7) 10 (7.9) 
 40-<50 4 (5.1) 37 (46.8) 30 (38.0) 8 (10.1) 
 ≥50 1 (6.3) 5 (31.3) 7 (43.8) 3 (18.8) 
      
2000-2003 Overall 4 (2.4) 60 (35.7) 74 (44.1) 30 (17.9) 
 Age group     
 20-<30 0 (0.0) 4 (36.4) 3 (27.3) 4 (36.4) 
 30-<40 1 (1.3) 35 (45.5) 28 (36.4) 13 (16.9) 
 40-<50 5 (7.7) 27 (41.5) 16 (24.6) 17 (26.2) 
 ≥50 5 (13.2) 15 (39.5) 10 (26.3) 8 (21.1) 
      
2004-2007 Overall 4 (2.2) 56 (30.8) 83 (45.6) 39 (21.4) 
 Age group     
 20-<30 0 (0.0) 3 (75.0) 1 (25.0) 0 (0.0) 
 30-<40 1 (2.1) 13 (27.7) 22 (46.8) 11 (23.4) 
 40-<50 1 (1.2) 26 (30.6) 39 (45.9) 19 (22.4) 
 ≥50 2 (4.4) 14 (30.4) 21 (45.7) 9 (19.6) 
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                       Table C1-2.  Time Trends BMI in Women with Type 1 Diabetes.                         
 
   BMI   
 N (%) <20 20-<25 25-<30 ≥30 
1986-1988 Overall 31 (12.7) 157 (58.8) 64 (24.0) 12 (4.5) 
 Age group     
 20-<30 19 (13.9) 77 (56.2) 37 (27.0) 4 (2.9) 
 30-<40 11 (10.4) 64 (60.4) 24 (22.6) 7 (6.6) 
 40-<50 4 (16.7) 16 (66.7) 3 (12.5) 1 (4.2) 
      
1988-1990 Overall 18 (8.6) 120 (57.1) 56 (26.7) 16 (7.6) 
 Age group     
 20-<30 9 (9.7) 51 (54.8) 27 (29.0) 6 (6.5) 
 30-<40 6 (6.6) 53 (58.2) 24 (26.4) 8 (8.8) 
 40-<50 3 (16.7) 16 (61.5) 5 (19.2) 2 (7.7) 
      
1990-1992 Overall 23 (11.0) 122 (58.4) 52 (24.9) 12 (5.7) 
 Age group     
 20-<30 8 (9.3) 46 (53.5) 29 (33.7) 3 (3.5) 
 30-<40 11 (12.9) 49 (57.7) 18 (21.2) 7 (8.2) 
 40-<50 4 (10.8) 26 (70.3) 5 (13.5) 2 (5.4) 
 ≥50 0 (0) 1 (100) 0 (0) 0 (0) 
      
1992-1994 Overall 19 (9.7) 99 (50.8) 60 (30.8) 17 (8.7) 
 Age group     
 20-<30 4 (6.8) 28 (47.5) 23 (39.0) 4 (6.8) 
 30-<40 8 (9.0) 46 (51.7) 25 (28.1) 10 (11.2) 
 40-<50 7 (17.1) 20 (48.8) 12 (29.3) 2 (4.9) 
 ≥50 0 (0) 5 (83.3) 0 (0) 1 (16.7) 
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               Table C1-2 continued 
 
1994-1996 Overall 21 (9.6) 109 (49.8) 66 (30.1) 23 (10.5) 
 Age group     
 20-<30 3 (6.0) 26 (52.0) 15 (30.0) 6 (12.0) 
 30-<40 7 (7.1) 50 (50.5) 30 (30.3) 12 (12.1) 
 40-<50 9 (14.3) 30 (47.6) 20 (31.8) 4 (6.4) 
 ≥50 2 (28.6) 3 (42.9) 1 (14.3) 1 (14.3) 
      
1996-1998 Overall 31 (12.3) 116 (46.0) 73 (29) 32 (12.7) 
 Age group     
 20-<30 2 (4.2) 20 (41.7) 17 (35.4) 9 (18.8) 
 30-<40 9 (8.3) 55 (50.5) 31 (28.4) 14 (12.8) 
 40-<50 13 (17.1) 32 (42.1) 23 (30.3) 8 (10.5) 
 ≥50 7 (36.8) 9 (47.4) 2 (10.5) 1 (5.3) 
      
2000-2003 Overall 11 (5.8) 81 (42.4) 57 (29.8) 42 (22.0) 
 Age group     
 20-<30 1 (0.0) 4 (50.0) 3 (37.5) 0 (0.0) 
 30-<40 1 (2.5) 20 (31.8) 31 (49.2) 12 (19.1) 
 40-<50 1 (1.2) 26 (35.6) 33 (45.2) 14 (19.2) 
 ≥50 2 (4.9) 10 (41.7) 7 (29.2) 4 (16.7) 
      
2004-2007 Overall 9 (4.6) 68 (34.7) 75 (38.3) 44 (22.5) 
 Age group     
 20-<30 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 
 30-<40 0 (0.0) 22 (41.5) 18 (34.0) 13 (24.5) 
 40-<50 4 (4.7) 25 (29.4) 38 (44.7) 18 (21.2) 
 ≥50 5 (8.8) 21 (36.8) 18 (31.6) 13 (22.8) 
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       Table C1-3.  Mixed models: Association of Baseline Age Group with Biennial BMI for up to 18 Years.    
 
 ß±SE  P-value 
Baseline Age Group   
 <20 years -0.95±1.42 0.50 
 20-29 years -0.05±1.03 0.96 
 30-39 years 0.28±0.70 0.69 
 40-49 years 0.0 N/A 
Baseline age -0.04±0.05 0.39 
Sex 0.18±0.27 0.50 
    Overall effect for age group p-value=0.26 
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    Table C1-4.  Association of Baseline Characteristics Weight Gain and Loss Adults with Type 1 Diabetes.     
 
 Gain  ≥ 5 kg/m² (n=119) Loss ≥ 2 kg/m² (n=40) 
 HR (95% CI) HR (95% CI) 
BMI (kg/m²) 1.20 (0.99-1.45) 1.50 (1.08-2.07) 
Age (years) 0.95 (0.78-1.15) 1.13 (0.82-1.57) 
Diabetes duration (years) 0.98 (0.81-1.18) 1.09 (0.79-1.49) 
HbA1c (%) 1.34 (1.10-1.64) 1.66 (1.18-2.35) 
Daily insulin dose (U/kg/dy) 1.05 (0.86-1.28) 1.12 (0.79-1.58) 
Insulin injections/day* 1.06 (0.90-1.25) 1.16 (0.88-1.52) 
Physical activity (kcal/week)* 0.91 (0.75-1.10) 0.69 (0.53-0.90) 
Albumin excretion rate (mg/dl)* 1.13 (0.94-1.36) 1.65 (1.23-2.20) 
Sex (female) 1.24 (0.86-1.78) 2.21 (1.12-4.34) 
Coronary artery disease 1.02 (0.42-2.50) 2.14 (0.66-6.98) 
Overt nephropathy                                     0.82 (0.51-1.30) 3.59 (1.89-6.81) 
Proliferative Retinopathy                        1.25 (0.84-1.85) 1.51 (0.77-2.99) 
Symptomatic autonomic   neuropathy       1.15 (0.46-2.86) 9.02 (3.68-22.12) 
Intensive insulin therapy                           0.83 (0.41-1.71) 2.09 (0.87-5.01) 
Family history of T2D 1.10 (0.68-1.78) 0.64 (0.23-1.79) 
Annual Household Income    
(<$20,000) 1.77 (1.18-2.64) 1.19 (0.59-2.37) 
Some college                                           1.15 (0.76-1.72) 1.02 (0.51-2.02) 
Current smoker                                          1.38 (0.91-2.11) 2.52 (1.30-4.89) 
Alcohol consumption ( 3+gl/wk)              0.64 (0.40-1.01) 0.79 (0.38-1.67) 
       BMI units=kg/m²   *Natural-logarithmically transformed before analysis.   
      All analyses, except baseline BMI, controlled for baseline BMI 
      Continuous variables expressed as per standard deviation change in the predictor variable  
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   Table C1-5. Baseline Predictors of Weight Gain and Loss in Adults with Type1 Diabetes.         
 
 ≥5 kg/m² Gain ≥ 2 kg/m² Loss 
 HR (95% CI) HR (95% CI) 
Sex (female)  3.57 (1.57-8.14) 
HbA1c (%)  1.62 (1.13-2.32) 
Overt nephropathy  3.27 (1.58-6.75) 
Symptomatic autonomic neuropathy  5.80 (2.13-15.78) 
Alcohol consumption (3+gl/wk) 0.53 (0.31-0.91)  
Current smoker  2.79 (1.28-6.06) 
Low household income (<$20,000/yr) 1.63 (1.08-2.47)  
Baseline BMI 1.18 (0.95-1.47) 2.79 (1.28-6.06) 
              Weight gain Cox stepwise selection model allowed for sex, age, HbA1c, intensive insulin therapy,  
              overt nephropathy, coronary artery disease, physical activity, alcohol consumption, and smoking. 
             Weight gain Cox stepwise selection model allowed for sex, age, HbA1c, physical activity, coronary  
artery disease, overt nephropathy, symptomatic autonomic neuropathy, and smoking. 
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C.2 TIME TRENDS IN INTENSIVE INSULIN THERAPY AND SELF MONITORING 
IN TYPE 1 DIABETES 
Andrea Rogers Fischl  Baqiyyah Conway  Trevor Orchard 
 
Since the results of the DCCT demonstrating a delay in the development or progression of 
complications in type 1 diabetes (T1D) for those on intensive insulin therapy, the use of intensive 
insulin therapy in the general T1D population has appeared to gradually increase. In addition to 
multiple dose insulin therapy (MDI), defined as at least 3 injections/day and or on the insulin 
pump, self monitoring of blood glucose levels is also an important component of treatment.  
Although there appears to be a rise in MDI, it is not clear to what extent those on MDI are also 
self-monitoring blood glucose levels at least four times a day as in the treatment arm of the 
DCCT.  We therefore investigated the use of intensive insulin therapy in 658 from the Pittsburgh 
Epidemiology of Diabetes Complications Study, an 18-year prospective study of childhood onset 
(age<17) T1D.   Intensive self-monitoring of blood glucose (SM) was defined as ≥4 times/day.  
Participants were categorized according to their MDI and SM status and were followed from 
1986-1988 to 2004-2007.  Those in these groups were compared by HbA1c level at the latest 
follow-up (2004-2007). Overall MDI rose from 6.7% in 1986-1988 to 82% in 2004-2007 (Figure 
8-5).  SM increased from 11.9% in 1990-1992 (when this data was first collected) to 53.1 % in 
2004-2007.   When intensive insulin therapy was defined as both MDI and SM, MDI rose from 
4.7% in 1990-1992 to 46.0% in 2004-2007.  At latest follow-up (2004-2007), HbA1c differed by 
MDI and SM category.  Those in the noMDI/noSM category had the highest mean HbA1c 
(p<0.0001) while those in the SM/MDI group had a lower mean HbA1c than those in the 
MDI/no SM group (Figure 8-5) (p<0.0001).  The prevalence of both MDI and of SM has 
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increased substantially over time; however, the prevalence of SM has not increased to the same 
degree as MDI.  Glycemic control is a function of both MDI and SM.  It is therefore equally as 
important to prescribe SM in addition to MDI as part of the diabetes management.  While the 
importance of intensive insulin therapy appears to have gotten across, more work needs to done 
on getting home the concomitant message of frequent self monitoring of blood glucose. 
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       Figure C2-1.  Time trends in intensive insulin therapy and self monitoring and their association with 
                                                                                      HbA1c. 
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C.3 INSULIN DOSE, HBA1C, AND CORONARY ARTERY DISEASE 
         Table C3-1.  Baseline Predictors of Nonfatal Coronary Artery Disease (CAD), mean (SD) or % (n).      
 
 Nonfatal CAD 
(n=109) 
Non-cases 
(n=463) 
p-value 
Sex (female) 42.2 (46) 51.4 (238) 0.09 
Age (years) 33.1 (6.3) 28.0 (6.6) <0.0001 
Duration (years) 24.8 (6.4) 19.2 (6.9) <0.0001 
BMI (kg/m²)  24.0 (3.3) 23.8 (3.0) 0.50 
Waist (cm)  82.1 (8.7) 79.7 (8.9) 0.01 
          males 85.4 (6.7) 83.5 (7.9) 0.08 
          females 77.5 (9.2) 76.1 (8.2) 0.30 
HbA1c (%)  8.9 (1.6) 8.7 (1.5) 0.25 
Daily insulin dose/kg body wt  0.71 (0.21) 0.78 (0.24) 0.009 
AER* (μg/min)  177.5 (13.3-935.6) 14.8 (7.6-100.6) <0.0001 
eGFR* (mg/min/1.73 m²) 98.8 (65.1-120.6) 110.4 (89.4-135.3) <0.0001 
WBC (x 10³/mm²) 7.4 (2.1) 6.5 (1.9) <0.0001 
SBP (mm Hg)  123.3 (21.8) 112.9 (14) <0.0001 
DBP (mm Hg) 79.1 (12.4) 72.3 (10.2) <0.0001 
Hypertension  39.5 (43) 12.1 (56) <0.0001 
Hypertension medication  17.9 (19) 3.0 (13) <0.0001 
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    Table C3-1 continued 
 
HDLc (mg/dl)  50.6 (11.4) 54.5 (12.9) 0.005 
          males 46.3 (8.2) 49.4 (10.0) 0.03 
          females 56.4 (12.6) 59.3 (13.4) 0.18 
Non-HDLc (mg/dl) 161.3 (42.0) 133.9 (40.7) <0.0001 
          males 167.9 (44.3) 136.4 (41.2) <0.0001 
          females 152.5 (37.3) 131.5 (40.2) 0.001 
Fibrinogen (mg/dl)*  323.1 (99.8) 281.3 (85.8) <0.0001 
Beck Depression Inventory* 
(n=506) 
7 (3-14) 5 (2-10) 0.02 
History of smoking**  54.2 (58) 38.2 (172) 0.003 
Physical activity* (kcal) 
(n=532) 
924 (420-2296) 1512 (616.5-2912.0) 0.09 
Overt Nephropathy (n=525) 50.9 (55) 24.9 (104) <0.0001 
Proliferative Retinopathy  65.7 (71) 25.5 (118) <0.0001 
Symptomatic Autonomic 
Neuropathy (n=459) 
19.8 (19) 6.6 (24) <0.0001 
History of hypoglycaemia 
resulting in unconsciousness 
(%) (n=544) 
58.1 (61) 41.9 (44) 0.004 
     AER=albumin excretion rate  eGFR=estimated glomerular filtration rate WBC=white blood cell count   
     SBP=systolic blood pressure   DBP=diastolic blood pressure  *Natural logarithmically transformed before    
     analysis   **Having smoked at least 100 cigarettes in a lifetime 
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     Table C3-2.  Baseline Predictors of Mortality from Fatal Coronary Artery Disease, mean (SD) or % (n).   
 
 Fatal CAD (n=48) Non-cases (n=544) p-value 
Sex (female) 45.8 (22) 49.5 (269) 0.63 
Age (years) 33.8 (6.1) 28.7 (6.7) <0.0001
Duration (years) 25.4 (6.3) 20.0 (7.1) <0.0001
BMI (kg/m²) 24.3 (3.6) 23.8 (3.0) 0.27 
Waist (cm) 82.9 (9.3) 80.0 (8.9) 0.03 
          males 86.0 (8.0) 83.8 (7.7) 0.18 
          females 79.1 (9.5) 76.1 (8.2) 0.09 
HbA1c (%) 9.2 (1.6) 8.7 (1.5) 0.03 
Daily insulin dose/kg body wt  0.77 (0.25) 0.76 (0.24) 0.91 
AER* (μg/min)  509.1 (71.6-1006.9) 16.6 (7.9-153.6) <0.0001
eGFR* (mg/min/1.73 m²) 90.4 (56.9-116.1) 109.3 (87.0-134.2) 0.002 
WBC (x 10³/mm²)  8.0 (2.1) 6.6 (1.9) <0.0001
SBP (mm Hg) 124.0 (21.9) 114.1 (15.4) 0.004 
DBP (mm Hg) 78.3 (13.5) 73.3 (10.7) 0.01 
Hypertension (%)  37.5 (18) 16.2 (88) 0.0002 
Hypertension medication (%)  12.8 (6) 5.4 (28) 0.04 
HDLc (mg/dL) 50.8 (13.1) 53.9 (12.6) 0.11 
          males 46.8 (9.9) 48.8 (9.7) 0.32 
          females 55.2 (14.9) 59.1 (13.1) 0.20 
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   Table C3-2 continued 
 
Non-HDLc (mg/dl)  166.1 (52.4) 137.9 (42.0) 0.0008 
          males 169.5 (60.8) 142.1 (42.5) 0.04 
          females 162.4 (42.4) 133.6 (41.2) 0.002 
Fibrinogen (mg/dl)*  328.2 (84.7) 287.5 (92.1) 0.001 
Beck Depression Inventory* 
(n=525) 
8 (5-14) 6 (2-10) 0.04 
History of smoking**  61.7 (29) 40.2 (213) 0.004 
Physical activity* (kcal) 
(n=550) 
1201 (574-2016) 1428 (616-2816) 0.07 
Overt Nephropathy (%) (n=541) 67.4 (31) 28.1 (139) <0.0001
Proliferative Retinopathy (%)  72.9 (35) 31.0 (168) <0.0001
Symptomatic Autonomic 
Neuropathy (%) (n=468) 
19.4 (7) 9.1 (39) 0.04 
History of hypoglycaemia 
resulting in unconsciousness 
(%) (n=563) 
44.4 (20) 46.0 (238) 0.85 
     AER=albumin excretion rate  eGFR=estimated glomerular filtration rate WBC=white blood cell count   
     SBP=systolic blood pressure  DBP=diastolic blood pressure  *Natural logarithmically transformed before   
     analysis  **Having smoked at least 100 cigarettes in a lifetime 
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    Table C3-3.  Predictors of the 18 Year Incidence of Nonfatal or Fatal Coronary Artery Disease in Type 1   
                                                                                      Diabetes. 
 
 Nonfatal  CAD events
109 cases; 463 non-cases 
CAD as the Primary Cause of 
Death 48 cases; 544 non-cases 
Risk Factors HR (95% CI) HR (95% CI) 
Diabetes duration (years) 2.07 (1.64-2.61) 1.95 (1.40-2.71) 
HbA1c (%)  1.55 (1.14-2.10) 
Daily insulin dose/kg body 
weight 
0.75 (0.57-0.97)  
AER (μg/min)  1.89 (1.38-2.57) 
eGFR (mg/min/1.73 m²) 0.73 (0.60-0.88)  
DBP (mm Hg) 1.52 (1.25-1.85)  
HDLc (mg/dl) 0.74 (0.59-0.92)  
Non-HDCc (mg/dl) 1.44 (1.20-1.73)  
WBC (x 10³/mm²) 1.42 (1.20-1.68) 1.48 (1.16-1.88) 
      AER=albumin excretion rate  eGFR=estimated glomerular filtration rate  DBP=diastolic blood pressure   
      SBP=systolic blood pressure  HDLc=high density lipoprotein cholesterol  Non-HDLc=non-high density  
      lipoprotein cholesterol  WBC=white blood cell count 
     Models  allowed for sex, diabetes duration, insulin dose/kg body weight, HbA1c, waist circumference, (log)   
     AER, (log) eGFR, DBP, use of hypertension medication, WBC, HDLc, non-HDLc, (log) fibrinogen, and a  
     history  of smoking. 
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C.4 
ASSOCIATION OF ADIPOSITY WITH THE 18-YEAR INCIDENCE OF 
COMPLICATIONS IN TYPE 1 DIABETES 
Table C4-1.  Association of Baseline Body Mass Index, Waist Circumference, and Hip Circumferences with 
                                         the 18-year Incidence of Complications of Type 1 Diabetes. 
 
 Coronary Artery 
Disease 
Overt 
Nephropathy 
Symptomatic 
Autonomic  
Neuropathy 
Proliferative 
Retinopathy 
Confirmed Distal 
Symmetrical 
Polyneuropthy 
Lower Extremity 
Arterial Disease 
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
BMI       
Underweight 1.12 (0.65-1.94) 1.37 (0.69-2.73) 1.26 (0.64-2.46) 0.96 (0.59-1.58) 1.16 (0.66-2.03) 1.13 (0.63-2.05) 
Normal Ref      
Overweight 1.50 (1.07-2.11) 0.72 (0.39-1.32) 1.13 (0.74-1.71) 1.04 (0.74-1.46) 1.07 (0.75-1.53) 1.13 (0.77-1.68) 
Obese 1.42 (0.62-3.25) 0.93 (0.22-3.82) 1.56 (0.62-3.91) 1.49 (0.66-3.40) 0.87 (0.35-2.16) 1.16 (0.42-3.17) 
Waist 
Circumference 
      
Quartile 1 1.19 (0.73-1.93) 0.69 (0.36-1.32) 0.62 (0.34-1.11) 0.91 (0.61-1.37) 1.07 (0.67-1.70) 1.56 (0.92-2.67) 
Quartile 2 Ref      
Quartile 3 1.22 (0.75-1.97) 0.69 (0.36-1.34) 0.76 (0.43-1.32) 1.09 (0.73-1.64) 1.09 (0.69-1.74) 1.29 (0.74-2.23) 
Quartile 4 2.38 (1.53-3.71) 0.85 (0.44-1.65) 1.40 (0.86-2.28) 1.23 (0.81-1.88) 1.69 (1.08-2.65) 2.12 (1.26-3.56) 
Hip 
Circumference 
      
Quartile 1 1.78 (1.14-2.79) 0.86 (0.46-1.60) 0.85 (0.49-1.49) 0.93 (0.62-1.40) 0.77 (0.48-1.22) 1.57 (0.98-2.50) 
Quartile 2 Ref      
Quartile 3 1.17 (0.74-1.87) 0.78 (0.43-1.44) 0.91 (0.55-1.51) 0.78 (0.52-1.18) 0.77 (0.49-1.21) 0.58 (0.33-1.03) 
Quartile 4 1.47 (0.94-2.30) 0.40 (0.19-0.83) 0.92 (0.56-1.51) 0.90 (0.61-1.33) 1.14 (0.76-1.70) 1.26 (0.78-2.02) 
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 Table C4-2.  Association of Updated Mean Body Mass Index, Waist Circumference, and Hip Circumference 
                                      with the 18-year Incidence of Complications of Type 1 Diabetes. 
 
 Coronary Artery 
Disease 
Overt 
Nephropathy 
Symptomatic 
Autonomic  
Neuropathy 
Proliferative 
Retinopathy 
Confirmed Distal 
Symmetrical 
Polyneuropthy 
Lower Extremity 
Arterial Disease 
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
BMI       
Underweight 1.42 (0.76-2.67) 1.98 (0.88-4.48) 1.37 (0.63-3.02) 1.16 (0.64-2.12) 1.17 (0.59-2.34) 0.96 (0.42-2.23) 
Normal Ref      
Overweight 1.09 (0.78-1.52) 1.07 (0.65-1.77) 0.73 (0.48-1.11) 1.22 (0.91-1.65) 1.20 (0.86-1.67) 1.18 (0.81-1.72) 
Obese 1.42 (0.83-2.40) 1.16 (0.49-2.77) 1.08 (0.57-2.04) 0.75 (0.40-1.40) 0.75 (0.40-1.40) 1.61 (0.92-2.85) 
Waist 
Circumference 
      
Quartile 1 1.10 (0.67-1.80) 3.23 (1.43-7.30) 1.03 (0.55-1.92) 0.96 (0.64-1.43) 0.78 (0.48-1.27) 0.29 (0.03-2.62) 
Quartile 2 Ref      
Quartile 3 1.30 (0.81-2.08) 2.63 (1.16-5.96) 1.41 (0.82-2.42) 1.20 (0.82-1.75) 1.00 (0.65-1.54) 1.01 (0.27-3.80) 
Quartile 4 2.32 (1.51-3.57) 3.40 (1.54-7.55) 1.52 (0.90-2.58) 1.43 (0.97-2.10) 1.62 (1.07-2.45) 0.94 (0.20-4.33) 
Hip 
Circumference 
      
Quartile 1 1.44 (0.93-2.34) 1.15 (0.60-2.22) 0.81 (0.48-1.37) 0.70 (0.47-1.04) 0.82 (0.50-1.33) 1.21 (0.72-2.04) 
Quartile 2 Ref      
Quartile 3 1.04 (0.66-1.63) 1.27 (0.69-2.36) 0.67 (0.40-1.13) 0.81 (0.55-1.19) 1.35 (0.87-2.08) 1.28 (0.78-2.11) 
Quartile 4 1.29 (0.83-1.99) 0.80 (0.40-1.59) 0.88 (0.54-1.43) 0.93 (0.64-1.35) 1.35 (0.88-2.08) 1.35 (0.82-2.22) 
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